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ABSTRACT
Dysfunction of the blood vessels that form the blood-brain barrier (BBB) is
observed across various neurological disorders, including multiple sclerosis (MS). As
barrier loss culminates in neuronal dysfunction and degeneration, a better understanding of
the mechanisms underlying BBB dysfunction is needed.
Tight junctions are multiprotein complexes maintained by the endothelial cells
lining the inner blood vessel wall to seal the intercellular space, and their disruption impairs
BBB function. In my first chapter, I focus on how tight junctions are altered in CNS
inflammatory demyelinating diseases (CNS-IDDs) like MS as BBB dysfunction is one of
the earliest known stages in their disease progression. Literature searches were conducted
for relevant studies involving three prominent tight junction protein families, namely the
claudins, tight junction-associated MARVEL proteins (TAMPs), and angulins. As few
studies analyzed patient tissues, additional literature searches were conducted for relevant
cell culture and animal models. Particular attention is paid to studies involving
pharmacological interventions or genetic manipulations as tight junctions are increasingly
being recognized as possible therapeutic targets for preserving or restoring BBB function
and, in turn, CNS homeostasis.
In my second chapter, I explore how the molecular composition of the vascular
basement membrane (BM) can influence barrier function. Under healthy conditions, the
vascular BM surrounding the endothelium fosters BBB function through cell-extracellular
matrix (ECM) protein interactions that promote the tight junction protein claudin-5. During
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inflammation, however, the molecular composition of the BM is perturbed. Recently, the
ECM proteins collagen type I and decorin, both of which are typically absent from the BM,
were observed surrounding vessels in the lesions of MS patients. As their roles in
inflammation are poorly understood, I investigated whether they can influence barrier
function

or

claudin-5

expression.

Using

a

mouse

model

of

inflammatory

encephalomyelitis, I found that decorin is present within the BM during early disease when
the onset of BBB dysfunction occurs. In complement, I conducted cell culture studies with
mouse BBB endothelial cells, overall finding an inverse relationship between decorin and
barrier function or claudin-5. Similar cell culture studies using collagen type I revealed a
similar inverse relationship between it and barrier function or claudin-5.
Overall, this work suggests that 1) tight junction proteins may be a viable
therapeutic target in restoring BBB dysfunction and 2) inflammation-associated alterations
to the vascular BM may contribute to BBB dysfunction by suppressing the tight junction
protein claudin-5.
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CHAPTER ONE: BLOOD-BRAIN BARRIER DYSFUNCTION & TIGHT JUNCTION
DYSREGULATION IN CNS INFLAMMATORY DEMYELINATING DISEASES
AND THEIR MODELS – A LITERATURE REVIEW.

CNS Inflammatory Demyelinating Diseases (CNS-IDDs)
CNS-IDDs are a diverse group of diseases that include multiple sclerosis (MS),
neuromyelitis

optica

spectrum

disorder

(NMOSD),

and

acute

disseminated

encephalomyelitis (ADEM).1,2 Despite their differences, all share the pathological
hallmarks of inflammatory demyelination1,2 and compromise of the blood-brain barrier
(BBB).3,4 Due to their idiopathic nature, therapeutic strategies historically have relied on
immunomodulatory or immunosuppressive drugs.5,6 However, the contribution of vascular
dysfunction to the pathogenesis of CNS-IDDs and other neurological disorders now
suggests the vasculature as a viable therapeutic target.7 Thus, a better understanding of the
mechanisms governing BBB function and dysfunction in CNS-IDDs may uncover new
treatment strategies applicable to patients suffering neurological disorders as a whole.
Multiple Sclerosis
Patients with MS primarily suffer lesions within the brain and spinal cord.8 Leakage
of plasma proteins like fibrinogen is variably observed across the life of the lesions,
including prior to the onset of demyelination.9,10 Although its underlying etiology remains
unknown, MS involves innate and adaptive immune responses against the myelin sheath. 11
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There are four main clinical forms of MS (Figure 1.1). Relapsing-remitting MS
(RR-MS), affecting ~80% of patients, has episodes of relapse interspersed by stable
remission (Figure 1.1A).12 Within 15 years, half of these patients will transition to
secondary-progressive MS (SP-MS), experiencing a gradual worsening of neurological
function independent of relapse (Figure 1.1B).13 Primary-progressive MS (PP-MS),
affecting ~10-15% of patients, involves the gradual worsening of neurological function
from the initial crossing above clinical threshold (Figure 1.1C).14 Finally, for ~5% of
patients, progressive-relapsing (PR-MS), distinguishes itself from PP-MS with clear
superimposed relapses throughout the progressive disease course (Figure 1.1D).12,14
Additionally, there are several rare variants. First, acute MS (Marburg’s disease)
follows a fulminant disease course, with rapid deterioration of health and death generally
within 12-18 months post-diagnosis.15,16 Next, concentric sclerosis (Balo’s disease) is
distinguished by lesions containing concentric rings of demyelination separated by rings
of preserved myelin.15,16 Finally, tumefactive sclerosis presents as large tumor-like lesions
that can cause mass effect and edema.15,16
Neuromyelitis Optica Spectrum Disorder
Originally thought to be a variant of MS, NMOSD is now classified separately.17
Patients with classic NMO (Devic’s disease) primarily suffer lesions within the optic nerve
or spinal cord, and are seropositive for pathogenic antibodies against the astrocyte water
channel protein aquaporin-4 (AQP4).18,19 Vascular leakage is observed primarily during
the early stages of lesion evolution when active astrocyte lysis is happening.20 As this
precedes oligodendrocyte dysfunction and death, classic NMO likely reflects a primary
astrocytopathy that triggers secondary demyelination.21 Revisions to the original diagnostic
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criteria have led to an expanded term, NMOSD, which recognizes that patients may also
exhibit lesions in the brain or brainstem, and may be seronegative for AQP4 but otherwise
fulfill the diagnostic criteria.19 Disease generally follows a relapsing-remitting course
(Figure 1.2A), with optic neuritis more prevalent during early disease and transverse
myelitis more prevalent during late disease.22
Acute Disseminated Encephalomyelitis
Patients with ADEM primarily suffer lesions within the brain or spinal cord.4,23
Although it can occur at any age, ADEM predominantly is observed in children or young
adults following viral infection.4,23 With rare exception, classic ADEM follows a
monophasic disease course with subsequent full recovery (Figure 1.2.B).4,23 However,
acute hemorrhagic leukoencephalomyelitis (AHLE) is a proposed rare variant that is
fulminant and is hallmarked by cerebral microhemorrhages. 4 Although its etiology is not
fully understood, it is hypothesized that molecular mimicry between pathogen and myelin
proteins or bystander activation of virus-specific immune cells may be responsible. 4,23
The Blood-brain Barrier in Neurovascular Unit Homeostasis
Neuronal activity is metabolically and energetically costly. 24 Despite the adult
human brain representing only 2% of the total body weight, it accounts for nearly 20% of
total energy consumption.25 To meet these needs, local neuronal activity is tightly coupled
to local blood flow which is regulated by vascular cells (endothelial cells, vascular smooth
muscle cells, pericytes) that work in tandem with glial cells (astrocytes, microglia, and
oligodendrocytes).24,25 Collectively, these cells form the neurovascular unit (NVU) as
shown in Figure 1.3.
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The Endothelium Forms the de facto BBB
The interior blood vessel surface is lined by a single layer of endothelial cells
(ECs).26,27 At the microvessel level, BBB-ECs are surrounded by pericytes and astrocytic
end-feet processes, plus a vascular basement membrane that provides structural support
and serves as a conduit for soluble factor signaling or cell-matrix protein interactions
(Figure 1.3).27 As it the endothelium that provides the physical and metabolic barrier
properties of the vessel, it is the de facto BBB.
Tight Junctions Confer Barrier Properties to the Endothelium
To fulfill their barrier functions, BBB-ECs maintain multi-protein complexes called
tight junctions at cell-cell contacts to seal shut the intercellular space.28 This physical
restriction of paracellular transport, in turn, contributes to metabolic barrier functionality
by ensuring that transcellular transport is the primary route for exchange.29
Tight junctions are formed by a branching network of transmembrane proteins that
act in homophilic or heterophilic fashion within the same cell membrane and across to the
opposing membrane.28 In turn, scaffolding proteins couple the transmembrane proteins to
the cytoskeleton for stability and establishment of signaling hubs. 30 Although the molecular
composition of tight junctions in BBB-ECs is still under investigation, three families of
integral proteins known to play key roles in barrier function and its regulation are the
claudin, tight junction-associated MARVEL protein (TAMP), and angulin families. 30,31
The Claudin Family
Claudins are tetraspan proteins (Figure 1.5) that fulfill barrier- or pore-forming
functions at bicellular junctions (Figures 1.4 & 1.5), with 27 putative members across
humans and rodents.32 Structurally, claudins contain a short intracellular N-terminal tail,
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two extracellular loops (ECLs), a short intracellular loop (IL), and an intracellular Cterminal tail.32 The first ECL contains a conserved W-GLW-C-C signature motif and can
confer ion selectivity depending on whether charged amino acids are present, while the
second ECL mediates trans-interactions.32 For most members, the C-terminus contains a
Postsynaptic Density Protein 95/Discs Large 1/Zonula Occludens-1 (PDZ)-binding motif
(Y-V) which is recognized by PDZ domain-containing scaffolding proteins like zonula
occludens-1 (ZO-1), thereby allowing coupling to the cytoskeleton.32 Additionally, Cterminal tails frequently contain phosphorylation, palmitoylation, and ubiquitination sites
for trafficking and regulation under healthy or disease conditions.32
Historically, claudin-5 has been considered the predominant barrier-forming
member in BBB-ECs.28 Its knockdown in immortalized human BBB-ECs increases their
permeability to small- or medium-sized tracers like Lucifer Yellow (457 Dalton (Da)) or 4
kiloDalton (kDa) fluorescein isothiocyanate (FITC)-conjugated dextran, but not large
tracers like 70 kDa FITC-dextran, and delays recovery of barrier integrity following
osmotic disruption with mannitol.33 Similarly, we have demonstrated that its knockdown
in primary mouse BBB-ECs increases their permeability to sodium fluorescein (NaFluor;
376 Da).34 On the organismal level, Cldn5-deficient mice die within 10 hours of birth and
suffer selective leakage of small molecules up to 800 Da in size,35 while persistent
endothelial-restricted knockdown in adult mice results in schizophrenia-like behavior,
vascular leakage of serum proteins (fibrinogen; ~340 kDa), and complete mortality.36 In
humans, deletion of 22q11.2, within which CLDN5 is located, is one of the strongest known
genetic risk factors for schizophrenia,37 especially for patients that also possess a single
nucleotide polymorphism (rs10314) within the 3’ untranslated region of CLDN5 that
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impairs its translation.36 In light of the above, claudin-5 has been described as an essential
gatekeeper for BBB function and CNS homeostasis. 38
Besides claudin-5, several other family members have been reported, including
claudins 1, 3, 11, and 12.28,39,40 However, actual member representation is still not settled.
Several transcriptional profiling studies have screened purified human or rodent brain
microvessels.39,41,42 Member presence and relative abundance varied, with isolation
technique appearing to have a significant effect (Appendix A). Furthermore, crossreactivity of antibodies is a known issue in the field due to the limited regions available for
binding and the generally conserved nature of the sequences in the available regions.43
Early studies that reported claudin-1 was enriched at tight junctions in human and mouse
BBB-ECs used an antibody that subsequently was shown to be cross-reactive with claudin3.44 Since then, claudin-1 generally has been reported absent or weakly present within the
cytoplasm, rather than at the tight junctions under homeostatic conditions. 39,45,46 Similarly,
two recent studies have demonstrated that commercial antibodies against claudin-3 or
claudin-12 can still localize to the tight junctions of the respective knockout animal. 47,48
Thus, more research is sorely needed to confirm which claudins are present in BBB-ECs.
The TAMP Family
TAMPs are tetraspan proteins (Figure 1.5) that share minimal homology with
claudins and that fulfill modulatory roles in barrier function.28,49 The TAMP family is
comprised of three members: occludin, tricellulin (gene name: MarvelD2), and
MarvelD3.49 Unlike claudins, TAMPs exhibit preferential localization at cell-cell
contacts.49,50 Under non-pathological conditions, occludin is enriched at bicellular
junctions, tricellulin at tricellular junctions, and MarvelD3 at both (Figures 1.4 & 1.5). 49,50
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TAMPs possess two ECLs, a short IL, and intracellular tails. 49,51 Additionally, all
three possess a MAL & Related Proteins for Vesicle Trafficking & Membrane Link
(MARVEL) domain which spans across all four transmembrane domains.49,51 However,
only occludin and tricellulin possess an Occludin/ELL (OCEL) domain in their Ctermini.52 For both, this domain is involved in trafficking to the tight junctions.31,52
Additionally, for occludin, it serves as a binding site for scaffolding proteins and is
necessary for internalization.52
Although all members are predicted to be phospho-proteins, to date, the role of
phosphorylation has only been explored with occludin.53 Increased tyrosine
phosphorylation is observed in primary human BBB-ECs experiencing oxidative stress54–
56

and in the brain microvessels of patients suffering from encephalopathy due to human

immunodeficiency virus (HIV) infection. 57,58 Separately, increased serine phosphorylation
promotes its removal from the bicellular junctions and its interaction with the E3 ubiquitin
ligase Itch for subsequent degradation in bovine retinal ECs following stimulation with
vascular endothelial growth factor (VEGF).59
Finally, multiple splice variants in humans and rodents for each of the members
have been reported.49,60–62 However, no studies have yet explored which variants are
expressed in BBB-ECs under healthy or pathological conditions, nor their relative
contributions to barrier function.
The Angulin Family
Unlike the other two families, angulins are single-pass proteins with extracellular
N-terminal tails containing immunoglobulin (IgG)-like domains (Figure 1.5).31 The
angulin family is comprised of three members: lipolysis-stimulated lipoprotein receptor
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(LSR), and immunoglobulin-like domain-containing receptors 1 and 2 (ILDR1 and
ILDR2).31 All three are enriched at tricellular junctions where they participate in central
sealing element formation (Figure 1.4).31
There is limited information regarding the expression or function of angulins in
BBB-ECs. Currently, only LSR has been reported to be expressed in vivo.63,64 Its knockout
is embryonically lethal in mice.64 At E14.5, when the BBB should be functional, knockout
embryos suffer leakage of Sulfo-NHS-Biotin (443 Da) but do not have altered bicellular
junctions, suggesting leakage is occurring via the tricellular junctions.64 As for the
remaining two members, a recent study that performed transcriptional analysis of primary
mouse BBB-ECs reported that Ildr2, but not Ild1, is additionally expressed.65 However, no
functional characterization was performed.
Inter- and Intra-Family Interactions
Tight junctions rely on the transmembrane and scaffolding proteins present to act
in concert. At bicellular junctions, claudins form an initial network of loose strands that
confers basic barrier functionality to the cell.66 However, incorporation of proteins like
occludin is required for the formation of branching strands between the lateral strands to
yield a continuous, anastomosing network.66 Similarly, at tricellular junctions, although
angulins form the initial central sealing element, recruitment of proteins like tricellulin is
required to couple the bicellular junctions to the central sealing element.66 Under this
framework, it is readily apparent that disruptions to any of these families will likely
negatively impact the others. However, intra-family interactions also exist.
Claudin Interactions. Sladojevic et al. reported that claudin-1 upregulation and its
incorporation into the tight junctions was associated with claudin-5 loss and BBB
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dysfunction in patients with chronic stroke and an animal model of chronic stroke.46
Furthermore, claudin-1 overexpression disrupted the cis- and trans-interactions of claudin5 and increased permeability to inulin in an immortalized mouse BBB-EC line.46 Similarly,
Berndt et al. reported claudin-5 knockdown led to claudin-1 upregulation, while claudin11 overexpression led to the formation of short, alternating claudin-5+ or claudin-11+
strands at the cell borders.39
TAMP Interactions. Studies that modeled hereditary forms of deafness due to
loss-of-function mutations in Ocln or MarvelD2 have repeatedly demonstrated that loss of
one results in the redistribution of the other at the cost of barrier integrity and cellular
degeneration.49,67–69 However, these interactions have not been investigated in BBB-ECs.
Angulin Interactions. The interplay amongst angulins is the least understood of
the three families. Based on studies that focused on the gut epithelium, kidney epithelium,
or cochlear hair cells, loss of one can be partially compensated by the others.70,71 As with
the TAMPs, interactions in BBB-ECs have not been reported.
Rationale for Systematic Literature Search
Given the close connection between tight junctions and BBB function, the
expression and localization patterns of tight junction proteins are commonly chosen as
surrogate markers for barrier dysfunction in CNS-IDDs and other CNS disorders.
Unfortunately, an all-too-common trend is to assess a single protein at a single stage of
disease. While this strategy may work well from a publication perspective, it has left the
field disjointed, with findings spread across scores of articles. Moreover, it too easily
allows for the oversimplification of the results to simple binary perspectives as to whether
tight junctions are disrupted or barrier function compromised. Consequently, this has left
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it challenging to understand the dynamics of tight junction protein expression and
localization across the disease course.
To address this outstanding defect, I have conducted a systematic literature search
for studies characterizing the claudin, TAMP, and angulin families in patients with CNSIDDs. To support these findings, I have additionally conducted searches for human-derived
CNS-EC culture models and commonly used animal models of CNS-IDDs, namely,
experimental autoimmune encephalomyelitis (EAE), experimental NMOSD (E-NMOSD),
Theiler’s murine encephalomyelitis virus (TMEV), and cuprizone.
Methodology
Literature Search Strategy
Searches were conducted following the preferred reporting items for systematic
reviews and meta-analyses (PRISMA) guidelines.72 The Web of Science platform (WoS;
Clarivate Analysis) was chosen for its ability to simultaneously search across multiple
databases, including Science Citation Index Expanded and MEDLINE. Databases were
queried from their inception through March 1 st, 2021.
Briefly, the ‘OR’ operator was used to generate data sets for each family member.
To avoid missing relevant results that did not mention the families in the title or abstract,
additional searches were performed using a wildcard approach (“tight junction*”). Then,
the ‘OR’ operator was used to unify the individual data sets. Analogously, the ‘OR’
operator was used to generate data sets for each disease or model and then to unify them.
Finally, the ‘AND’ operator was used to restrict the unified tight junction data set with the
unified disease and model data set, yielding 657 unique results (Figure 1.8). For the
complete search strategies used, see Appendix B.
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Inclusion Criteria
Results were independently screened by two individuals for peer-reviewed studies
with full-text availability in the English language. Additionally, conference abstracts and
review articles were examined to identify relevant publications not found by the database
searches (Figure 1.6). This yielded an additional thirteen studies (Figure 1.8).
Studies were assessed for inclusion on four points: 1) analysis specific to one or
more of the queried diseases or models, 2) analysis specific to one or more of the queried
families, 3) analysis specific to the endothelial blood-CNS barriers in patient tissues or
human-derived CNS-EC cultures involving patient serum or IgG, and 4) an assessment
about the member in the disease or model, rather than its usage as a cell marker (Figure
1.7). Ultimately, sixty-six studies fulfilling all four points were included for qualitative
synthesis (Figures 1.9-11, 1.13-14, 1.16-25, Appendices C-F). However, forty studies
failing only the third point are summarized in Appendices C-F. Disagreements between
reviewers were resolved through discussion until consensus was achieved.
Summary of Literature Search
CNS-IDD Patient Samples
First, of the fifty-nine MS studies identified, plus two not found by WoS, fortythree were excluded as they did not meet the second eligibility point. Of the remaining
eighteen studies, eight met all four points (Figures 1.9 & 1.10, Appendix C), seven met all
points except the third (Appendix C), and three were excluded as the members were used
solely as CNS-EC73,74 or myelin markers.75 Next, of the two NMOSD studies identified,
one met all four points (Figure 1.13, Appendix C) and one met all points except the third
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(Appendix C). Finally, one ADEM study was identified, but was excluded as it did not
meet the second point.
Human CNS-EC Culture Models
First, of the eight MS studies identified, plus one not found by WoS, six met all
four points (Figure 1.11, Appendix D), and the remaining three met all points except the
third (Appendix D). Next, of the four NMOSD studies identified, plus one not found by
WoS, four met all four points (Figure 1.14, Appendix D), while the remaining study met
all points except the third (Appendix D). Finally, no studies for ADEM were found.
Animal Models
First, of the 116 EAE studies identified, plus two not found by WoS, forty-eight
were excluded as they did not meet the second eligibility point. Of the remaining sixtyeight studies, forty-six met all four points (Figures 1.16-1.22, Appendix E), twenty met all
points except the third (Appendix E), and two were excluded as the members were used
solely as CNS-EC markers.76,77 Next, of the two E-NMOSD studies identified, one was
excluded as it did not meet the second point. The remaining study met all four points
(Figure 1.23, Appendix F). Third, of the six TMEV studies identified, one was excluded as
it did not meet the second point. The remaining five studies met all four points (Figure
1.24, Appendix F). Finally, of the four cuprizone studies identified, plus one not found by
WoS, three were excluded as they did not meet the second eligibility point. Of the
remaining two studies, one met all four points (Figure 1.25, Appendix F), while the other
met all points except the third (Appendix F).
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Alterations in Patients with MS
MS Lesions Staging
White matter (WM) lesions are temporally classified into pre-active, active, or
chronic stages based on the presence or absence of two key pathological figures – activated
microglia/macrophages and demyelination (Figure 1.9A).78,79 Conversely, grey matter
(GM) lesions are spatially classified as one of four types (Figure 1.10A).80
WM Lesions
Pre-active Lesions. Activated microglial clusters with variable other pathology but
without demyelination have been termed pre-reactive lesions (Figure 1.9A – left).81
However, not all clusters evolve into active lesions, nor are they unique to MS.81
From a mixed patient group, Horssen et al. selected a subset based on their high
incidence of activated clusters.82 These clusters were distant from microvessels and lacked
astrogliosis, fibrinogen leakage, or T cell presence. 82 Claudin-5 was present in crosssectional views of vessels, but no comparisons with normal-appearing WM (NAWM) or
control donors were performed.82 Next, in a group of patients primarily with SP-MS, Plumb
et al. reported that areas with clusters had a greater proportion of abnormal tight junctions
compared to NAWM based on the proportion of vessels with altered occludin or ZO-1
staining.83 Additionally, the authors noted the presence of leukocytes around the vessels
with disrupted tight junctions.83 Finally, in a study of patients with RR- or SP-MS, Alvarez
et al. observed disruption and loss of claudin-5 and occludin in areas with activated clusters
that also exhibited astrogliosis, plasma protein leakage, and sparse lymphocytic infiltrates.9
Active Lesions. Active lesions are dense with activated macrophages and microglia
variably laden with myelin degradation products (Figure 1.9A – middle).78,79 Active lesions
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are most common in patients with limited disease duration or RR-MS, and decrease in
prevalence over time.84
In a group of patients primarily with SP-MS, Plumb et al. reported that occludin
was disrupted or lost in lesional vessels.83 Furthermore, these disturbances were prominent
in regions with macrophage clusters, leukocytic infiltrates, or fibrinogen leakage.83 When
the authors tallied the number of vessels with altered occludin or ZO-1 staining, they found
a high proportion of abnormal tight junctions regardless of how many lipid-laden cells were
present, or the degree of their activation.83 Separately, Wosik et al. measured a decreased
peak fluorescence intensity and strand thickness for occludin in lesional vessels compared
to NAWM from a group of MS patients whose clinical forms were not provided.85
Chronic Lesions. Lesions without active demyelination and lack microglia or
macrophages except at the rim are termed chronic active, while lesions generally lacking
cells are considered inactive (Figure 1.9A – right).78,79 Both are most common in patients
with prolonged disease duration or progressive MS, and increase in prevalence over time. 84
In a group of patients primarily with progressive MS, van Horssen et al. reported
that vessels in inactive lesions were sporadically negative for claudin-5.86 Separately,
Cunnea et al. measured gene expression in brain microvessels isolated from patients with
progressive forms of MS.87 The authors initially found an increase in occludin for chronic
active lesions versus NAWM using microarray analysis (MA).87 Subsequent validation by
quantitative polymerase chain reaction (qPCR), however, measured a decrease in occludin
for chronic active or inactive lesions versus NAWM. 87
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GM Lesions
Based on early studies using post-mortem samples, it was thought that
demyelination in cortical lesions occurs by different mechanisms based on a general
absence of observable inflammation.88,89 Consequently, a spatial classification system was
established instead (Figure 1.10A).88,89 However, follow-up studies that included patient
biopsies have since shown that inflammation and barrier dysfunction are present in cortical
lesions, albeit mostly during early MS.88,89 Interestingly, the presence of meningeal
inflammation is topographically associated with cortical lesion presence, suggesting that
the meninges may act as a backdoor for entry into the cortical tissues.89
In a study using post-mortem tissues from a patient group diagnosed primarily with
progressive MS, van Horssen et al. observed that fibrinogen and IgG were still luminally
confined in pure GM lesions or the GM portion of mixed GM-WM lesions.86 In line, the
vessels in pure GM lesions and adjacent normal-appearing GM (NAGM) were comparably
reactive for claudin-5.86
Studies with Partial Staging
In a group of patients with RR-MS, Musolino et al. reported disruption and loss of
claudin-5 in the vessels of demyelinated WM lesions, but additional staging information
was not available.90 Separately, Uchida et al. noted a disruption and loss of claudin-11 in
frontal lobe brain and spinal cord vessels from patients whose clinical forms were not
provided.40 As a further complication, the analysis considered the entire tissue section and
did not distinguish between matter types or lesion presence.
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Summary
Across the eight studies that included patient tissues, only bicellular tight junction
proteins (claudin-5, claudin-11, and occludin) have been characterized.
For WM lesions, studies suggest that bicellular tight junction disruption and barrier
dysfunction precedes demyelination and variably persists throughout the life of the lesion.
Conversely, for GM lesions, despite visible demyelination, bicellular tight junctions and
barrier function do not appear disturbed compared to NAGM. However, given the findings
of the more recent biopsy tissue-based studies, the results of this post-mortem tissue-based
study likely reflect late MS and may not be indicative of what occurs in cortical lesions
during early MS. Therefore, follow-up studies with cortical lesions exhibiting active
inflammation are needed before conclusions about tight junction disruption or the viability
of their therapeutic targeting can be made.
Alterations in Cell Culture Models of MS
Cell Lines Used in Studies
All studies used the hCMEC/D391 or TY series92–94 of brain endothelial cell lines.
Serum- or IgG-induced Alterations
Shimizu et al. reported that the serum of patients who fulfilled the 2010 revised
McDonald diagnostic criteria during the acute phase of disease had no impact on total
claudin-5 or occludin protein, or transendothelial electrical resistance (TEER).95 Similarly,
Tasaki et al. found no difference in total claudin-5 protein, nor TEER, using serum from a
comparable patient group.96 Conversely, Shimizu et al. measured a loss of total claudin-5
protein and TEER using serum from patients with SP-MS or RR-MS during relapse, but
not from patients with RR-MS in remission.97 However, a loss of total occludin protein
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was only detected with serum from patients with SP-MS.97 The loss of total claudin-5
protein and TEER followed incubation with IgG isolated from the serum of patients with
SP-MS, but not the IgG from either RR-MS group.97 However, no patient IgG altered total
occludin protein.97 Finally, Sheikh et al. measured a decreased mean intensity fluorescence
for occludin using the serum of patients with RR-MS by flow cytometry.98 This was
accompanied by decreased TEER and increased permeability to 70 kDa FITC-Dextran.98
Interventions
Inhibition of matrix metalloproteinases (MMPs) or proinflammatory
cytokines. Using serum from patients who fulfilled the 2010 revised McDonald diagnostic
criteria during the acute phase of disease, Tasaki et al. found no alteration in total claudin5 protein or TEER using GM6001, a pan-MMP inhibitor.96 Conversely, Shimizu et al.
identified a rescue in total claudin-5 protein and TEER, but not total occludin protein, using
GM6001 with serum from patients with RR-MS during relapse.97 GM6001 was ineffective
for rescue of either protein with serum from patients with SP-MS.97 The authors also found
a rescue in total claudin-5 protein and TEER using an anti-VEGF antibody, but not
antibodies against tumor necrosis factor alpha (TNF-α), interferon gamma (IFN-γ), or
interleukin 17 (IL-17), with serum from patients with RR-MS during relapse.97 However,
total occludin protein was unaltered with any antibody for serum from patients with RRMS during relapse, and all of the antibodies were ineffective for either protein with serum
from patients with SP-MS.97 Notably, patient MMP and VEGF serum concentrations were
comparable to control donors, suggesting autocrine MMP & VEGF secretion.97
Sphingosine 1-Phosphate Receptor (S1PR) Modulation. Fingolimod is a Food
and Drug Administration (FDA)-approved S1PR modulator for patients with RR-MS.99
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Nishihara et al. found a rescue for total claudin-5 protein and TEER with serum from
patients with SP-MS or RR-MS following monolayer pre-treatment with fingolimod.100
However, no rescue was found for total occludin protein with any of the patient sera.100
Additionally, a rescue for claudin-5 gene expression was measured.100 In this case,
however, all patient groups were considered as a single disease group.
Vitamin D Receptor (VDR) Agonism. Takahashi et al. found a rescue for total
claudin-5 protein with serum from patients with RR-MS during relapse, but not RR-MS in
remission or SP-MS, following monolayer pre-treatment with Vitamin D3.101
Summary
Across the six studies that used human-derived BBB-EC cultures with patient
serum or IgG, only bicellular junction proteins (claudin-5 and occludin) have been
characterized.
Incubation with patient serum, but not IgG, generally led to the loss of bicellular
tight junction proteins and barrier dysfunction. These findings are supported by studies that
incubated mouse- or rat-derived EC cultures with patient serum and reported suppression
of claudin-5 and occludin expression on the mRNA and protein levels (Appendix D).
However, the results of mixed cell culture models can be difficult to interpret, especially
given the known differences in human and rodent immunology.102 Nevertheless, successful
therapies will likely require consideration of patient type and pro-inflammatory autocrine
signaling in CNS-ECs.
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Alterations in Patients with NMOSD
NMOSD Lesion Staging
Historically, six lesion types have been described based in NMOSD on their
pathology.103 However, this classification system could not infer lesion progression or how
the types related to each other. Just this year, Takai et al. proposed the first temporal staging
system which is focused on astrocyte morphology (Figure 1.12).104
At their earliest stages, lesions exhibit active astrocyte lysis, perivascular
complement deposition, oligodendrocyte damage, and inflammatory cuffs. 21,104 Following
astrocyte depletion, activated macrophages and microglia remain. 21,104 Over time, astrocyte
repopulation and partial oligodendrocyte regeneration occurs, although astrocytes remain
reactive and form characteristic honeycomb-like gliotic scarring.21,104
Alterations in Patient Lesions
In a group of patients with NMOSD, Winkler et al. reported that claudin-5 was
present in cross-sectional views of lesions with completed astrocyte loss, demyelination,
and primarily activated macrophages and microglia, but without fibrinogen leakage.20
Although the serostatus of the patients was not known, all patients fulfilled at least two
core NMOSD characteristics.20 Lesions were located within the hippocampus, basal
ganglia, or spinal cord, and the proportion of claudin-5+ lesional or perilesional vessels did
not differ from control donors.20 Additionally, the authors noted that claudin-3 and
occludin were present in transverse sections from a single spinal cord lesion with partial
astrocyte repopulation and were comparable to control donors.20
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Summary
Only a single study that included patient samples was identified. In it, only
bicellular tight junction proteins (claudin-3, claudin-5, and occludin) were characterized.
Barrier dysfunction is most prominent during active astrocyte lysis. However, all
lesions assessed for tight junction disruption already had completed astrocyte lysis and
generally lacked markers of recent vascular leakage. Thus, the finding that bicellular tight
junction protein presence in patient lesions was comparable to control donor tissues is not
unexpected. Follow-up studies involving early lesions with active astrocyte lysis are
needed before conclusions about tight junction disruption or the viability of their
therapeutic targeting can be made.
Alterations in Cell Cultures of NMOSD
Cell Lines Used in Studies
All studies used the TY08 brain endothelial cell line. 92
Serum- or IgG-induced Alterations
Shimizu et al. reported a loss of total claudin-5 protein and TEER, but not total
occludin protein, with serum from patients with NMO during the acute phase of disease.95
Similarly, Tasaki et al. observed a loss of total claudin-5 protein and TEER, plus increased
permeability to NaFluor, with serum from patients with NMOSD during the acute phase
of disease.96 Patients were diagnosed with definitive NMO or longitudinally extensive
transverse myelitis (LETM).96 However, no loss in total claudin-5 protein was detected
using serum from patients in remission. 96
Tasaki et al. also reported no changes in total claudin-5 protein, TEER, or
permeability to NaFluor with IgG from NMOSD patients during the acute phase of
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disease.96 Similarly, using a transwell co-culture system with astrocytes, Takeshita et al.
found that pooled NMO-IgG was insufficient to alter claudin-5 localization or permeability
to 10 kDa FITC-dextran when the astrocytes did not express AQP4. 105 Conversely,
Shimizu et al. reported a disruption and loss of claudin-5 with pooled NMO-IgG.106 In this
case, however, the authors identified an anti-endothelial cell antibody (AECA) against
glucose-regulated protein 78 (GRP78).106 Incubation with patient-derived recombinant
antibodies was sufficient to replicate claudin-5 loss and barrier hyperpermeability. 106
Interventions
Inhibition of MMPs. Tasaki et al. reported a rescue for total claudin-5 protein and
TEER using GM6001 or inhibitors specific to MMPs 2 or 9 with sera from patients with
NMOSD during the acute phase of disease.96 The inhibitors likely targeted endothelialderived MMPs as patient sera did not have elevated levels compared to controls.96
Inhibition of proinflammatory cytokines. Shimizu et al. found a rescue in total
claudin-5 protein and gene expression using serum from patients with NMO during the
acute phase of disease with an anti-VEGF antibody, but not antibodies against IFN-γ, TNFα, transforming growth factor beta (TGF-β), interleukin-6 (IL-6), or IL-17.97 While a rescue
for occludin gene expression was observed using the anti-IL-17 antibody, no alteration on
the total protein level was detected.97 In line, TEER was rescued with the anti-VEGF
antibody, but not the anti-IL-17 antibody.97 The anti-VEGF antibody likely targeted
endothelial VEGF as patient serum did not have elevated levels compared to controls.97
Depletion of humoral factors. Shimizu et al. found a rescue in total claudin-5
protein and TEER comparing the serum from two patients with NMO after therapeutic
plasma exchange (TPE) against their serum before TPE.95 Separately, the authors incubated
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patient serum for 30 or 150 minutes with astrocyte cultures overexpressing AQP4. 95
Although depletion of anti-AQP4 antibodies not achieved until the second time point,
increased total claudin-5 protein and TEER was achieved with serum from either time
point.95 Taken together, depletion of humoral factors other than pathogenic AQP4
antibodies was likely responsible for the rescue. 95
Summary
Across the four studies that used human-derived BBB-EC cultures with patient
serum or IgG, only bicellular tight junction proteins (claudin-5 and occludin) have been
characterized.
Like the studies with MS sera, incubation with patient serum generally resulted in
loss of bicellular tight junction proteins and barrier dysfunction regardless of classic NMO
versus expanded NMOSD diagnosis. Patient IgG generally had no impact unless cocultures with AQP4-expressing astrocytes were used, underscoring the relationship
between local pathology and barrier dysfunction. Notably, a sub-set of patients with
NMOSD additionally appear to possess pathogenic AECAs capable of triggering tight
junction disruption and barrier compromise. Thus, successful therapies will likely require
consideration of pathogenic antibodies besides those against AQP4, plus pro-inflammatory
autocrine signaling in CNS-ECs.
Alterations in EAE Models
Background
In the classic EAE model, animals are immunized with CNS tissue homogenates or
myelin protein-derived peptides to produce a CD4+ T cell-driven disease.107,108 This
manifests as an initial period without observable neurological deficit followed by
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ascending flaccid paralysis, although the kinetics and resolution are antigen- and straindependent.107,108 Broadly speaking, models can be classified as chronic, relapsingremitting, or monophasic based on the observed disease course (Figure 1.15). Additionally,
to circumvent the initial induction phase responsible for T cell priming, transgenic mice
that express myelin-reactive T cell receptors (TCRs) or adoptive transfer of primed CD4 +
T cells into naïve animals is frequently performed. 107,108
MOG35-55 Peptide-based Models
Immunization of C57BL/6 mice with a peptide corresponding to residues 33-55 of
myelin oligodendrocyte glycoprotein (MOG35-55) yields a chronic disease course.107,108
Alterations in the Base Disease State
Pre-onset Stage. Paul et al. reported no apparent disruption of claudin-5 in thoracolumbar spinal cord capillaries or venules, despite focal IgG deposition, about halfway
between induction and onset.109 In two subsequent studies, however, the authors noted its
disruption in venules with infiltrates close to onset.110,111 Separately, we have demonstrated
a loss of claudin-5 in isolated brain microvessels from animals with barrier dysfunction
close to onset.34 Additionally, we measured a lowered claudin-5 density at the tight
junctions and loss of total claudin-5 protein in microvessel homogenates.34
Onset-to-Early Stages. Argaw et al. reported disruption and loss of claudin-5 in
lumbar spinal cord vessels with barrier dysfunction at onset. 112 Similarly, at the early stage,
the authors noted disruption and loss of claudin-5 and occludin in vessels with barrier
dysfunction, or those near strong VEGF-A staining.112 In line, Paul et al. observed the
disruption and loss of claudin-5 in thoraco-lumbar spinal cord venules with infiltrates. 109
Moreover, claudin-5 density at the tight junctions was lower at the early stage than at the
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pre-onset stage.109 In the brain, Errede et al. noted worsened disruption and loss of claudin5 in the cortical and subcortical vessels of animals with more severe disability than those
with milder disability.113 Disruption and loss of occludin in cortical vessels was only
apparent in mice with severe disability. 113 Conversely, Welser et al. did not measure a
difference in the ratio of claudin-5+ per CD31+ reactive area in the medulla oblongata.114
Peak Stage. Niu et al. noted a loss of occludin in spinal cord vessels. 115 Similarly,
Li et al. observed a disruption and loss of claudin-5 and occludin in spinal cord vessels,116
while Wang et al. demonstrated the disruption and loss of claudin-5 in lumbar spinal cord
vessels and brain vessels.117 Separately, Welser et al. measured a decreased ratio of
claudin-5+ per CD31+ reactive area for the medulla oblongata, 114 while Bittner et al.
reported no changes for claudin-5 gene expression from isolated brain microvessels across
two separate experiments, but a loss of occludin mRNA for one of the two. 118 Finally,
Uchida et al. noted disruption and loss of claudin-11 in brain and spinal cord vessels.40
Late Stage. Argaw et al. observed disruption and loss of claudin-5 and occludin in
lumbar spinal cord vessels with fibrinogen or albumin leakage. 112 In line, Paul et al.
reported disruption and loss of claudin-5 in thoraco-lumbar spinal cord venules, but not
capillaries, with infiltrates.110 Furthermore, claudin-5 density at the tight junctions was
decreased in the venules, but not the capillaries. 110 Likewise, Zhang et al. noted a loss of
claudin-5 in lumbar spinal cord vessels,119 while Bénardais et al. tallied fewer claudin-5+
spinal cord vessels per field of view.120 Separately, Errede et al. observed worsened
disruption and loss of claudin-5 and occludin in cortical vessels from animals with more
severe disability versus those with milder disability.113 Likewise, Eilam et al. reported
disruption and loss of claudin-5 in cortical vessels. 121
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Estimated Staging. Sohet et al. reported a loss of LSR reactivity in spinal cord
vessels with infiltrates and IgG leakage at 4 days post-onset (d.p.o.), suggesting early
staging.64 Chapouly et al. reported disruption and loss of claudin-5 in lumbar spinal cord
vessels of animals with paraparesis or paraplegia at 15-18 days post-induction (d.p.i.),
suggesting early-to-peak staging.122 Additionally, claudin-5 presence negatively correlated
with VEGF and thymidine phosphorylase (TYMP) presence.122 Separately, Becker et al.
observed disruption and loss of claudin-5 in the spinal cord vessels of animals with no
provided clinical scores or staging,123 while Mora et al. measured a decrease in claudin-5
gene expression from isolated spinal cord microvessels at 13 d.p.i., suggesting onset-toearly staging.124 Separately, Alt et al. measured a decrease of claudin-11 and occludin gene
expression in brain microvessels from animals at 12 d.p.i. with limp tails, suggesting onsetto-early staging.125 Finally, Ferrara et al. and Girolamo et al. both observed disruption and
loss of claudin-5 and occludin reactivity in cortical vessels.126,127 Staging was not explicitly
defined in either study, but related experiments suggest late or peak staging, respectively.
Interventions
Inhibition of astrocyte signaling. Argaw et al. noted VEGF upregulation in the
astrocytes of diseased mice.128 The authors inhibited endothelial nitric oxide synthase
(eNOS) activity, a downstream target, with cavtratin following onset of disability. 128 The
treatment group at peak exhibited a rescue in claudin-5 and fibrinogen leakage in lumbar
spinal cord vessels, plus lessened disability, demyelination, and CD45 + infiltration.128
Similarly, Chapouly et al. noted VEGF and TYMP upregulation in the astrocytes of
diseased mice.122 The authors inhibited eNOS activity, TYMP activity, or both, with
cavtratin, 2-deoxy-L-ribose (2DLR), or both, following onset of disability.122 All treatment
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groups at peak exhibited a rescue in claudin-5 and fibrinogen leakage in lumbar spinal cord
vessels, plus lessened disability, demyelination, and CD45+ infiltration.122
Promotion of the Nrf2 antioxidant pathway. Bénardais et al. administered
dimethyl fumarate, an FDA-approved fumaric acid ester for patients with RR-MS,129
starting at induction.120 Although the treatment group exhibited lessened disability at a late
stage, there was no rescue in the proportion of claudin-5+ spinal cord vessels.120
Conversely, Li et al. administered sulforaphane, an isocyanate found in cruciferous
vegetables, starting at induction.116 The treatment group at peak exhibited a rescue in
claudin-5 and occludin and barrier dysfunction in spinal cord vessels, plus lessened
demyelination and smaller infiltrates. 116 Similarly, Niu et al. administered naringenin, a
flavonoid found in citrus fruits, starting at four weeks pre-induction.115 The treatment group
at peak exhibited a rescue of occludin and barrier dysfunction in spinal cord vessels. 115
Immunomodulators. Hou et al. administered minocycline, interferon beta (IFNβ)-secreting mesenchymal stem cells (MSCs), or both, following onset of disability.130 All
treatment groups exhibited a rescue of occludin in lumbar spinal cord vessels at a late stage,
plus lessened disability and barrier dysfunction. Separately, Eilam et al. administered
glatiramer acetate, an FDA-approved synthetic peptide mixture for patients with RRMS,131 before peak disability.121 The treatment group at a late stage exhibited a rescue of
claudin-5 in cortical vessels, plus lessened disability and greater pericyte coverage. 121
Inhibition of NF-κB signaling. Zhang et al. administered tetramethylpyrazine
(TMP) or IKK-16, following onset of disability. 119 Both treatment groups exhibited a
rescue of claudin-5 in lumbar spinal cord vessels at a late stage, plus diminished
astrogliosis, demyelination, and barrier dysfunction. 119
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Inhibition of Glutamate Signaling. Bittner et al. measured a rescue of occludin
mRNA, but unaltered claudin-5 mRNA, at peak disability in brain microvessels isolated
from animals administered riluzole either at induction or following onset of disability,
although it was unclear which of the two intervention strategies was reported.118
Non-Claudin-involved Genetic Manipulations
Bradykinin receptor B1 (B1R). Göbel et al. observed strong B1R upregulation in
vessels within lesions of MS patients whose form was not provided. 132 The authors reported
a rescue for occludin gene expression, but for claudin-5, in brain microvessels isolated at
peak from knockout (KO) animals, along with lessened disability.132
Immunity-related GTPase family M protein 1 (IRGM1). Wang et al. observed
strong IRGM1 upregulation in multiple cell types, including astrocytes, in wild-type (WT)
diseased animals.117 KO animals at peak exhibited a rescue for claudin-5 in brain and spinal
cord vessels, plus lessened disability, astrocyte swelling, or infiltrates. 117
Potassium channel subfamily K member 2 (KNCK2). Bittner et al. observed loss
of KNCK2 in vessels within lesions of MS patients whose form was not provided. 118 KO
animals exhibited no difference in claudin-5 or occludin gene expression, nor in barrier
dysfunction, but suffered worsened disability. 118 Additionally, in spinal cord vessels from
lesions whose staging was not defined, but likely also at peak, there was no difference in
occludin intensity for KO animals.118
Neuron-glial antigen 2 (NG2). Ferrara et al. observed strong NG2 upregulation in
pericytes and splenocytes of WT diseased animals.126 KO animals exhibited a rescue for
claudin-5 and occludin in cortical vessels, plus lessened disability or barrier dysfunction,
at an unclear staging, but likely at a late stage. 126 Additionally, using bone marrow
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chimeras, the authors reported worsened disruption and loss of claudin-5 and occludin in
the cortical vessels of WT recipients than KO recipients at a late stage, regardless of donor
genotype.126 However, recipients of WT bone marrow exhibited worsened disability and
demyelination than recipients of KO bone marrow.126 Separately, Girolamo et al. observed
strong NG2 presence in pericytes and oligodendrocyte precursor cells of diseased WT
animals.127 In line, KO animals exhibited a rescue for claudin-5 and occludin in cortical
vessels, plus diminished barrier dysfunction, for KO animals whose staging was not
defined, but likely at peak.126
Liver X receptor alpha (LXRα). Wouters et al. initially observed barrier
dysfunction, loss of claudin-5, and elevated monocyte migration in LXRα-knockdown
hCMEC/D3 cells.133 Similarly, KO animals exhibited a lower claudin-5+ area in the brain
at post-peak.133
Acid sphingomyelinase (ASM). Becker et al. reported a rescue in claudin-5 in
spinal cord vessels of KO animals at a non-specified stage.123 Additionally, KO animals
exhibited lessened disability, infiltrate presence, and barrier dysfunction.123
Interferon Gamma Receptor (IFNγR). Ni et al. reported worsened loss of
claudin-5 in the cerebellar vessels of KO animals at peak.134 KO animals exhibited
worsened disability, greater infiltrate presence in the spinal cord and cerebellum, and
atypical behavior like head tilting or ataxia. 134 However, endothelial-restricted expression
of IFNγR rescued claudin-5 at peak compared to KO animals, and animals exhibited
lessened infiltrate presence in the cerebellum or atypical behavior. 134
Leptin receptor (LR). Ouyang et al. observed an initial rise, then loss, for LR gene
expression in cortical and spinal cord vessels isolated from diseased WT animals over the
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disease course.135 KO animals exhibited a rescue at peak for occludin gene expression, but
not for claudins 1, 2, 3, or 5, in spinal cord vessels, plus lessened disability and infiltrate
presence in the spine.135
Integrin beta 4 (ITGB4). Welser et al. observed strong upregulation of ITGB4 in
medulla oblongata vessels of diseased WT animals over the disease course.114 KO animals
at peak exhibited a worsened loss of claudin-5, plus aggravated disability, barrier
dysfunction, and infiltrate presence.114
C-C Motif Chemokine Ligand 2 (CCL2). Paul et al. observed strong upregulation
of CCL2 in spinal cord ECs and astrocytes of diseased wild-type animals at 16 d.p.i.109
Endothelial-restricted or astrocyte-restricted knockout (ECKO and ACKO, respectively)
animals exhibited a rescue in claudin-5 density at the tight junctions in the spinal cord
venules at 9 or 16 d.p.i. compared to their WT counterparts at the same time points. 109
Density remained unchanged between the two time points in the EC KO animals, but
decreased in the ACKO animals.109 However, disability was not reported until 20 d.p.i. in
the ECKO animals and 14 d.p.i. in the ACKO animals compared to 11 d.p.i. for their WT
counter parts, complicating direct comparison by stage.109
Vascular endothelial growth Factor A (VEGF-A). Argaw et al. observed a
strong upregulation of VEGF-A in spinal cord astrocytes of diseased wild-type animals.128
ACKO animals exhibited a rescue for claudin-5 in spinal cord vessels at peak, plus lessened
disability, barrier dysfunction, demyelination, or infiltrate presence.128
Dominant-negative mutant of NF-κB inhibitor alpha (IκBα). Brambilla et al.
reported no rescue for claudin-5 in thoracic spinal cord vessels from diseased animals with
astrocyte-restricted expression of a dominant-negative mutant of IκBα post-peak or at a
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late stage.136 However, dominant-negative animals exhibited lessened peak-to-late
disability, which was associated with improved remyelination processes. 136
Claudin-involved Genetic Manipulations
Claudin-1. Pfeiffer et al. generated an animal with inducible expression of claudin1 in endothelial cells under the control of doxycycline. 45 Although only 30% induction was
achieved in brain vessels, this was sufficient to ameliorate disability at a late stage, but not
during peak disease.45 Additionally, while knockin animals had a comparable number of
inflammatory cuffs, claudin-1+ cuffs exhibited lessened barrier dysfunction. 45
Claudin-5. Paul et al. generated an animal with constitutive expression of an eGFPclaudin-5 fusion protein in endothelial cells.111 The authors observed disruption of eGFPclaudin-5 in thoraco-lumbar spinal cord venules with infiltrates close to onset.111 Using the
same animal line, Lutz et al. employed intravital two-photon microscopy (IV-2PM) to
observe eGFP-claudin-5 in lumbar spinal cord venules.137 At pre-onset, early, or peak, the
authors observed disruption of eGFP-claudin-5+ tight junctions in venules with fibrinogen
leakage.137 Furthermore, the authors found rapid remodeling of eGFP-claudin-5+ tight
junctions at all three stages, while non-continuous, or tortuous eGFP-claudin5+ patterns
were observed only in animals exhibiting disability. 137 Additionally, the authors crossed
the eGFP-claudin-5 knockin line with a caveolin-1 knockout line.137 The absence of
caveolin-1, however, did not alter the proportion of eGFP-claudin-5+ tight junctions with
protrusions, gaps, or tortuosity close to onset. 137
Claudin-12. Castro Dias et al. generated an animal whose open reading frame
(ORF) was replaced with a beta-galactosidase (LacZ) reporter cassette.48 Complete KO
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animals followed a comparable disease course to their WT counterparts, and no difference
in severity of barrier dysfunction was noted between the two.48
MOG1-125 Peptide-based Models
Immunization of rats with a peptide corresponding to residues of 1-125 of MOG
(MOG1-125) yields a variable disease course depending on the strain. 138 Generally, it is
either chronic or relapsing-remitting.138
Adzemovic et al. generated a congenic DA rat that carries the Eae18b locus, which
contains CCLs 1, 2, 7, 11, and 12, from the EAE-resistant PVG.av1 rat line.139 The
congenic DA line exhibited a rescue in occludin shortly post-onset, plus diminished Ccl11
gene upregulation in spinal cord homogenates (SCH).139
MBP Peptide- or Full-length Protein-based Models
Immunization of rodents with full-length myelin basic protein (MBP) or MBPderived peptides yields a disease course that is monophasic and generally reaches
remission, although demyelination is generally limited in rats. 108
Using Lewis rats, Morgan et al. observed disruption and loss of claudin-5 and
occludin in lumbar spinal cord vessels with infiltrates at peak.140 Separately, using wildtype or inducible nitric oxide synthase (iNOS) knockout CBA mice, Ninkovic et al.
observed a comparable loss of occludin in forebrain sections at a late stage between
genotypes.141 Additionally, administration of agmatine to WT or KO animals starting at
induction resulted in a comparable rescue in occludin reactivity at a late stage between
genotypes compared to their vehicle-control counterparts.141

32
PLP139-151 Peptide-based Models
Immunization of SJL mice with residues 139-151 of proteolipid protein (PLP139-151)
yields a disease course that is relapsing-remitting in nature.107,108
Halder et al. noted a disruption and loss of occludin in lumbar spinal cord vessels
at peak.142 However, the authors found a partial rescue in occludin for diseased animals
exposed to chronic mild hypoxia (CMH – 10% oxygen) starting at induction.142 This was
accompanied by lessened disability, demyelination, or barrier dysfunction. 142 In a
subsequent study, the authors noted a disruption and loss of occludin at peak and
remission.143 Intervention with CMH following onset of disability failed to rescue occludin
at peak, but did rescue it at three separate time points during remission. 143 This was
paralleled by lessened disability, demyelination, or barrier dysfunction during remission,
but not at peak.143 Separately, Lanz et al. administered LY317615, a protein kinase C-beta
(PKC-β) inhibitor to animals at unclear time point (possibly at peak), and the treatment
group exhibited a rescue of claudin-5 in spinal cord vessels.144
SCH-based Models
Immunization of rodents with syngeneic or guinea pig SCH yields a variable
disease course depending on the strain and sex.138 Generally, it is either monophasic or
relapsing-remitting.138
Using syngeneic SCH in SJL mice, Wolburg et al. observed loss of claudin-1 and
claudin-3 in brain vessels near infiltrates in paraplegic mice. 44 While claudin-5 and
occludin were still detectable in the vessels, the authors noted that altered vessel
morphology precluded assessment of subcellular localization. 44 Using SD rats, Huang et
al. noted a worsened disruption and loss of claudin-5 in cerebellar vessels of diseased
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animals with severe disability versus those with mild disability.145 The authors found a
rescue in claudin-5 at peak in animals administered ImKTx88, a voltage-gated potassium
channel blocker, starting at induction or post-onset of disability.145 This was accompanied
by lessened disability, demyelination, and barrier dysfunction.145
Using guinea pig SCH, Shou et al. noted a loss of claudin-5 in brain vessels of
diseased Wistar rats at onset, peak, and late stages. 146 The average optical density (AOD)
for claudin-5 decreased between onset and peak, with a modest increase by the late stage. 146
In line, Yang et al. observed a loss of claudin-5 and occludin in brain vessels of Lewis rats
at peak. The authors found a rescue for both proteins, plus barrier dysfunction, at peak for
animals administered Tanshinone IIA, an immunomodulatory diterpenoid, at two separate
dosages.147 There was a greater increase for both proteins at the higher dosage. 147
Separately, Grygorowicz et al. reported the loss of total claudin-5 protein in brain
microvessels isolated from the GM of diseased Lewis rats at four times points before onset
of disability, plus at peak disability.148 A similar trend was noted for claudin-5 reactivity.148
Additionally, when the authors administered Brilliant Blue G (BBG), a purinergic receptor
P2X 7 (P2X7R) antagonist, starting at induction, they found a rescue in total claudin-5
protein, although onset of disease was delayed in the treatment group, complicating direct
comparison of stages.148 Finally, Viñuela-Berni et al. reported a loss in total claudin-5
protein in brain and spinal cord vessels isolated from diseased Lewis rats at peak.149 When
the authors administered Conivaptan, an arginine vasopressin receptor (AVPR) antagonist,
starting at induction, they found an intermediate rescue in total claudin-5 protein.149 This
was accompanied by lessened disability and barrier dysfunction.149
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Transgenic EAE Models
TCR-1640 mice carry a TCR specific to residues 92-106 of MOG (MOG92-106).9
On an SJL background, this yields a disease course that is spontaneous, although in females
it is generally relapsing-remitting, while in males it generally is chronic.9
Alvarez et al. considered the relationship between local pathology and barrier
dysfunction in TCR-1640 animals prior to onset.9 The authors noted disruption and loss of
occludin in cerebellar vessels in areas with astrogliosis and macrophage infiltrates. 9 There
was a specific and progressive loss in pixel intensity for occludin, but not claudin-3 or
claudin-5, over the time points selected.9
Summary
Of all the queried diseases or models, the EAE model accounts for the majority of
studies found and included for synthesis. In line, the greatest number of members were
identified, with six claudins (1, 2, 3, 5, 11, & 12), one TAMP (occludin), and one angulin
(LSR). It is also the only model that has assessed tricellular junction proteins (LSR).
Most studies focused on the post-onset stages of diseases, where tight junction
disruption and barrier dysfunction are expected. However, several induction- and
transgenic-based models have considered the pre-onset timeframe. In the MOG35-55 model,
claudin-5-containing tight junctions appear intact in spinal cord microvessels halfway
between induction and onset,110 but by 1-2 days pre-onset, they are disrupted.109,111 Using
this model, we recently demonstrated barrier dysfunction and decreased claudin-5 density
at tight junctions in brain microvessels isolated from animals close to onset.34 Similarly,
total claudin-5 protein was diminished in brain microvessels isolated from Lewis rats
induced with guinea pig spinal cord at several times pre-onset.148 Most interesting,
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however, are the findings from the TCR-1640 model, where barrier dysfunction and tight
junction alterations are observed weeks before observable neurological deficit.9 Taken
together, it is clear that BBB compromise is an early event in disease progression.
Many therapeutic interventions have been tested with the EAE model. Most studies
that reported successful rescue of neurologic function also reported rescues in barrier
function and tight junction expression. For instance, Eilam et al. reported that
administration of the FDA-approved drug glatiramer acetate rescued disability and claudin5 expression.121 This outcome is most likely due to the immunomodulatory properties of
glatiramer acetate rather than direct targeting of the BBB. 150 However, it is worth pointing
out that other FDA-approved drugs, including glucocorticoids,151 S1PR agonists,152 and
IFN-β,153 have been demonstrated to promote BBB-EC function and tight junction protein
expression. Thus, therapeutic strategies that target the CNS vasculature directly could
prove valuable in treating patients with CNS-IDDs.7
Finally, genetic manipulations involving the claudin family in EAE have shed light
on the contributions of its members in health and disease. Endothelial-restricted claudin-1
overexpression rescued disease and vascular leakage during the chronic stage of the
MOG35-55 model,45 suggesting that promotion of claudins could be a viable therapeutic
target. Endothelial-restricted expression of a eGFP-CLDN5 fusion protein identified that
its localization and turnover dynamics at the tight junctions is altered pre-onset in the
MOG35-55 model,74 suggesting that tight junction remodeling is an early regulatory
mechanism in disease progression. Lastly, global claudin-12 knockout mice exhibited a
comparable disease course in the MOG35-55 model, and LacZ reporter mice suggest that
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claudin-12, in fact, is mostly expressed in other CNS cells than BBB-ECs, calling into
question whether it plays a role in barrier function. 48
Alterations in Experimental NMOSD Models
Background
Animal models follow one of three approaches, each partially recapitulating
NMOSD pathology. EAE-induced animals can be administered pathogenic IgG without or
without complement, adoptive transfer of AQP4-specific T cells and injection of
pathogenic IgG into animals can be performed, or animals can be directly co-injected into
the CNS with complement and pathogenic IgG. 154 Of the three, the last has become the
preferred choice as it eliminates the complications of an EAE-based background.154
Alterations in Recombinant AQP4-IgG-Complement-based Models
Winkler et al. intracortically injected recombinant AQP4-IgG and complement into
Lewis rats (Figure 1.23).20 Onset of neutrophil infiltration, astrocyte loss, and barrier
dysfunction occurred by 6 hours post-injection.20 At this point, the authors reported a
lowered proportion of occludin+ vessels compared to animals administered a control
antibody.20 By 10 and 24 hours post-injection, occludin was generally absent, and did not
fully return until 6 days post-injection.20 Conversely, the proportion of claudin-3+ or
claudin-5+ vessels was unchanged over the same duration. 20
Interventions
Immune cell depletion. Winkler et al. depleted ~90% of circulating neutrophils, T
cells, and B cells by administration of a rabbit anti-polymorphonuclear (PMN) antiserum
before and after disease induction. 20 This rescued the proportion of occludin+ vessels at 6
hours post-injection, along with astrocyte loss and barrier dysfunction. 20 The proportion of
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claudin-3+ or claudin-5+ vessels, however, was unaltered with respect to disease or
intervention.20
Summary
Only a single study that involved an E-NMOSD model was identified. In it, only
bicellular tight junction proteins (claudin-3, claudin-5, and occludin) were characterized.
Like NMOSD, barrier dysfunction in the E-NMOSD model was most prominent
during active astrocyte lysis. During this timeframe, immunoreactivity for occludin, but
not claudins 3 or 5, was lost. From this, the authors concluded that occludin was selectively
affected in the E-NMOSD model and that its loss was the sole factor for barrier dysfunction
in the model. However, in light the study by Lutz et al. that demonstrated that claudin
turnover at the tight junctions is altered under pathological conditions using IV-2PM,137
caution must be exercised when correlating bicellular tight junction protein presence with
unaltered regulation or contribution to barrier dysfunction.
Alterations in TMEV Models
Background
TMEV is an RNA virus from the Picornaviridae family that is injected
intracranially into susceptible mouse lines.155,156 The classic model follows a biphasic
disease course that culminates in chronic spinal cord demyelination, 155,156 while the
peptide-induced fatal syndrome (PIFS) model resembles AHLE.157 PIFS exploits CD8+ T
cells that are specific for a peptide from the VP2 capsid protein (VP2 121-130).158,159
Intravenous injection of the peptide at peak CNS expansion leads to rapid astrogliosis and
neuron-derived VEGF secretion, followed by barrier dysfunction, microhemorrhages,
demyelination, and death within 24-72 hours (Figure 1.24).160
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Alterations in PIFS-based Models
Astrogliosis and barrier dysfunction peak at 4 and 12 hours post-peptide injection
(h.p.p.), respectively.159 At these time points, Suidan et al. found a decrease in total
occludin protein, but unaltered total claudin-5 protein, in isolated brain microvessels.159 By
24 h.p.p., there was a partial recovery in total occludin protein and an increase in total
claudin-5 protein.159 Separately, Johnson et al. and Willenbring et al. noted disruption and
loss of both proteins in areas with extensive barrier dysfunction at 12 and 24 h.p.p.161,162
Interventions
Immune cell depletion. Johnson et al. found that depletion of CD8+ T cells with
antibodies against granulocyte receptor 1 (GR-1) preserved claudin-5 and occludin
localization at the tight junctions and minimizes barrier dysfunction. 161 However, depletion
of neutrophils with antibodies against lymphocyte antigen 6 complex locus G6D (Ly6G)
failed to rescue tight junction disruption or barrier dysfunction.161
Inhibition of VEGF signaling. Suidan et al. observed VEGF upregulation in the
neurons of diseased animals.163 The authors administered a peptide-based antagonist for
neuropilin-1 (NRP-1), a co-receptor for VEGF receptor 2 (VEGFR2), before and after
injection of the VP2121-130 peptide.163 The treatment group exhibited a rescue of total
occludin protein in isolated brain microvessels and barrier dysfunction. 163
Genetic Manipulations
Perforin-1 (Prf1). Suidan et al. reported that total claudin-5 and occludin protein
are preserved in isolated brain microvessels of homozygous KO mice.159 In line,
Willenbring et al. observed no apparent disruption of claudin-5 in homozygous KO mice
and minimal barrier dysfunction.162 Conversely, the authors reported an intermediate
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phenotype for hemizygous KO mice as modest disruption of claudin-5 and fibrinogen
leakage were observed.162 Finally, Johnson et al. demonstrated that adoptive transfer of
perforin-competent CD8+ T cells into KO mice restores susceptibility to PIFS, as evidenced
by disruption of claudin-5 and occludin, barrier dysfunction, and astrogliosis.164
Summary
Across the five studies with the PIFS model, only bicellular tight junction proteins
(claudin-5 and occludin) have been characterized.
The PIFS model is unique amongst animal models as it yields a fulminant disease
course that is marked by microhemorrhaging. However, patients with MS165 or NMOSD166
generally do not exhibit cerebral microbleeding. Thus, the findings of the PIFS model are
likely most relevant for patients with AHLE, for which no literature exists with respect to
blood-brain barrier dysfunction (past the obvious occurrence of microbleeds) or tight
junctions. Early PIFS-based studies identified losses of occludin, but not claudin-5 protein,
in isolated microvessels.159 However, this total protein approach failed to identify that
alterations were primarily occurring at the level of subcellular localization.161,162 This
underscores the point that the expression level of tight junction proteins alone does not
necessarily correlate with barrier function under pathological conditions. Rather, their
subcellular localization is as critical, if not more, for maintaining barrier function.
As the PIFS model is CD8+ T cell-mediated, the interventions and genetic
manipulations reported may also have translational importance for other CD8 + T cellmediated CNS diseases like Susac syndrome which is an autoimmune disease directed
against the endothelium, with microhemorrhaging driven by release of cytotoxic molecules
like Granzyme B and perforin.167 Regardless, like the other models, the PIFS model
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underscores the close connection between local pathology and BBB dysfunction, as well
as highlighting that preservation of BBB function as a valid strategy in CNS-IDDs.
Alterations in Cuprizone Models
Background
The cuprizone model is a toxic demyelination model that involves the
administration of the toxin at low concentrations in the animal’s chow. 168,169 In acute
demyelination models, cuprizone is administered for 5-6 weeks, then withdrawn, allowing
for re-myelination (Figure 1.25).168,169 However, continued intoxication past this timeframe
permanently impairs re-myelination capability.168,169 Although the exact mechanisms are
poorly understood, it is well-established that cuprizone intoxication results in preferential
oligodendrocyte (OL) dysfunction and apoptosis.168,169 Thus, demyelination in this model
likely reflects a primary oligodendropathy with secondary demyelination.168,169
Early permeability studies using horseradish peroxidase (HRP) demonstrated
luminal restriction, suggesting that the blood-brain barrier was intact.170,171 However,
several recent studies now challenge this assessment. Berghoff et al. demonstrated
increased extravasation of Evans Blue (EB) and NaFluor after only five days of feeding,
with preferential leakage of both observed in the corpus callosum compared to the
cortex.172 In the same study, the authors observed leakage of 70 kDa FITC-Dextran into
the corpus callosum following five weeks of feeding, 172 while in two separate studies, they
identified leakage of EB in the corpus callosum within the same timeframe. 172,173 In line,
Shelestak et al. observed increased EB permeability after three, seven, or fourteen days of
feeding.174 Taken together, it is clear that barrier dysfunction is not only present in the
cuprizone model but that it occurs before demyelination and persists during demyelination.
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Alterations in Cuprizone-based Models
Berghoff et al. reported the disruption and loss of occludin in corpus callosum
vessels following five weeks of administration. 172 Demyelination, astrogliosis, and
activated microglia were prominent, with few mature OLs left. Furthermore, leakage of 70
kDa FITC-dextran was present, while tight junction disruption was evident by electron
microscopy.172 However, no significant alteration of occludin was observed in cortical
vessels.172 Moreover, pathology in the cortex was mild compared to the corpus callosum.172
Taken together, the authors concluded that the loss of occludin and barrier dysfunction was
due to local pathology rather than any potential toxicity to the endothelium. 172
Summary
Only a single study with the cuprizone model was identified. In it, only bicellular
tight junction proteins (occludin) were characterized.
As with the preceding models, the severity of barrier dysfunction and bicellular
tight junction disruption was closely associated with the severity of local pathology. These
findings are supported by reported decreases in claudin-5 and occludin gene expression
and total protein expression in corpus callosum homogenates (Appendix F). However, it
must be kept in mind that such experimental approaches prevent direct attribution of the
changes to the BBB-ECs. Nevertheless, this underscores that global assessments of barrier
function or tight junction expression may fail to identify pathological changes when they
occur in a spatiotemporal-dependent manner.

42
Discussion
Following the completion of my systematic literature search, I have identified and
summarized the known alterations of the claudin, TAMP, and angulin families at the
endothelial blood-CNS barriers in patients with CNS-IDDs and their models (Figures 1.911, 1.13-14, 1.16-26, Appendices C-F). For completeness, I have also summarized relevant
studies whose analyses were non-CNS-EC-specific (Appendices C-F).
Eight MS studies covered most clinical forms (RR-MS, SP-MS, and PP-MS), plus
one rare variant (Acute MS). Across these studies, only claudin-5, claudin-11, and occludin
have been characterized (Figures 1.9 & 1.10). Additionally, one study for NMOSD
characterizing claudin-3, claudin-5, and occludin was identified (Figure 1.13), but no
studies were found for ADEM (Figure 1.26).
In support, eight studies that incubated human BBB-ECs with the sera or IgG from
patients with MS or NMOSD were identified (Figures 1.11 & 1.14), but none were found
for ADEM (Figure 1.26). Across these studies, only claudin-5 and occludin were analyzed.
As for animal models, EAE was the predominant model, with forty-six studies identified
(Figures 1.14-1.22). In contrast, five TMEV studies (Figure 1.23) and a single study each
for experimental NMOSD or cuprizone were found (Figures 1.24 & 1.25). Across all four
models, claudins 1, 3, 5, 11, and 12, occludin, and LSR have been characterized.
Barrier Dysfunction & Tight Junction Disruption Are Early Events
Overall, the literature points to a close connection between the severity of local
pathology and barrier dysfunction or tight junction disruption, both of which occur early
in CNS-IDD lesion progression.
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In NMOSD, lesions rapidly evolve from a state of active astrocyte lysis, prominent
pathology, and barrier dysfunction to a state of completed astrocyte depletion, diminished
pathology, and restoration of barrier integrity, followed by slow astrocyte repopulation and
oligodendrocyte regeneration.20,104 In parallel, the proportion of claudin-5+ vessels from
lesions with already completed astrocyte depletion were comparable to control donors,
while the reactivity of claudin-3 and occludin in vessels from a single lesion with partial
astrocyte repopulation was comparable to control donors.20 Unfortunately, lesions with
active astrocyte lysis have yet to be studied. While intracortical injection of recombinant
AQP4-IgG and complement into Lewis rats resulted in the preferential loss of occludin
during active astrocyte loss,20 analysis of patient lesions is needed for confirmation.
In MS, barrier dysfunction is detected in pre-active lesions with activated microglia
and macrophages, astrogliosis, and sparse lymphocyte infiltrates, 9 but not activated
microglial clusters alone.82 In parallel, focal disruption of claudin-5 or occludin is observed
in pre-lesional vessels near activated microglia and macrophages, astrogliosis, and
lymphocytic infiltrates,9,83 but not activated microglial clusters alone. 82 Similarly, barrier
dysfunction and fragmented occludin in the TCR-1640 model is noted following
macrophage activation and astrogliosis, but before strong lymphocyte infiltration. 9
An Incomplete Landscape
Bicellular Junctions. As mentioned in the introduction, claudin family
representation is not yet settled. Given that the claudin family forms the backbone of
bicellular tight junctions and confers the barrier- and pore-forming properties to the BBB
endothelium, solving which members are present under homeostatic or pathological
conditions is an important hurdle that must be overcome. Without this information,
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researchers considering the claudins as therapeutic targets to modulate barrier function may
inadvertently trigger disruptive claudin-claudin interactions. For example, the findings by
Pfeiffer et al. would suggest that promoting claudin-1 expression in patients with CNSIDDs could limit barrier dysfunction.45 However, the more recent findings by Sladojevic
et al. strongly argue against this approach since claudin-1 overexpression disrupts the
constitutive cis- and trans-interactions of claudin-5.46
Tricellular Junctions. The molecular composition and ultra-structure of tricellular
junctions are less defined than for bicellular tight junctions.31 No patient studies have
considered their alterations, nor their relative contribution to barrier dysfunction (Figure
1.26). However, one study that used the MOG35-55 model reported that LSR was lost at 4
days post-onset in areas of inflammation.64 While this provides evidence for tricellular tight
junction disruption in CNS-IDDs, it remains unknown whether their alterations parallel
those of the bicellular tight junctions or follow a different course.
Future Considerations
As mentioned in the rationale, tight junction proteins are commonly used as
surrogate markers for barrier integrity and could be therapeutically targeted to rescue
barrier dysfunction in patients. However, researchers must keep in mind two recently
developed concepts in the field when assessing the tight junctions.
First, barrier dysfunction does not require complete tight junction dismantlement.
Rather, changes to the stability and density of the proteins at the cell-cell contacts can be
sufficient. In primary human BBB-ECs, barrier function improved in tandem with
increased stability of claudin-5 and occludin in membrane fractions following
administration of lithium chloride, 175 but worsened with loss of occludin in lipid raft
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fractions after exposure to lipid raft-disrupting drugs.85 In EAE, transgenic eGFP-claudin5 mice exhibit rapid turnover of the fusion protein in spinal cord venules, 137 while wildtype mice exhibit diminished claudin-5 density in thoraco-lumbar spinal cord venules109,110
or isolated brain microvessels.34 In patients with MS, occludin+ strands are thinned85 or
focally disrupted.83 Thus, researchers must be careful to not assume that the tight junctions
and barrier function are preserved without considering the possibility of altered stability or
density in a disease state or following administration of pharmacologic agents.
Second, endothelial heterogeneity exists along the arteriovenous axis, by CNS
region, and by matter type.176 Analysis frequently is performed on thin tissue sections and
from a cross-sectional profile, limiting the conclusions that can be made. Using 3D
contour-based quantification, Paul et al. measured claudin-5 density at the tight junctions
of mouse spinal cord capillaries and venules in 60 µm-thick sections.110 Density was
inversely related to vessel diameter in healthy animals, while a selective loss of density
occurred in post-capillary venules of EAE-induced animals, with contiguous capillaries
often unaffected.110 Thus, where possible, researchers should sample thicker tissue sections
and employ image reconstruction techniques or longitudinal profiling of vessels, plus
report the anatomical locations, vessel types, and matter types analyzed.
Limitations
During the early stages of planning, I observed on multiple occasions that the title
or abstract of relevant studies did not always specify which tight junction proteins were
analyzed. Consequently, relevant studies were not being identified by the WoS platform.
To address this, I 1) performed additional searches for studies that generically referenced
the tight junctions, 2) screened all results, even those that initially appeared not relevant,
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and 3) examined conference abstracts and reviews, then followed up with the
corresponding authors. As this identified thirteen additional results not found by WoS, four
of which were included in the qualitative synthesis, I believe my methodology ensured that
the as many relevant studies as possible were found.
Nevertheless, I apologize in advance to any authors whose works I missed – your
exclusion does not reflect on the quality of your science, but rather the current limitations
faced when conducting literature searches.
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Chapter One Figures

Figure 1.1.

Disease Courses of MS.

Disease in patients with MS follows one of four courses based on clinical form. A.
Patients with RR-MS experience episodes of relapse (R) that are separated with periods
of stable remission (S). B. Patients with SP-MS are RR-MS patients who have
transitioned to a progressive (P) disease course. C. Patients with PP-MS suffer
progressive disability from onset. D. Patients with PR-MS follow a similar course to PPMS, but also experience episodes of relapse. Created with BioRender.com.
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Figure 1.2.

Disease Courses of NMOSD & ADEM.

A. Patients with NMOSD generally follow a course similar to RR-MS, with episodes of
relapse (R) that are separated with periods of stable remission (S). B. Most patients with
ADEM will only ever experience a single episode (solid line). In rare cases, additional
episodes may occur (dotted line). Created with BioRender.com.
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Figure 1.3.

The BBB in Relationship to the NVU.

Endothelial cells (green) line the interior of the microvessels that serve the other NVU
members. At the level of the capillary and post-capillary venule, the endothelium is
immediately surrounded by pericytes (red) which are situated within a vascular basement
membrane (cyan). In turn, they are enveloped by the endfoot processes of astrocytes
(yellow) that acts as intermediaries between neurons (light blue) and the microvessels to
couple blood flow with neuronal activity. Additionally, astrocytes interact with
oligodendrocytes (not shown) to maintain the myelin sheath (pink), while interneurons
(purple) innervate the microvessel as another mechanism to regulate blood flow. Finally,
microglia (dark blue) are the primary resident innate immune cells within the CNS.
Figure minimally adapted from Brown et al.177 in Frontiers in Cellular Neuroscience
(2019, Vol. 30) under a Creative Commons License (CC-BY).
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Figure 1.4.

Bicellular and Tricellular Junction Ultrastructure & Composition.

Bicellular tight junctions (blue) are established between two neighboring endothelial
cells. When viewed by freeze-fraction electron microscopy, a continuous, anastomosing
network is observed. These tight junctions are composed of a claudin-based backbone
that is regulated by members of the TAMP family. Tricellular tight junctions (red,
yellow) are established at the meeting point of three adjacent endothelial cells. The
angulin family forms the central sealing element (red) which connects to the bicellular
strands via members of the TAMP family (yellow). Created with BioRender.com.

Protein Structure of the Claudin, TAMP, and Angulin Families.

Claudins (blue) are enriched at bicellular junctions. They have a short N-terminal tail (N), two extracellular loops (ECLs), a short
intracellular loop (IL), and a C-terminal tail (C). Most possess a binding motif (PDZ) for coupling to scaffolding proteins. TAMPs –
occludin (green), tricellulin (red), and MarvelD3 (yellow) – are enriched at bicellular, tricellular, or both types of junctions,
respectively. Although all contain a similar transmembrane-helix architecture (MARVEL domain), they differ in size of their tails.
Moreover, only occludin and tricellulin share a regulatory occludin/ELL domain (OCEL). Angulins are enriched at tricellular
junctions, but information about their structure is limited. Thus far, it has been reported that their extracellular tail contains an
immunoglobulin-like (Ig-like) domain. Created with BioRender.com.

Figure 1.5.

51

52

Figure 1.6.

Flow Diagram Depicting the Initial Screening Process.

To identify relevant studies not found by database searches through the WoS platform,
non-primary articles like reviews and meeting abstracts were also screened. Created with
BioRender.com.
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Figure 1.7.

Flow Diagram Depicting the Inclusion Process.

To identify relevant studies, results were assessed for eligibility on four specific points.
Studies that passed all four points were included for qualitative synthesis. For
completeness, however, studies that passed all points except the third are summarized in
Appendices C-F. Created with BioRender.com.
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Figure 1.8.

PRISMA Flow Diagram.

A graphic summary for the number of studies that were ultimately included or excluded
for the claudin, TAMP, and angulin families in three CNS-IDDs (MS, NMOSD, and
ADEM) and four animal models (EAE, E-NMOSD, TMEV, and cuprizone). Note: no
studies involving ADEM were found. Additionally, studies often included more than one
disease or model. This means that the total number of studies included (n = 98) does not
equal the sum of the studies listed across all tables (n = 107). Created with
BioRender.com.

Alterations in Stageable MS White Matter Lesions.

A. At their earliest stages, lesions contain activated microglial clusters [1]. As the lesion evolves, macrophages are recruited [2].
During active demyelination, microglia and macrophages are laden with myelin debris [3] and remain following cessation of
demyelination [4]. With time, microglia and macrophages are lost, radiating outwards from the center [5-6]. B. Summary of studies
whose findings could be staged within the framework presented in A. of this figure. ND: Clinical form not available. IF:
Immunofluorescence-based immunohistochemistry (IHC). qPCR: Quantitative polymerase chain reaction. IE: Immunoenzyme-based
IHC. Created with BioRender.com.

Figure 1.9.
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A. Grey matter lesions are classified based on their location within the cortical tissues (Types I-IV). Only type I lesions involve the
adjacent white matter; all others (II-IV) are purely within the grey matter. B. Summary of studies whose findings could be staged
within the frameworks presented in A. of this figure. ND: Clinical form not available. IE: Immunoenzyme-based
immunohistochemistry (IHC). C. Summary of studies whose findings could not be staged within the frameworks presented in A. of
this or the preceding figure. ND: Clinical form not available. IF: Immunofluorescent-based IHC. Created with BioRender.com.

Figure 1.10. Alterations in Stageable MS Grey Matter Lesions or Non-stageable MS Lesions.
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A. Summary of studies involving patient sera. MS: Patients fulfilled the 2010 revised McDonald diagnostic criteria but lacked a
clinical form. RR-R: Patients with RR-MS during a relapse. RR-S: Patients with RR-MS during a stable phase. TEER:
Transendothelial electrical resistance. Dex: Dextran. WB: Western blot. FC: Flow cytometry. B. Summary of studies involving patient
IgG. C. Summary of studies involving pharmacologic interventions and patient sera. MMP: Matrix metalloproteinase. Ab: Antibody.
TNF-α: Tumor necrosis factor alpha. IFN-γ: Interferon gamma. IL-17: Interleukin-17. VEGF: Vascular endothelial growth factor.
VDR: Vitamin D receptor. S1PR: Sphingosine 1-phosphate receptor. All: All three patient groups were treated as a single disease
group for comparison. Created with BioRender.com

Figure 1.11. Alterations in Human-derived CNS-EC Culture Models of MS.
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Figure 1.12. Temporal Staging of NMOSD Lesions according to Takai.
Based on histopathological analysis of autopsy tissues from eight patients who were
seropositive for AQP4-IgG, Takai et al. developed a temporal staging system for
NMOSD lesions centered around astrocyte morphology. Following initial complementmediated astrocyte lysis [1], astrocyte progenitor cells are recruited to replace the lost
cells [2]. However, these new astrocytes eventually turn gliotic [3], and form scars that
exhibit a distinctive honeycomb-like appearance [4]. Figure minimally adapted from
“Staging of Astrocytopathy and Complement Activation in Neuromyelitis Optica
Spectrum Disorders” by Takai et al.104 in Brain (2021, Vol. 144, Issue 8) with
permission from Oxford University Press.
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Figure 1.13. Alterations in NMOSD Lesions.
Summary of studies whose findings could be staged within the framework presented in
Figure 1.12. Note: The estimated staging for the two lesion types described in Winkler et
al. is provided in parentheses based on the histopathological description of the astrocyte
presence and morphology. IF: Immunofluorescence-based immunohistochemistry.
Created with BioRender.com.

A. Summary of studies involving patient sera. NMO-A: Patients with NMO during an acute phase (relapse). NMOSD-A: Patients with
NMOSD during an acute phase (relapse). NMOSD-S: Patients with NMOSD during a stable phase. TEER: Transendothelial electrical
resistance. NaFl: Sodium fluorescein. WB: Western blot. B. Summary of studies involving mono-cultures incubated with patient
antibodies. IgG: Immunoglobulin. rAb: Recombinant antibody. Dex: Dextran. IF: Immunofluorescence-based immunohistochemistry.
C. Summary of studies involving co-cultures incubated with patient IgG. AC: Astrocyte. AQP4: Aquaporin-4. D. Summary of studies
involving therapeutic interventions with patient sera. TNF-α: Tumor necrosis factor alpha. IFN-γ: Interferon gamma. IL-6: Interleukin6. IL-17: Interleukin-17. VEGF: Vascular endothelial growth factor. TGF-β: Transforming growth factor beta. MMP: Matrix
metalloproteinase. qPCR: Quantitative polymerase chain reaction. Created with BioRender.com.

Figure 1.14. Alterations in Human CNS-EC Culture Models of NMOSD.
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Depending on the antigens or transgenic lines used for EAE, one of three disease courses is generally observed. If animals only
experience one episode before entering remission, the model is monophasic (grey – dashed line). If the animals experience multiple
episodes with periods of partial or full remission separating them, the model is relapsing-remitting (orange – dotted line). If the
animals experience one episode that plateaus and doesn’t enter remission, the model is chronic (blue – solid line). Created with
BioRender.com.

Figure 1.15. Disease Courses in EAE.
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Summary of studies that employed the MOG35-55-based EAE model (chronic in nature) and whose findings could be classified within
the framework presented in Figure 1.15. Studies whose staging was estimated is denoted by a double dagger (‡). The super-imposed
trend line (black) reflects the kinetics of tight junction protein disturbance. Points in the disease course lacking information are
denoted by a question mark (?). IF: Immunofluorescence-based immunohistochemistry (IHC). MV: Microvessel. WB: Western blot.
MA: Microarray analysis. qPCR: Quantitative polymerase chain reaction. IE: Immunoenzyme-based IHC. Created with
BioRender.com.

Figure 1.16. Alterations in MOG35-55-based EAE Model (Base Disease).
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A. Summary of studies that employed the MBP-based EAE model (monophasic in nature) and whose findings could be classified
within the framework presented in Figure 1.15. The super-imposed trend line (black) reflects the kinetics of tight junction protein
disturbance. Points in the disease course lacking information are denoted by a question mark (?). IF: Immunofluorescence-based
immunohistochemistry (IHC). IE: Immunoenzyme-based IHC. B. Summary of studies that employed the PLP139-151-based EAE
model (relapsing-remitting in nature) and whose findings could be classified within the framework presented in Figure 1.15. Created
with BioRender.com

Figure 1.17. Alterations in MBP- & PLP139-151-based EAE Models (Base Disease).
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A. Summary of studies that used syngeneic or guinea pig CNS homogenates (variable disease courses) and whose findings could be
classified within the framework presented in Figure 1.15. Studies whose staging was estimated is denoted by a double dagger (‡ ). The
super-imposed trend line (black) reflects the kinetics of tight junction protein disturbance. WB: Western blot. IF:
Immunofluorescence-based immunohistochemistry. MV: Microvessel. B. Summary of studies that employed the TCR1640-based EAE
model (chronic in males, relapsing-remitting in females) and whose findings could be classified within the framework presented in
Figure 1.15. Points in the disease course lacking information are denoted by a question mark (?). Created with BioRender.com.

Figure 1.18. Alterations in CNS Homogenate- and Transgenic-based EAE Models (Base Disease).
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Summary of studies that assessed intervention strategies using the MOG 35-55-based EAE model and whose findings could be classified
within the framework presented in Figure 1.15. Intervention duration is represented by a black line, with solid portions reflecting
continual administration and dotted portions reflecting no administration. Rescues in tight junction proteins are denoted by a check
mark (✓) and non-rescues by a cross-mark (). Studies with ambiguous language describing the start or end dates of intervention are
denoted by a question mark (?). 2-dLR: 2-deoxy-L-ribose. DMF: Dimethyl fumarate. MSC-IFN-β: Interferon beta-secreting
mesenchymal stem cells. TMP: Tetramethylpyrazine. MV: Microvessel. IF: Immunofluorescence-based immunohistochemistry
(IHC). qPCR: Quantitative polymerase chain reaction. IE: Immunoenzyme-based IHC. Created with BioRender.com.

Figure 1.19. Interventions in MOG35-55-based EAE Models.
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Summary of studies that assessed intervention strategies using MBP-, PLP139-151-, or CNS homogenate-based EAE model and whose
findings could be classified within the framework presented in Figure 1.15. Intervention duration is represented by a black line.
Rescues in tight junction proteins are denoted by a check mark (✓) and non-rescues by a cross-mark (). Studies with ambiguous
language describing the start or end dates of intervention are denoted by a question mark (?). CMH: Chronic mild hypoxia. BBG:
Brilliant Blue G. BMV: Brain microvessel. SMV: Spinal microvessel. IF: Immunofluorescence-based immunohistochemistry (IHC).
IE: Immunoenzyme-based IHC. WB: Western blot. Created with BioRender.com.

Figure 1.20. Interventions in Other Antigen-based EAE Models.
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Summary of studies that assessed transgenic animals using MOG35-55- or MBP-based EAE models and whose findings could be
classified within the framework presented in Figure 1.15. Studies whose staging was estimated is denoted by a double dagger (‡ ).
CCL2: Chemokine (C-C motif) ligand 2. ECKO: Endothelial-restricted knockout. ACKO: Astrocyte-restricted knockout. ITGB4:
Integrin beta 4. IRGM1: Immunity-related GTPase family M protein 1. KO: Knockout. NG2: Neuron-glial antigen 2. IFN-γ:
Interferon gamma. EConly: Endothelial-restricted expression. VEGFA: Vascular endothelial growth factor-A. KNCK2: Potassium
channel subfamily K member 2. B1R: Bradykinin B1 receptor. LR: Leptin receptor. LXRα: Liver X receptor alpha. IκBα-dn:
Dominant-negative mutant for nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha. AConly: Astrocyterestricted expression. iNOS: Inducible nitric oxide synthase. MV: Microvessel. IF: Immunofluorescence-based immunohistochemistry
(IHC). IE: Immunoenzyme-based IHC. qPCR: Quantitative polymerase chain reaction. Created with BioRender.com.

Figure 1.21. Non-Claudin-involved Genetic Manipulations in Antigen-based EAE Models.
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Summary of studies that assessed transgenic animals using MOG35-55- based EAE models and whose findings could be classified
within the framework presented in Figure 1.15. ECKI: Endothelial-restricted knockin. eGFP: Enhanced green fluorescent protein. KO:
Knockout. LacZ: β-Galactosidase reporter cassette that replaced the encoding exon of claudin-12. IF: Immunofluorescence-based
immunohistochemistry. TJ: Tight junction. IV-2PM: Intravital two-photon microscopy. β-Gal: Beta-galactosidase. Created with
BioRender.com.

Figure 1.22. Claudin-involved Genetic Manipulations in MOG35-55-based EAE Models.
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A. In this model, Lewis rats are intracranially co-injected with a recombinant AQP4 antibody and human-derived complement. This
yields a disease course marked by rapid astrocyte loss (grey), BBB dysfunction (red), and neutrophil infiltration (blue), followed by
barrier restoration and astrocyte repopulation. AQP4: Aquaporin-4. Ab: Antibody. IgG: Immunoglobulin. B. Summary of studies
whose findings could be classified within the framework presented in A. IF: Immunofluorescence-based immunohistochemistry.
PMN: Polymorphonuclear. Created with BioRender.com.

Figure 1.23. Alterations in E-NMOSD Models.
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A. In this model, C57Bl/6 mice are intracranially infected with TMEV, then injected with a peptide for the immunodominant epitope
of a viral protein (VP2121-130) during peak CD8+ T cell expansion. This yields a fulminant disease marked by microhemorrhaging and
loss of neurologic function (grey). BBB dysfunction (red) closely follows secretion of vascular endothelial growth factor (VEGF)
from neurons. B, C. Summary of studies whose findings could be classified within the framework presented in A. for base disease (B),
genetic manipulations (C – left), or pharmacologic interventions (C – right). WB: Western blot. IF: Immunofluorescence-based IHC.
WT: Wild-type. KO: Knockout. NRP-1: Neuropilin-1. Ly6G: Lymphocyte antigen 6 complex locus G6D. GR-1: granulocyte receptor1 antigen. Created with BioRender.com.

Figure 1.24. Alterations in TMEV Models.
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A. Persistent intoxication of C57BL/6 mice with cuprizone results in oligodendrocyte (OL) dysfunction and death over the first two
weeks. This is followed by progressive demyelination (grey) that reaches its lowest point in the corpus callosum at ~5 weeks. In acute
models, cuprizone administration is halted, allowing remyelination to occur (grey – dotted line), while in chronic models, continued
intoxication results in abortive remyelination (grey – solid line). Concurrent with these changes, BBB dysfunction (red) in the model
has been demonstrated prior to detectable demyelination and at peak demyelination in the corpus callosum. Furthermore, BBB
dysfunction is preferentially observed in areas with pathology such as astrocyte and microglial gliosis (yellow and blue, respectively),
suggesting a close relationship between local pathology and barrier dysfunction. NaFl: Sodium Fluorescein. EB: Evans Blue. B.
Summary of studies whose findings could be classified within the framework presented in A. IF: Immunofluorescent-based
immunohistochemistry. Created with BioRender.com.

Figure 1.25. Alterations in Cuprizone Models.
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Figure 1.26. Summary of Studies Identified for Each Tight Junction Family.
Across the three families, six members of the claudin family (1, 2, 3, 5, 11, & 12), one
member of the TAMP family (occludin), and one member of the angulin family (LSR)
have been characterized in one or more of the CNS-IDDs or their models. For
comparison purposes, the number of studies found for each member is listed in
parentheses. Created with BioRender.com.
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CHAPTER TWO: INFLAMMATION-ASSOCIATED ALTERATIONS TO THE
VASCULAR BASEMENT MEMBRANE IMPAIR BLOOD-BRAIN BARRIER
FUNCTION AND SUPPRESS CLAUDIN-5 EXPRESSION.

The Blood-Brain Barrier in Health & Disease
The blood-brain barrier (BBB) serves as a physical and metabolic interface between
the peripheral circulation and the nervous tissues. 27 To fulfill these functions, microvessels
are lined with endothelial cells (ECs) that restrict paracellular transport with multiprotein
complexes called tight junctions.178 However, their dysregulation is a common hallmark in
neurodegenerative disorders like multiple sclerosis (MS) 38,179 and Alzheimer’s
disease,180,181 insults to the CNS like ischemic stroke46,182 and traumatic brain injury
(TBI),183,184 and psychiatric disorders like schizophrenia and major depression. 36,185 As
BBB dysfunction compromises neurovascular unit (NVU) homeostasis, 29,38 a better
understanding of the mechanisms that regulate BBB function is needed.
Claudin-5 in Blood-Brain Barrier & Neurologic Function
Tight junctions are formed by a branching network of transmembrane proteins that
act in homophilic or heterophilic fashion within the same cell membrane and across to the
opposing membrane.30 The claudin family of tetraspan proteins form the backbone of tight
junctions at bicellular contacts to provide either barrier- or pore-forming properties.32 Of
the 27 members across humans and rodents, claudin-5 is the dominant barrier-forming
member in BBB-ECs.28 Although its loss is not embryonically lethal in mice, deficient
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animals perish within 10 hours of birth and suffer size-selective leakage of small
molecules.35 Similarly, knockdown of claudin-5 in adult mice results in BBB leakage,
schizophrenia-like behavior, and mortality within 40 days.36 Saliently, its loss in areas with
barrier dysfunction is frequently observed in neurological disorders and their respective
animal models.38 Taken together, it is clear that claudin-5 is a gatekeeper of BBB and
neurologic function that could serve as a therapeutic target to modulate or promote barrier
function.38 However, the regulatory mechanisms that govern claudin-5 expression and
localization, especially under pathological conditions, are still under investigation.
The Vascular Basement Membrane in Health
Besides providing structural support, the vascular basement membrane (BM)
contributes to the regulation of barrier function and tight junctions by acting as a conduit
for ‘outside-in’ signaling via soluble factors and cell-matrix protein interactions.186 The
vascular BM primarily consists of collagen type IV, laminins, and a select number of other
glycoproteins.186–188 Among these, the contributions of collagen type IV, specifically the
[α1(IV)]2α2(IV) trimer, to barrier integrity are the most well-characterized. Loss-offunction studies in rodents for Col4a1 or Col4a2 result in embryonic lethality, vascular
defects, or intracerebral hemorrhage, comparable to human patients with cerebral small
vessel disease due to COL4A1 mutations.189 Furthermore, these contributions are integrin
β1-dependent as its blockade in primary mouse BBB-ECs impairs barrier function and
claudin-5 expression, while endothelial-restricted β1-knockout animals or wild-type
animals injected with a blocking antibody suffer vascular leakage. 190,191 Taken together,
these studies suggest that disruption of endothelial-collagen type IV interactions is likely
to be anti-BBB in nature.
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The Vascular Basement Membrane in Disease
Alterations to the vascular BM are commonly observed in CNS diseases, including
MS.186,192 Besides secretion of proteases to degrade the constitutive BM, deposition of
proteins normally absent from the BM occurs.186 For example, in the active and chronic
demyelinated white matter (WM) lesions of patients with MS, deposits of various fibrilforming collagens and members of the small leucine-rich proteoglycan (SLRP) family were
observed.193 Moreover, their strongest presence was around vessels within the core of the
lesion and in areas of immune cell infiltration.193 Recently, collagen type I and the class I
SLRP decorin were identified as part of a core BBB dysfunction module of differentially
expressed genes shared across four mouse disease models, including experimental
autoimmune encephalomyelitis (EAE; Figure 2.1 & 2.2).194 As with the MS lesions,
deposits of both were detected.194 However, the purpose of their deposition during disease
is unclear given the differing pathologies underlying each of these four models. Moreover,
how BM composition may influence endothelial function, especially under pathological
conditions, is a poorly addressed topic in the literature.
Rationale for Study
Although most research involving MS and its animal models have focused on BBB
dysfunction and tight junction disruption during the active stages of disease, both are, in
fact, early events in their progression. Pre-active WM lesions from patients with MS or
transgenic mice carrying T cell receptors against their myelin (TCR-1640) suffer BBB
dysfunction and their vessels exhibit aberrant tight junctions before onset of demyelination
(see Chapter One for more detail).9 In line, we recently showed that loss of BBB integrity
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and claudin-5 density at the tight junctions of isolated brain microvessels occurs before
observable neurological deficit in EAE-induced mice (Figures J.1A & J.1B).34
Given the close connection between collagen type IV, BBB function, and claudin5, deposition of BM proteins like collagen type I or decorin during inflammation could
contribute to barrier dysfunction and claudin-5 loss by interfering with already established
cell-matrix interactions or forming new ones. However, no studies have considered their
expression patterns during the pre-active stages of disease.193,194 Moreover, only two early
studies for collagen type I195,196 and no studies for decorin have even considered their
possible influence on BBB-EC barrier function.
As less is known about decorin, in this dissertation I first investigate 1) its
expression pattern in EAE-induced mice at the pre-onset stages of disease, 2) whether its
presence in constructed basement membranes impacts the gene expression of claudin-5 and
barrier function using primary mouse BBB-EC monolayers, and 3) whether its gene
silencing may be beneficial. Additionally, I share preliminary data I’ve collected for
collagen type I using similar approaches to those for decorin.
Methodology
Reagents, Primers, Antibodies, and Software
Complete listings for each are provided in Appendix G.
RNA-Seq Analysis
For the data presented in Figures 2.1 and 2.2, a recent bulk RNA-Seq data set that
identified differently expressed genes in CNS-ECs common to four animal models of
disease across active stages of disease (acute, sub-acute, and chronic) was used.194 Namely,
the kainic acid model of epilepsy, MOG35-55-based EAE, middle cerebral artery occlusion
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(MCAO) model of stroke, and focal cortical impact model of pediatric TBI were compared.
This data set was queried for expression of collagen type I (Col1a1 and Col1a2) and
decorin (Dcn), and heat maps were created using the provided log 2-transformed fold
changes with respect to controls.
For the data presented in Appendix I, two bulk RNA-Seq data sets for various cell
types isolated from mouse197 or human cortices,198 a bulk RNA-Seq data set for mouse
brain and peripheral endothelial cell types, 199 a single-cell RNA-Seq data set for various
cell types isolate from mouse whole brains, 200 and a single-cell RNA-Seq data for brain
endothelial cells types isolated from mouse whole brains199 were used. Data sets were
queried for expression of α1 or α2 integrins (Itga1 and Itga2, respectively) using the
publicly accessible web portals created by the authors. The URL and data of accession for
each data set are listed in the respective figure legend.
Animal Use
Wild-type C57BL/6J mice and fluorescent Cre reporter mice on a C57BL/6J
background (Ai14; Stock No: 007914) were purchased from Jackson Laboratory (US).
Dcn-floxed (Dcntm1.1Debi; MGI: 6119511) and Bgn-floxed (Bgntm1.1Debi; MGI: 6119512)
mice on a C57BL/6 background were a kind gift from Dr. David E. Birk (University of
South Florida, US). The two single floxed lines were crossed to achieve a dual Dcn-floxed
x Bgn-floxed line. Pan-endothelial inducible Cre mice (Tg(Tek-cre/ERT2)1Arnd; MGI:
2450312) were purchased from the European Mouse Mutant Archive (EMMA, Germany),
while BBB-EC-restricted inducible Cre mice (Tg(Slco1c1-iCre/ERT2)1Mrks; MGI:
5301361) were a kind gift from Dr. Markus Schwaninger (University of Lübeck,
Germany). To generate inducible pan-endothelial or BBB-EC-restricted knockout lines,
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the Dcn-, Bgn-, or dual Dcn-floxed x Bgn-floxed lines were crossed with the respective
inducible Cre lines. All experimental mice were genotyped by Transnetyx (US).
Animals were maintained under a 12-hour light-dark schedule with food and water
ad libitum. All experiments were approved by the Institutional Animal Care and Use
Committees (IACUC) at University of South Florida or Boise State University and were
performed in accordance with the Guide for the Care and Use of Laboratory Animals. All
experiments have been reported in compliance with ARRIVE guidelines.
Induction of Active EAE
Active MOG35-55-based EAE was induced in wild-type C57BL/6J mice as we have
previously described.34 Briefly, animals were immunized with MOG35-55 peptide
suspended in complete Freund’s adjuvant using a commercially available kit according to
manufacturer’s instructions (Hooke Labs, US). Pertussis toxin (80 ng/animal) was
administered intraperitoneally (i.p.) on days 0 and 1 post-induction. At 8 days postinduction (d.p.i.), animals were scored from 0.0 to 5.0 according to the rubric established
by Hooke Laboratories (Appendix H). Animals lacking a clinical score (CS) were
harvested. As a healthy control group, non-induced animals were harvested in tandem with
the diseased animals.
Analysis of BBB Integrity in vivo
The small fluorescent tracer sodium fluorescein (NaFluor; 376 Da) was used as we
have previously described.34 Briefly, animals were injected i.p. at 5 µL per gram body
weight with a 10% NaFluor solution prepared in saline. After allowing the tracer sufficient
time to circulate (2 hours), animals were anesthetized with isoflurane, their blood collected
via cardiac puncture, and then flushed with Ringer’s lactate solution. Following
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decapitation, whole brains were excised, and the meninges and pial vessels removed. The
remaining tissue was weighed, and then homogenized in 1 mL of phosphate-buffered saline
(PBS). Homogenates were centrifuged at 12,000 x g for 15 minutes at 4°C, and the
supernatant collected. Next, a freshly prepared 20% trichloroacetic acid (TCA) solution
was used for protein precipitation. Brain supernatants were directly diluted 10-fold with
TCA, while blood sera were first diluted 10-fold with PBS, then diluted 10-fold with TCA.
Following incubation overnight at 4°C, supernatants and sera were centrifuged at 12,000 x
g for 15 minutes at 4°C. Samples were then diluted with equal volumes of 50 mM borate
buffer, pH 10. Finally, sample fluorescence was measured (Ex./Em. = 480/538 nm) and
compared against standard curves of fluorescein prepared in solutions containing 10%
TCA and 25 mM borate buffer, pH 10. The ratio of brain-to-serum concentrations was
normalized to brain weight, then fold-change was calculated with respect to controls.
Tomato Lectin Staining
Demarcation of the brain vasculature was achieved using a tomato-derived lectin
(TL; Lycopersicon esculentum agglutinin) that preferentially labels the endothelium. 201
Briefly, animals were anesthetized with isoflurane, then transcardially injected with 50 µL
of a 1 mg/1 mL solution containing a commercially prepared TL conjugated with DyLight
649 (Vector Laboratories, US). After allowing the lectin sufficient time to circulate (3
minutes), animals were flushed with normal saline solution. Following decapitation, whole
brains were excised, and the meninges and pial vessels removed.
Immunohistochemistry
Brains were post-fixed by immersion in a 2% paraformaldehyde (PFA) solution
overnight at 4°C. They were then washed three times with PBS, embedded in low-melting
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point agarose, and cut into 100 µm thick sections. For the data presented in Figures 2.5 and
2.6, slices were permeabilized with 0.5% Triton X-100, then blocked with 10% donkey
serum. Free-floating sections were incubated with an AF488-conjugated anti-decorin
antibody (1:50) overnight at 4°C. Sections were washed six times with PBS (hour-long
washes), mounted with Vectashield on PFTE-coated microscope slides, and coverslipped.
For the data presented in Figure 2.26, slices were directly mounted with Vectashield on
PFTE-coated microscope slides and coverslipped. Prepared slides were examined with a
Zeiss LSM 510 Meta inverted confocal microscope (Zeiss, Germany) using the 488, 543,
or 633 nm laser lines and appropriate filter settings. Confocal images were analyzed using
the ZEN imaging software (Zeiss, Germany).
Primary Mouse BBB-EC Isolation
Based on a publication by Watson et al. that described the isolation of primary rat
brain or spinal cord ECs,202 we devised a six-part protocol for the isolation of primary
mouse BBB-ECs from 7-to-10 day-old pups using a combination of density centrifugation,
enzymatic digestion, and positive selection (for an explanatory graphic, see Figure 2.6). To
cover the surface of a T25 flask, 8-10 pups per isolation were required.
First, pups were euthanized by cervical dislocation, then decapitated. Whole brains
were excised, and the meninges and pial vessels removed with a tissue. Second, the
remaining tissue was homogenized (7-10 strokes with a loose-fitting 40 mL Dounce
homogenizer) in 25 mL of chilled isolation buffer containing Hanks Buffered Salt Solution
(HBSS) supplemented with 10 mM HEPES and 0.1% BSA. The homogenate was
centrifuged at 4°C for 5 minutes at 500 x g, then the supernatant discarded. Third, the pellet
was suspended in warmed digestion buffer containing Dulbecco’s Modified Eagle’s
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Medium (DMEM) supplemented with collagenase/dispase and DNAse I at 2 mg/mL and
20 µg/mL, respectively, then slowly rotated for 30 minutes at 37°C using a tube rotator.
The mixture was centrifuged at 4°C for 5 minutes at 400 x g, then the supernatant
discarded. Fourth, the pellet was suspended in a warmed separation buffer containing 22%
BSA prepared in HBSS, centrifuged at 4°C for 7 minutes at 3000 x g, and the supernatant
discarded. The pellet was then washed with DMEM prior to centrifugation at 4°C for 5
minutes at 500 x g. Fifth, the pellet was suspended in warmed digestion buffer and slowly
rotated for 25 minutes at 37°C using a tube rotator. The mixture was centrifuged at 37°C
for 5 minutes at 500 x g, then the supernatant discarded. The pellet was then washed with
DMEM prior to centrifugation at 37°C for 5 minutes at 500 x g. Sixth, the pellet was
suspended in warmed complete mouse endothelial cell medium (Cellbiologics, US) and
seeded into T25 flasks coated with collagen type I (1 µg/cm2). For the first three days postseeding (d.p.s.), wells were rinsed with HBSS prior to the addition of fresh complete mouse
endothelial cell medium supplemented with 3 µM puromycin. Daily media changes were
continued with puromycin-containing media until ready for passaging (5-7 d.p.s.).
T Cell Activation
Fresh spleen and lymph node cells isolated from wild-type C57BL/6J mice induced
with MOG35-55-based EAE were purchased from Hooke Laboratories (US), then activated
according to the provider’s instructions. Briefly, cells were pooled and suspended at a final
concentration of ~3.5 million cells per mL in RPMI 1640 media supplemented with 10%
HEPES, 10% fetal bovine serum (FBS), 2 mM L-glutamine, 1X penicillin-streptomycin
solution, 1X MEM non-essential amino acids solution, 1 mM sodium pyruvate, and 55 µM
2-mercaptoethanol. Next, MOG35-55 peptide, recombinant mouse interleukin-12 (IL-12),
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and anti-mouse IFN-γ antibodies were added to a final concentration of 20 µg/mL, 20
ng/mL, and 10 µg mL, respectively. Cells were cultured for 72 hours before being pelleted
via centrifugation for 10 minutes at 300 x g for determination of cell count. As controls,
fresh spleen and lymph node cells isolated from naïve mice were also purchased from
Hooke Laboratories (US).
Generation of Conditioned Media
Conditioned media (CM) from astrocytes, T cells, and neutrophils (PMNs) were
created via sequential co-culture steps (for an explanatory graphic, see Figure 2.7). The
spontaneously immortalized mouse astrocyte line C8-D1A was maintained in DMEM
supplemented with 10% FBS, and 1X penicillin-streptomycin. Cells were cultured in 12well plates, then activated T cells were added to the wells (50,000 each) for 24 hours. As a
control, cells isolated from naïve mice were also used. The conditioned media from both
groups (ETcA-CM and NTcA-CM, respectively) was collected and centrifuged at 10,000
x g for 10 minutes to remove any cellular debris. In turn, 50,000 naïve neutrophils isolated
from the bone marrow of wild-type C57BL/6J mice using positive selection columns
(Miltenyi Biotec) were exposed to the ETcA-CM or NTcA-CM for 6 hours. The
conditioned media from both groups (PMN-ETcA-CM and PMN-NTcA-CM, respectively)
was collected and centrifuged at 10,000 x g for 10 minutes to remove any cellular debris.
All conditioned media were kept at -80°C until ready for usage in experiments.
RNA Isolation & Analysis
RNA was isolated from BBB-ECs and analyzed as previously described.34 Briefly,
cells were lysed using RNAzol RT (Molecular Research Center, US) according to
manufacturer’s instructions, then total RNA was isolated according to manufacturer’s
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instructions, including the optional step involving 4-bromoanisole. Sample quantity and
purity were assessed using 260/280 and 260/230 absorbance ratios. Reverse transcription
was completed with the iScript cDNA Synthesis kit according to manufacturer’s
instructions (Bio-Rad, US) using 500 ng total RNA per 20 µL reaction. Quantitative
polymerase chain reaction (qPCR) was performed using SsoAdvanced Universal SYBR ®
Green Supermix and PrimePCR™ PCR primers for mouse Cldn5 or Dcn according to
manufacturer’s instructions (Bio-Rad, US) using a LightCycler 96 instrument (Roche,
Switzerland). Relative quantification of target gene expression was calculated through the
2-ΔΔCq method using Actb as the reference gene.
TAT-Cre-mediated Recombination in BBB-ECs
To efficiently recombine floxed genes in primary mouse BBB-ECs, we adapted a
cell-penetrating peptide-based Cre recombinase-delivery system devised by Wadia et al.
(Figure 2.12).203 Primary mouse BBB-ECs isolated from Ai14 mice were cultured in black,
clear-bottom 96-well plates coated with collagen type IV (10 µg/cm2). Following
maturation (5-7 d.p.s.), empirical testing with varying concentrations of TAT-HA2 and
TAT-Cre identified that a single hour of incubation with serum-free media (Cellbiologics,
US) containing 5 µM TAT-HA2 and 50 U/cm2 TAT-Cre was most optimal with respect to
recombination efficiency when assessed 48 hours later (see next section).
Live-cell imaging & Immunocytochemistry
For the data presented in Figure 2.13, media was exchanged with an equivalent
volume of Live Cell Imaging Solution (Invitrogen, US), then monolayers were visualized
with an EVOS FL Auto Imaging System equipped with a red fluorescent protein (RFP)based filter set. For the data presented in Figure 2.14, monolayers were first fixed with a
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4% PFA solution for 10 minutes, rinsed with PBS, permeabilized with a 0.1% Triton-X
100 solution for 10 minutes, rinsed with PBS, and blocked with 10% donkey serum for an
hour at room temperature. Following overnight incubation with an AF488-conjugated anticlaudin-5 antibody (1:200 dilution) at 4°C, monolayers were washed five times with PBS
supplemented with 0.1% TWEEN-20 (5 minutes each). Following a rinse with PBS, Live
Cell Imaging Solution was added and monolayers were visualized with an EVOS FL Auto
Imaging System equipped with green fluorescent protein (GFP)- and RFP-based filter sets.
Barrier Function Assessment
Barrier function of primary mouse BBB-ECs was assessed using permeability
assays or electric cell-substrate impedance sensing-transendothelial electrical resistance
(ECIS-TEER). The principles of each are shown in Figures 2.10 and 2.15, respectively.
Permeability Assays. Primary wild-type mouse BBB-ECs were seeded in 24-well
transwell inserts coated with collagen type I, collagen type IV, decorin, or various
combinations of each (10 µg/cm2). Following maturation (5-7 d.p.s.), NaFluor was added
at a final concentration of 0.5 mg/mL to the upper chamber. After allowing the tracer
sufficient time to circulate (~30 minutes), aliquots were taken from the upper (luminal) and
lower (abluminal) chambers. Next, samples were processed in an analogous fashion to the
brain homogenate and blood sera to determine the tracer concentration in each sample.
Finally, the apparent permeability coefficient (Papp) was calculated using the equation
𝑃𝑎𝑝𝑝 =

[𝐴𝑏]
𝑡

1

𝑉𝑜𝑙

𝐴𝑏
∗ 𝑆𝐴 ∗ [𝐿𝑢𝑚]
where [Ab] is the abluminal concentration, t is the time elapsed, SA

is the surface area of the insert membrane, VolAb is the volume of the abluminal chamber,
and [Lum] is the luminal concentration.
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ECIS-TEER assays. For the data presented in Figures 2.18 and 2.19, primary wildtype mouse BBB-ECs were seeded at confluence into 8W10E+ PET arrays coated with
collagen type I or collagen type IV (10 µg/cm2). Following maturation (5-7 d.p.s.), data
was collected by a 16-well ECIS Zθ station (Applied Biophysics, US) using the multiple
frequency per time (MFT) option to collect readings from 62.5 Hertz to 64 kiloHertz (kHz).
ECIS software was then used to derive the parameters Rb, α, and Cm (for their definitions,
see Figure 2.15) using a cell-free well as a reference. For the data presented in Figure 2.16,
Dcn-floxed BBB-ECs were cultured 5-7 d.p.s., incubated with serum-free mouse
endothelial cell medium (Cellbiologics, US) containing 5 µM TAT-HA2 with or without
50 U/cm2 TAT-Cre for one hour, and then allowed to recover for 48 hours prior to
incubation with 30% ETcA-CM for 24 hours. Readings were collected at a single
frequency (4 kHz) to monitor barrier integrity. 204
Tamoxifen-induced Cre-mediated Recombination in vivo
A 20 mg/mL solution of tamoxifen was prepared in a 10% ethanol-90% corn oil
mixture. Animals were injected i.p. at 50 mg per kg body weight every 12 hours for five
consecutive days, then allowed to recover at least fourteen days. For the data presented in
Figure 2.25, animals were then induced with active EAE and scored as described above.
For the data presented in Figure 2.26, animals were then anesthetized with isoflurane and
processed for TL staining and confocal microscopy as described above.
Genomic DNA Isolation & Analysis
Brain microvessel (MV)-enriched pellets were isolated from mice as previously
described.34 Briefly, animals were anesthetized with isoflurane, transcardially perfused
with saline until clear, and then decapitated. Whole brains were excised, the meninges and
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pial vessels removed with a tissue, and the remaining tissue cut midsagittal with a sterile
razor. The right hemisphere of each animal was homogenized (7-10 strokes with a loosefitting 40 mL Dounce homogenizer) in PBS. The homogenate was mixed 1:1 with a 36%
dextran (~71 kDa) solution prepared in DMEM supplemented with 2% FBS, then
centrifuged at room temperature for 10 minutes at 10,000 x g. The supernatant was
discarded, and the remaining MV-enriched pellets were immediately processed using a
Phire Tissue Direct PCR kit according to manufacturer’s instructions (ThermoFisher
Scientific, US). PCR was completed using primers and thermocycling protocols provided
by Dr. Birk for biglycan excision (Appendix G). Reaction products were then resolved on
a 2% agarose gel containing ethidium bromide (2.5 µL/50 mL agarose) and visualized
using a ChemiDoc Imaging System (Bio-Rad, US).
In-Cell Western Assay
To identify compounds that may promote claudin-5 expression in BBB-ECs, an incell western (ICW) protocol was designed using near-infrared (NIR) dyes (for an
explanatory graphic, see Figure 2.28).205,206 Immortalized mouse BBB-ECs (bEnd.3) were
cultured in black, clear-bottom 96-well plates coated with collagen type IV (10 µg/cm2).
Monolayers were allowed to partially mature (2 days), then were administered
methylprednisolone (MP; 10 µg/mL) with or without demethylasterriquinone B1 (DMAQB1; 5 µM), or a vehicle control. Twenty-four hours later, cells were fixed with a 4% PFA
solution for 10 minutes, rinsed with PBS, permeabilized with a 0.1% Triton-X 100 solution
for 10 minutes, rinsed with PBS, and blocked with a commercial blocking buffer for 30
minutes (LI-COR, US). Monolayers were incubated overnight with an anti-claudin-5
antibody overnight (1:200), washed five times with PBS supplemented with 0.1%
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TWEEN-20 (5 minutes each), incubated for an hour at room temperature with an IRDye ®
800CW-conjugated donkey anti-mouse antibody (1:1000) and CellTag™ 700 Stain
(1:1000), and washed five times with PBS supplemented with 0.1% TWEEN-20 (5 minutes
each). Following removal of all liquid from the well, plates were imaged using an Odyssey
CLx (LI-COR, US) with a focus offset of 4 mm, 169 µm resolution, and intensities for the
700 and 800 nm channels set to auto. For quantification, the ICW analysis tool for Image
Studio software was used according to developer’s instructions (LI-COR, US). Briefly, a
circular region of interest was drawn for each well. Next, the claudin-5 signals (800 nm
channel) of each well were normalized to the CellTag signal (700 nm) and background
subtraction was performed using wells incubated only with the IRDye® 800CW secondary
antibody. Finally, the normalized and corrected claudin-5 signals were divided by the
surface area of the 96-well plate (0.32 cm2) to calculate the claudin-5 signal per square
centimeter of cells.
Statistical Analysis
All statistical analyses were performed with Prism (GraphPad Software, Inc.). α
was set at 0.05 a priori for statistical significance. No specific blinding was performed in
these studies.
Results
Decorin is Deposited into the Vascular BM During the Pre-Onset Stage of EAE
Thus far, studies involving decorin deposition into the vascular BM during MS or
EAE have not considered the early stages of disease.193,194 Therefore, we induced MOG3555-based

EAE in wild-type C57BL/6J mice and sacrificed them at 8 days post-induction

88
(d.p.i.) – a time point at which we’ve previously shown BBB dysfunction and claudin-5
loss without observable neurological deficit (Figures J.1A & J.1B).34
As an initial step, we confirmed BBB dysfunction using a sodium fluorescein
(NaFluor) extravasation assay. As shown in Figure 2.3, compared to animals not induced
with EAE, diseased animals exhibited significantly increased leakage into their brain (n =
6 for each group; p < 0.05, unpaired Student’s t-test). Separately, we examined the brains
of diseased animals for decorin expression via confocal microscopy. Intense deposits of
decorin were observed along the length of cerebellar vessels of diseased animals (Figure
2.4 – right). Indeed, the deposits were sufficiently prevalent that micrographs of the 488
nm channel alone were sufficient to demarcate the microvessels without the need of the
tomato lectin (TL) stain (Figure 2.4 – top-right). Furthermore, cross-sectional profiles of
cerebellar microvessels revealed the decorin deposits to be immediately abluminal or
overlapping with TL stain (Figure 2.5). Conversely, in the brains of non-induced animals
only a few minor puncta were observed (Figure 2.4 – left).
Taken together, these data indicate that decorin deposition into the vascular BM
starts prior to the onset of observable neurological deficit in EAE-induced animals
exhibiting BBB dysfunction.
Conditioned Media Induce Decorin & Suppress Claudin-5 in primary mouse BBB-ECs
A veritable laundry list of chemokines and cytokines are involved in MS or
EAE.207–210 Rather than exhaustively screening every possible combination to identify
those which may be sufficient to induce decorin expression, we chose to generate diseaserelevant conditioned media. As a first step, immortalized mouse astrocytes were incubated
with activated T cells isolated from wild-type C57BL/6J mice induced with MOG35-55-
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based EAE to mimic the known cross-talk between astrocytes and T cells in MS and
EAE.211,212 This yielded a conditioned medium termed ETcA-CM (Figure 2.7A – left). In
turn, naïve mouse neutrophils (PMNs) isolated from the bone marrow were added to ETcACM to mimic the neutrophil activation and degranulation observed in MS and EAE. 213,214
This yielded a conditioned medium termed PMN-ETcA-CM (Figure 2.7A – right). For
control conditioned media, naïve T cells isolated from non-induced mice were used instead.
This yielded NTcA-CM and PMN-NTcA-CM, respectively (Figure 2.7B).
Exposure of wild-type primary BBB-ECs to control conditioned media did not
significantly alter claudin-5 or decorin gene expression at 24 hours (Figure 2.8 – purple
and blue; p > 0.05, one-way ANOVA with post-hoc Tukey’s for both). Conversely,
exposure to PMN-ETcA-CM led to strong induction of decorin (Figure 2.8A – orange; p
< 0.05, one-way ANOVA with post-hoc Tukey’s) and loss of claudin-5 (Figure 2.8B –
orange; p < 0.05, one-way ANOVA with post-hoc Tukey’s). Finally, exposure to ETcACM led an intermediate induction of decorin which was significantly greater than the
control conditioned media but less than the PMN-ETcA-CM (Figure 2.8A - red; p < 0.05,
one-way ANOVA with post-hoc Tukey’s), while a non-significant decrease in claudin-5
was measured (Figure 2.8B – red; p > 0.05, one-way ANOVA with post-hoc Tukey’s).
As the PMN-ETcA-CM yielded the strongest response for decorin and claudin-5,
we conducted a time-course to better understand their gene expression patterns. Decorin
was significantly elevated at 3 and 6 hours, and further increased at 12 hours (Figure 2.9A;
p < 0.05, one-way ANOVA with post-hoc Tukey’s). A mirror opposite trend was observed
for claudin-5, with its lowest levels at 12 hours (Figure 2.9B; p < 0.05, one-way ANOVA
with post-hoc Tukey’s).
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Taken together, these data indicate that conditioned media created using astrocytes,
activated T cells, and neutrophils are sufficient to induce decorin and suppress claudin-5
gene expression in wild-type primary mouse BBB-ECs. Furthermore, elevated decorin
gene expression is associated with lower claudin-5 gene expression.
Decorin Impairs Barrier Function & Claudin-5 Gene Expression
To more closely investigate this inverse relationship, wild-type primary mouse
BBB-ECs were cultured in wells coated with collagen type IV, decorin, both, or neither.
Monolayers cultured on collagen type IV had higher levels of claudin-5 compared to those
on decorin or plastic (Figure 2.11A – columns 1-3; p < 0.05, one-way ANOVA with posthoc Tukey’s). Interestingly, monolayers cultured on decorin exhibited a downwards trend
compared to those on plastic, albeit non-significant (Figure 2.11A – columns 1 & 2; p >
0.05, one-way ANOVA with post-hoc Tukey’s). Finally, the additional presence of decorin
impaired the pro-claudin-5 effects of collagen type IV (Figure 2.11A – columns 3 & 4; p
< 0.05, one-way ANOVA with post-hoc Tukey’s).
To determine whether barrier function was impacted, NaFluor permeability assays
were conducted (for an explanatory graphic, see Figure 2.10) with wild-type primary
mouse BBB-ECs cultured in transwell inserts coated with collagen type IV, decorin, both,
or neither. Monolayers cultured on collagen type IV exhibited lower permeability
compared to those on decorin or plastic (Figure 2.11B – columns 1-3; p < 0.05, one-way
ANOVA with post-hoc Tukey’s). Moreover, monolayers on decorin exhibited higher
permeability than those on plastic (Figure 2.11B – columns 1 & 2; p < 0.05, one-way
ANOVA with post-hoc Tukey’s). Finally, the additional presence of decorin impaired the
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pro-barrier effects of collagen type IV (Figure 2.11B – columns 3 & 4; p < 0.05, one-way
ANOVA with post-hoc Tukey’s).
Taken together, these data indicate that the decorin not only counteracts the
beneficial effects of collagen type IV on claudin-5 gene expression and barrier function,
but also appears to be a worse substrate than plastic alone.
Loss of Decorin Partially Rescues Barrier Dysfunction & Claudin-5 Gene Expression
Given the seemingly deleterious role of decorin, we wanted to investigate whether
its silencing could be beneficial. However, it is challenging to efficiently silence genes in
primary BBB-ECs using methods like small interfering RNA (siRNA). Therefore, we
adapted a cell-penetrating peptide-based Cre recombinase-delivery system developed by
Wadia et al.203 Recombination of genes flanked by loxP (floxed) sites is achieved by a
recombinant Cre enzyme fused with the protein transduction domain (PTD) of the HIV-1
TAT protein (TAT-Cre). Additionally, to promote endosomal escape, a fusogenic peptide
consisting of the N-terminal portion of influenza hemagglutinin with the same PTD
sequence from TAT is used.
To optimize recombination efficiency, we isolated primary mouse BBB-ECs from
Cre reporter mice (Ai14; Figure 2.12A) and allowed them to mature. Subsequently, they
were incubated in serum-free media containing various concentrations of TAT-Cre and
TAT-HA2. Cells were allowed to recover, then visualized using live-cell imaging.
Ultimately, a concentration of 5 µM TAT-HA2 and 50 U/cm2 of TAT-Cre was chosen as
it yielded in a high proportion of TdTomato-expressing cells (Figure 2.13 – right).
Furthermore, fixed cells still exhibited circumferential staining of claudin-5 when
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visualized with an epifluorescent microscope (Figure 2.14 – right), suggesting minimal
perturbation to the tight junctions.
With this method, decorin gene ablation was performed in primary mouse BBBECs isolated from Dcn-floxed mice (Figure 2.16) prior to their incubation with PMNETcA-CM. To assess changes in barrier integrity in real-time, we employed an electric
cell-substrate impedance sensing system to measure the transendothelial electrical
resistance of the monolayers (ECIS-TEER; for an explanatory graphic, see Figure 2.15).
Compared to non-recombined monolayers (Figure 2.16A – grey), loss of resistance was
less severe in recombined monolayers (Figure 2.16A – orange). At sixteen hours, when
both groups reached their lowest point in resistance, knockout monolayers had a significant
rescue in resistance (Figure 2.16B; p < 0.05, unpaired Student’s t-test).
Taken together, these indicate that loss of decorin expression can have a positive
outcome on barrier function under proinflammatory conditions.
Collagen Type I Does Not Foster Barrier Function or Claudin-5 Gene Expression
Only a handful of early studies have considered how collagen type may influence
endothelial function or tight junctions. 195,196,215 To continue where they left off, wild-type
primary mouse BBB-ECs were cultured in wells coated with collagen type IV or type I.
Monolayers cultured on collagen type IV had higher levels of claudin-5 gene expression
compared to those on collagen type I (Figure 2.17A; p < 0.05, unpaired Student’s t-test).
Next, to determine whether barrier function was impacted, NaFluor permeability assays
and ECIS-TEER experiments were conducted. Wild-type primary mouse BBB-ECs
cultured in transwell inserts coated with collagen type IV had lower permeability compared
to those on collagen type I (Figure 2.17B; p < 0.05, unpaired Student’s t-test). Similarly,
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monolayers cultured in arrays coated with collagen type IV (Figure 2.18 – blue) exhibited
higher resistances than those on collagen type I (Figure 2.18 – orange). Furthermore,
collection of readings across a wide range of frequencies (62.5 Hz to 64 kHz) allowed for
modeling of the parameters Rb (cell-cell adhesion) and α (cell-substrate adhesion) by the
ECIS software (for their definitions, see Figure 2.15). Monolayers cultured on collagen
type IV had overall higher Rb and α values (Figures 2.19A & B – blue) compared to those
culture on collagen type I (Figures 2.19A & B – orange).
Taken together, these preliminary data suggest that collagen type I is sub-optimal
compared to collagen type IV with respect to claudin-5 gene expression and barrier
function. Additionally, diminished cell-cell and cell-substrate adhesions are both observed
for monolayers cultured on collagen type I.
Discussion
When it was first discovered, the BM was considered a static structure that merely
provided structural support for the tissues it served. 186,216 However, it is now understood
that the biochemical and biophysical characteristics of the BM can influence the cellular
processes of the adjacent tissues, including the endothelium. 186,216
Importance of Molecular Composition
Endothelial cells anchor themselves to the BM by establishing focal adhesions rich
in integrin dimers that recognize and bind the collagen type IV and laminin networks.217,218
In turn, cytoplasmic scaffolding proteins couple the integrin dimers to the cytoskeletal
network and form regulatory hubs.217,218 Thus, changes in the molecular composition can
modulate intracellular signaling in an “outside-in” manner.
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Collagen Type IV. Taken together, my studies (Figures 2.11, 2.17-19) strongly
suggest that collagen type IV fosters barrier function and tight junction expression in BBBECs. Collagens are recognized by several integrin dimers, including α1β1 and α2β1.219 The
α1β1 dimer preferentially binds collagen type IV over type I, and vice versa for α2β1
dimer.219 While no studies have systematically compared their expression in BBB-ECs,
three bulk RNA-Seq data sets and two single-cell RNA-Seq data set all suggest α1 to be
the main isoform under basal conditions (Appendix I).
Two separate studies have demonstrated that blockade of β1 integrin with a
monoclonal antibody (clone: Ha2/5) for 24 hours suppresses claudin-5 and impairs barrier
function in primary mouse BBB-EC monolayers cultured on collagen type IV (Figure
2.20A).190,191 Strictly speaking, integrins that bind laminin isoforms (α3β1, α6β1) or
fibronectin (α4β1, α5β1) also contain the β1 isoform.220 While the antibody was unlikely to
block endothelial-fibronectin interactions given that both dimers are poorly expressed in
endothelial cells not actively undergoing angiogenesis, 220 it cannot be excluded the
possibility that the antibody may have additionally targeted laminin-binding integrins. In
fact, one of the studies also cultured cells on laminin 111 (α 1β1γ1 isoform) under the same
conditions and observed similar reductions in claudin-5.191 Regardless, it is clear that β1containing integrin dimers are important for mediating endothelial-matrix protein
interactions and are needed for claudin-5 expression and barrier integrity.
Unfortunately, little is known about the downstream signaling. Izawa et al.
reporting that knocking down integrin-linked kinase (ILK), which associates with the
cytoplasmic tail of β1 integrins, 221,222 suppresses total claudin-5 expression (Figure
2.20B).191 Despite its name, ILK is a putative pseudo-kinase that instead exerts its effects
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primarily by acting as an adapter protein for ILK-particularly interesting new cysteinehistidine-rich protein (PINCH)-parvin (IPP) complexes that couple integrins to the actin
cytoskeleton for stability and recruit signaling proteins to the adhesion sites.221,222
Decreased activity of the kinase Akt was observed following adenovirus-mediated Cre
recombination in primary lung microvascular endothelial cells (LMVECs) isolated from
Ilk-floxed mice, with co-transduction of a wild-type ILK construct restoring activity. 223 A
similar loss in Akt activity was reported in human umbilical vein endothelial cells
(HUVECs) following siRNA-mediated silencing of ILK as well as in the retinal
endothelium of endothelial-restricted inducible Ilk-knockout mice.224 We and others have
shown that Akt phosphorylates the transcription factor forkhead box protein O1 (FoxO1)
to prevent its nuclear accumulation and formation of a transcriptional repressor complex at
the claudin-5 promoter with other transcription factors, including beta-catenin (βcatenin).34,225,226 As such, it is possible that the decreases in total claudin-5 expression
reported by Izawa et al. is in part due to diminished Akt activity (Figure 2.20B). In support,
Yau et al. reported that administration of QLT-0254, a small molecule inhibitor (SMI)
against ILK, was associated with decreased Akt activity and decreased FoxO1
phosphorylation in an orthotopic pancreatic tumor mouse model. 227 The efficacy of the
SMI may be explained by the requirement of ILK for ATP binding as part of its
coordinating with PINCH and parvin.228
Future studies that are needed include: 1) using α isoform-specific blocking
antibodies are needed to isolate the contribution of collagen-binding integrins and 2)
studies investigating the downstream targets of IPP complex signaling are needed to clarify
the connection between ILK and claudin-5.
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Collagen Type I. Taken together, my preliminary data for collagen type I (Figures
2.17-19) strongly suggest that collagen type I is a sub-optimal substrate for BBB-ECs
compared to collagen type IV. Previously, several early studies have considered collagen
type I with respect to barrier function or tight junction proteins. First, Tagami et al. showed
that bovine aortic endothelial cells (BAECs) co-cultured with primary rat astrocytes
exhibited lower leakage of horseradish peroxidase and fewer plasmalemmal vesicles when
cultured on collagen type IV versus collagen type I. 195 Next, Savettieri et al. found that rat
immortalized BBB-ECs (RBE.4) cultured on collagen type IV had higher levels of gene
expression for the tight junction protein occludin compared to those on type I. 229 Finally,
Tilling et al. demonstrated that primary porcine BBB-ECs cultured on rat tail collagen,
which primarily is comprised of collagen type I, exhibited lower TEER values compared
to those on type IV.196
While several downstream intracellular signaling pathways have been identified
across various endothelial cell types, none have directly been connected to claudin-5
expression. Consequently, interferences between studies are required. First, Whelan et al.
demonstrated that engagement of α1β1 or α2β1 dimers by collagen type I suppresses cyclic
adenosine monophosphate (cAMP) levels and protein kinase A (PKA) activity in primary
human dermal microvascular endothelial cells (DMVECs). 230 As cAMP levels and PKA
activity are positively associated with barrier function and claudin-5 expression in primary
porcine BBB-ECs,231 collagen type I could impair both by suppressing cAMP- or PKAdependent pathways (Figure 2.21A). This may include an axis recently described by
Kakogiannos et al. involving the guanine nucleotide exchange factor (GEF) exchange
protein directly activated by cAMP (EPAC) that promotes claudin-5 expression through
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the binding of the transcriptional factor CCAAT/enhancer-binding protein α (C/EBP-α) to
the claudin-5 promoter.232 Alternatively, Lee et al. have reported that FoxO1 is a substrate
for PKA and that knock down or inhibition of PKA was associated with enhanced FoxO1
activity in human aortic endothelial cells (HAECs). 233
Next, Liu et al. demonstrated that stimulation of the small GTPase Ras homologue
family member A (RhoA) and the kinase Src is β 1 integrin-dependent in primary human
DMVECs cultured on collagen type I (Figure 2.21B).234 In primary human BBB-ECs,
administration of lysophosphatidic acid, a known activator of RhoA, triggered the
phosphorylation of claudin-5 via Rho-associated kinase (ROCK), which was closely
followed by loss of barrier integrity in immortalized mouse BBB-ECs (bEnd.3).58 As such,
collagen type I could directly modulate claudin-5 through posttranslational modification.
Alternatively, the Src family of kinases (SFKs) negatively regulate the adherens junction
protein vascular endothelial-cadherin (VE-CAD; gene: Cdh5) which sequesters β-catenin
to the cell-cell contacts.235 Thus, collagen type I could trigger the destabilization of VECAD which, in turn, liberates β-catenin. In support of this, Liu et al. noted that inhibition
of Src using a pan-SFK inhibitor (PP2) or through transduction of a dominant-negative
construct preserved VE-CAD presence at the cell-cell contacts.234
Finally, González-Santiago reported a suppression of ILK kinase activity in a β1
integrin-dependent manner for primary HUVECs cultured on collagen type I compared to
collagen type IV (Figure 2.21C).236 As ILK is a putative pseudo-kinase, these results likely
reflect partial co-purification of kinases that associate with ILK or IPP complexes. 237,238
Indeed, recombinant ILK expressed in bacteria or endogenous ILK subjected to multiple
rounds of purification does not exhibit kinase activity. 237,238 If interpreted through the lens
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of a co-immunoprecipitation assay, collagen type I may disrupt the interaction of ILK or
IPP complexes with undetermined adhesion-associated kinases. Thus, as with the findings
by Izawa et al. involving knockdown of Ilk,191 Akt activity may be impaired, in turn
allowing nuclear accumulation of FoxO1 at the claudin-5 promoter.
Future studies that are needed include: 1) using α isoform-specific blocking
antibodies are needed to isolate the contribution of collagen-binding integrins, 2)
investigating the relative occupancy of activating or repressing transcription factors at the
claudin-5 promoter to determine whether collagen types differentially regulate expression
at the level of transcription, and 3) characterizing the phosphorylation profile of claudin-5
to determine whether collagen types differentially regulate stability at the tight junctions.
Decorin. Taken together, my data for decorin (Figures 2.11 & 2.16) strongly
suggest that decorin not only is a sub-optimal substrate for BBB-ECs to collagen type IV,
but it can also interfere with BBB-EC-collagen type IV interactions and its silencing under
pro-inflammatory conditions can partially rescue barrier dysfunction.
Originally named for its ability to “decorate” collagen strands, decorin was
originally ascribed a regulatory role in collagen fibrillogenesis. 239 The protein core adopts
a banana-like tertiary structure with twelve leucine-rich repeats (LRRs) providing a
concave surface of parallel β-sheets (Figure 2.22) that interact with collagen fibrils. 240
However, to regulate their diameter and orientation, decorin additionally requires the
covalent attachment of a sulfated glycosaminoglycan (GAG) chain close to its N-terminus
(Ser34).241 Given the deposition of fibril-forming collagens during inflammation,193,194 it
is straightforward to speculate that decorin may be secreted to combat any untoward
fibrosis. In support of this, multiple groups have reported successful suppression or
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dissolution of fibrotic scars in rodents subjected to spinal cord injury models following
administration of recombinant decorin to the injury site. 242
To complicate matters, however, it is now understood that decorin can play
stimulatory or inhibitory roles in the interconnected processes of wound repair,
angiogenesis, tumorigenesis, and autophagy, all in a highly context-specific manner.243–245
In fact, as of 2016, decorin has been demonstrated to interact with at least 69 proteins,
including integrins, growth factors, cytokines, and receptor tyrosine kinases. 244 Among
these, the most notable are α2β1, transforming growth-factor beta (TGF-β), tumor necrosis
factor-alpha (TNF-α), and vascular endothelial growth factor receptors (VEGFRs). Under
acellular conditions, decorin interacts with the ectodomain of α 2β1, but not α1β1, via its
GAG chain and can modulate the interactions of α2β1 with a recombinant mini-collagen
(FC3).246 These interactions were allosteric as decorin did not interact with FC3 or the
collagen-binding region of α2β1.246 As for the others, dysregulated TGF-β-, TNF-α-, and
VEGF-dependent signaling are all observed in MS. 247–249 Moreover, all can impair barrier
function and claudin-5 expression in cultured BBB-ECs.112,250,251 From this perspective,
decorin could play a protective or damaging role in BBB function depending on which
proteins it interacts with and at what point in the disease course.
Decorin is a known transcriptional target of FoxO1 in primary HUVECs and
primary bovine LMVECs when angiopoietin (Ang)-Tie receptor signaling is altered.252,253
Under healthy conditions, pericyte- and astrocyte-derived Ang-1 binds to endothelial Tie2
receptors which promotes Akt-dependent phosphorylation of FoxO1 (Figure 2.23A).252–257
Additionally, basal expression of Ang-2 by endothelial cells promotes Tie2 signaling in
the presence of the orphan receptor Tie1.258 During inflammation, however, the
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ectodomain of Tie1 is cleaved and Ang-2 expression increases, shifting it to an antagonistic
role (Figure 2.23B).258–261 Interestingly, Ang-2 itself is a transcriptional target of FoxO1,
suggesting a positive feedback loop between it and FoxO1 during inflammation. 256
Recently, Li et al. reported that Ang-2 is upregulated in EAE.261 Moreover, mice
with endothelial-restricted overexpression of Ang-2 (Ang2-ECKI) suffered worsened
disease and barrier dysfunction, while prophylactic blockade of Ang-2 in wild-type mice
ameliorated disease and minimized barrier leakage.261 Separately, Gurnik et al. reported
that the brain microvessels isolated from Ang2-ECKI mice had lower total claudin-5
protein.260 In line, Blecharz et al. reported that blockade of Ang-2 rescued barrier function
and claudin-5 gene expression in immortalized mouse BBB-ECs (cEND) incubated with
sera from patients with Moyamoya disease. 262 Thus, altered Ang-Tie signaling during
inflammation may concurrently promote decorin and suppress claudin-5 through FoxO1.
Future studies that are needed include: 1) using decorin with or without its GAG
chain to isolate the contribution of each, 2) using substrates containing decorin and
collagen type I to determine whether the additional presence of decorin modulates the
response by BBB-ECs to collagen type I, and 3) using Ang-2 or FoxO1-specific inhibitors
to probe whether they are involved in decorin deposition during inflammation.
Conclusion
In this dissertation, I have explored how deposition of inflammation-associated
proteins into the vascular BM may contribute to BBB dysfunction or claudin-5 expression.
Specifically, I focused on the proteins decorin and collagen type I, both of which are
observed in MS and EAE during active disease.193,194 I analyzed the brains of mice induced
with EAE at the pre-onset stage and observed decorin in the BM of mice already suffering

101
BBB dysfunction. Additionally, I conducted cell culture studies using primary mouse
BBB-ECs, overall finding an inverse relationship between decorin or collagen type I with
barrier function or claudin-5. Taken together, this work suggests that inflammationassociated alterations to the BM occur early in the disease progression and can contribute
to BBB dysfunction by suppressing expression of tight junction proteins like claudin-5.
Future Directions of Our Lab
Evaluating SLRP-knockout in vivo
Given the results using our cell culture model (Figure 2.16), we plan to test whether
silencing decorin rescues BBB dysfunction in vivo. At the beginning of this project, we
acquired Dcn-floxed mice (a kind gift from Dr. David Birk, University of Florida) and panendothelial-restricted Cre (Tie2-Cre) mice. However, a complicating factor when assessing
decorin in vivo is that another class I SLRP, biglycan, can functionally compensate for its
loss under certain circumstances. 263 Therefore, we additionally acquired Bgn-floxed mice
from Dr. Birk with the goal of creating a three experimental lines: Tie2-Cre x Bgn-floxed
(TB), Tie2-Cre x Dcn-floxed (TD), and Tie2-Cre x Bgn-floxed x Dcn-floxed (TBD).
Over the course of breeding, we isolated primary mouse BBB-ECs from Crenegative littermates and incubated them with PMN-ETcA-CM following recombination
with our TAT-Cre-based strategy (note: the data presented in Figures 2.16 & 24 are from
the same experiment). Although each knockout group initially had different tracing profiles
over the first 8 hours, all three plateaued to a comparable level by 16 hours (Figure 2.24D;
p > 0.05, one-way ANOVA with post-hoc Tukey’s). For all three, a significant rescue in
barrier dysfunction was found compared to Dcn-floxed monolayers incubated with TATHA2 only as a control (Figures 2.24A-C; p < 0.05 for each, one-way ANOVA with post-
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hoc Tukey’s). Strictly speaking, the Dcn-floxed allele was not completely fixed at the time
of this experiment in the BD line, meaning that these monolayers still carried a single wildtype allele. Regardless, complete ablation of biglycan and hemizygous ablation of decorin
was sufficient to ameliorate barrier dysfunction.
Because biglycan is carried on the X chromosome, 264 we achieved the TB line
before the others. Following twice daily injection of tamoxifen for five consecutive days,
a cohort of TB mice and their Cre-negative littermates were allowed to recover for 14 days,
then were induced with EAE. To our surprise, the disease course for both groups was
comparable over 31 d.p.i. (Figure 2.25). Concerned that we may not be achieving efficient
recombination in vivo, we crossed Tie2-Cre mice with Ai14 mice (TA). Offspring with the
TA genotype were injected with tamoxifen, allowed to recover, then had their brains
harvested for analysis by confocal microscopy. As shown in Figure 2.26, only a small
number of TL-stained vessels (red) exhibited TdTomato expression (green) in the
cerebellum, suggesting poor recombination efficiency.
To circumvent this, we started our breeding over with a Slco1c1-Cre line (a kind
gift from Dr. Markus Schwaninger, University of Lübeck, Germany) as its expression is
primarily restricted to BBB-ECs.265 Again, we achieved the Slco1c1-Cre x Bgn-floxed line
(SB) before the Slco1c1-Cre x Dcn-floxed (SD) or Slco1c1-Cre x Bgn-floxed x Dcn-floxed
(SBD). To compare recombination efficiency, we injected SB, TB, or Cre-negative
littermates with tamoxifen, allowed them to recover, then isolated their brain mi7rovessels
for analysis by PCR and agarose gel electrophoresis. As shown in Figure 2.27, products
for the floxed allele were observed for all three lines. However, a product for the excised
allele was only observed in the SB mice, suggesting that our tamoxifen regimen was not at
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fault for the poor recombination in TB mice. As cohorts of SB, SD, and SBD mice become
available, studies with EAE will be conducted to determine whether SLRP-knockout alters
the disease course, BBB dysfunction, or claudin-5 expression.
Therapeutic Targeting of Tight Junctions to Rescue Barrier Function
Given their importance in barrier integrity, preservation or restoration of tight
junctions for diseases in which BBB dysfunction occurs could be a viable strategy. 38
Strictly speaking, several FDA-approved disease-modifying drugs already have known
pro-barrier or pro-tight junction properties. For example, glucocorticoids (GCs) can
promote endothelial barrier function through transactivation of claudin-5 and occludin
gene expression in human and bovine retinal ECs266,267 or in mouse BBB-ECs.268,269
Moreover, their administration undoes pro-inflammatory cytokine-induced suppression of
claudin-5 or occludin in mouse BBB-ECs.269,270 However, their long-term administration
is not ideal for chronic diseases like MS as it elevates a patient’s risk for infection or for
other diseases like osteoporosis and cardiovascular disease. 271,272 Similarly, sphingosine 1phosphate receptor (S1PR) modulators like fingolimod promote barrier function and
claudin-5 gene expression in human BBB-ECs, including those exposed to the sera from
patients with RR-MS during relapse (Figure 1.11). As with GCs, unfortunately,
administration of S1PR modulators is associated with increased risks of infection. 273
Furthermore, they are contraindicated for patients with pre-existing cardiovascular
conditions.274 Thus, the identification of alternative compounds is warranted.
We recently demonstrated the utility of the selective insulin receptor (IR) agonist
demethylasterriquinone B1 (DMAQ-B1) to rescue BBB dysfunction close to the onset of
disease in EAE.34 A single dose of DMAQ-B1 (5 mg/kg) via oral-gavage at 7 days post-
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induction minimized the extravasation of NaFluor and EB, plus preserved total claudin-5
protein levels in the brain homogenates of treated animals (Figures J.7E-H).34
Complementary cell culture studies using primary mouse BBB-ECs revealed that DMAQB1 dose-dependently promoted claudin-5 expression (Figure J.4D) and barrier function
(Figures J.6A-C). Also, morphometric assessment of claudin-5 in DMAQ-B1-treated cells
using Imaris software showed increased claudin-5 density at the tight junctions (Figure
J.5). Taken together, these data suggest that promotion of claudin-5 via IR agonism during
inflammation can preserve BBB function.
As its name suggests, DMAQ-B1 is a quinone derivative.275,276 Unfortunately,
quinones are non-ideal backbones for drug molecules as long-term they are cytotoxic.277
To facilitate the identification of other potentially beneficial compounds, we have
optimized an in-cell Western (ICW) assay for claudin-5 using a 96-well format (for an
explanatory graphic, see Figure 2.28). As a proof-of-principle, we seeded immortalized
mouse BBB-ECs (bEnd.3) at confluence into wells coated with collagen type IV. However,
monolayers were administered methylprednisolone (MP; 10 µg/mL) with or without
DMAQ-B1 (5 µM) when they were still only partially mature (2 d.p.s.) to ensure that their
claudin-5 expression would not be maximal. As shown in Figure 2.29B, administration of
MP significantly increased claudin-5 (p < 0.05, one-way ANOVA with post-hoc Tukey’s).
In turn, the additional presence of DMAQ-B1 further increased claudin-5 and was
significantly greater than MP alone (p < 0.05, one-way ANOVA with post-hoc Tukey’s).
With this assay established, our lab will be able screens compounds across multiple
concentrations or combinations in a more rapid manner than traditional formats.
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Chapter Two Figures

Figure 2.1.

Collagen Type I Gene Expression is Upregulated in CNS Disease.

A publicly available RNA-Seq data set that identified differently expressed genes in
CNS-ECs common to four animal models across their disease course was queried for
expression of collagen type I (Col1a1 & Col1a2).194 A heat map for each model was
created, with the scale reflecting the log2-transformed fold-change with respect to the
control. A. Kainic acid model of epilepsy. B. MOG35-55-based EAE. C. Middle cerebral
artery occlusion model of stroke. D. Controlled focal cortical impact model of pediatric
traumatic brain injury.
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Figure 2.2.

Decorin Gene Expression is Upregulated in CNS Disease.

A publicly available RNA-Seq data set that identified differently expressed genes in
CNS-ECs common to four animal models across their disease course was queried for
expression of decorin (Dcn).194 A heat map for each model was created, with the scale
reflecting the log2-transformed fold-change with respect to the control. A. Kainic acid
model of epilepsy. B. MOG35-55-based EAE. C. Middle cerebral artery occlusion model
of stroke. D. Controlled focal cortical impact model of pediatric traumatic brain injury.
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Figure 2.3.

BBB Integrity is Compromised Before Onset in EAE.

Wild-type C57BL/6 mice (n = 6) were induced with active MOG35-55-based EAE. 8 days
post-induction, animals lacking clinical scores were injected i.p. with sodium fluorescein
(NaFluor). Two hours later, animals were sacrificed, tracer concentrations in their brain
homogenates and blood sera were determined, and the ratio of the brain concentration to
the serum concentration was calculated. As controls, animals not induced with EAE (n =
6) were treated in the same manner. Error bars represent the standard deviation of the
mean. Groups marked with different letters are statistically different from each other (p <
0.05, Student’s t-test).
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Figure 2.4.

Decorin is Deposited Before Onset in EAE.

Wild-type C57BL/6 mice (n = 6) were induced with active MOG35-55-based EAE. 8 days
post-induction, animals lacking clinical scores were anesthetized and injected t.c. with
TL-DyLight 649 to label the endothelium (red). Animals were then flushed, decapitated,
and their brains processed for immunolabeling with an antibody against decorin
conjugated with AF488 (green). As controls, animals not induced with EAE (n = 6) were
treated in the same manner. A representative micrograph for each group is shown above.
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Figure 2.5.

Decorin is Deposited at the Pre-Onset Stage of EAE.

Wild-type C57BL/6 mice (n = 6) were induced with active MOG35-55-based EAE. 8 days
post-induction, animals lacking clinical scores were anesthetized and injected t.c. with
TL-DyLight 649 to label the endothelium (red). Animals were then flushed, decapitated,
and their brains processed for immunolabeling with an antibody against decorin
conjugated with AF488 (green). Scale bar = 5 µm.
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Figure 2.6.

Primary Mouse BBB-EC Isolation Protocol.

A six-part protocol was devised and optimized to isolate primary mouse BBB-ECs from
7–10-day-old pups. Created with BioRender.com.
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Figure 2.7.

Experimental Design for Generating Conditioned Media.

A. Lymphocytes isolated from wild-type C57BL/6 mice induced with MOG35-55-based
EAE were pooled and activated in the presence of MOG35-55 peptide, IL-12, and an antiIFN-γ antibody. Incubation of these cells with astrocytes yielded conditioned media
(CM) termed ETcA-CM. In turn, incubation of naïve neutrophils (PMN) with this media
yielded a second media termed PMN-ETcA-CM. B. Control CM were generated using
lymphocytes isolated from animals not induced with EAE (naïve). Incubation of these
cells with astrocytes yielded media termed NTcA-CM. In turn, incubation of naïve
PMNs with this media yielded a second media termed PMN-NTcA-CM. Created with
BioRender.com.
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Figure 2.8.

CM-induced Alterations in Cldn5 & Dcn Expression.

Wild-type primary BBB-ECs were incubated with one of four conditioned media: Naïve
T cell-Astrocyte (NTcA – purple), Effector T cell-Astrocyte (ETcA – red), NeutrophilNaïve T cell-Astrocyte (PMN-NTcA – blue), or Neutrophil-Effector T cell-Astrocyte
(PMN-NTcA – orange). 24 hours later, cells were lysed and assessed for expression of
Cldn5 (A) or Dcn (B). For the reference gene, Actb was used. Technical duplicates were
performed for each group (n = 2 wells each), and then 2 -ΔΔCq values were calculated with
the NTcA group arbitrarily set as the control group. Error bars represent the standard
deviation of the mean. Groups marked with different letters are statistically different from
each other (p < 0.05, one-way ANOVA with post-hoc Tukey’s test).
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Figure 2.9.

CM-induced Alterations in Cldn5 & Dcn Expression.

Wild-type primary BBB-ECs were incubated with PMN-ETcA-CM for 0, 3, 6, or 12
hours. Cells were lysed and assessed for expression of Cldn5 (A) or Dcn (B). For the
reference gene, Actb was used. Technical duplicates were performed for each group (n =
2 wells each), and then 2 -ΔΔCq values were calculated with the zero-hour group arbitrarily
set as the control group. Error bars represent the standard deviation of the mean. Groups
marked with different letters are statistically different from each other (p < 0.05, one-way
ANOVA with post-hoc Tukey’s test).
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Figure 2.10. Principle of Permeability Assay for Modeling Barrier Function.
1. A known concentration of a tracer, such as sodium fluorescein, is added to the upper
chamber of the transwell insert, upon which a cell monolayer has formed. 2. The tracer is
allowed to pass across the monolayer. 3. Sampling of the lower chamber to determine
tracer concentration and, in turn, calculation of the apparent permeability coefficient
(higher coefficients reflect lower barrier function). Created with BioRender.com.
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Figure 2.11. Modulation of Barrier Function by Decorin.
B. Mouse BBB-ECs were seeded at confluence into wells coated with decorin (DCN),
collagen type IV (COL4), both, or neither. Following maturation, cells were lysed and
assessed for expression of Cldn5 or Actb as a reference gene. Technical duplicates were
performed for each group (n = 3 wells each), and then 2 -ΔΔCq values were calculated with
the no-substrate group arbitrarily set as the control group. Error bars represent the
standard deviation of the mean. Groups marked with different letters are statistically
different from each other (p < 0.05, Student’s t-test). B. Mouse BBB-ECs were seeded at
confluence into transwell inserts coated with decorin (DCN), collagen type IV (COL4),
both, or neither. Following maturation, the apparent permeability coefficient (P app) for the
small solute tracer sodium fluorescein (NaFluor) was used to assess barrier permeability
for each group (n = 3 inserts each). Error bars represent the standard deviation of the
mean. Groups marked with different letters are statistically different from each other (p <
0.05, Student’s t-test).
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Figure 2.12. Principle of Cre-mediated Recombination.
A. The Cre reporter line Ai14 carries a cassette containing a loxP-Stop-LoxP (LSL)
sequence upstream of an open reading frame for the fluorophore TdTomato. Prior to
recombination, the LSL sequence prevents transcription of TdTomato. In the presence of
Cre, however, the stop sequence and one of the loxP sites are excised, permitting
transcription of TdTomato. B. The Dcn-floxed line harbors loxP sites immediately
upstream and downstream of exon 3. In the presence of Cre, the exon and one of the loxP
sites are excised, thereby ablating decorin expression. Created with BioRender.com.
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Figure 2.13. TAT-HA2 + TAT-Cre Efficiently Recombines Floxed Genes.
Mouse BBB-ECs isolated from Ai14 mice were seeded at confluence onto glass-bottom
wells coated with collagen type IV. Following maturation, monolayers were incubated
for an hour with 5 µM TAT-HA2 in serum-free media alone (left) or additionally with 50
U/cm2 TAT-Cre (right). Following a media change and 48 hours of recovery, monolayers
were visualized with an epifluorescent microscope. Note: the dark spaces in the
TdTomato channel (right) reflect non-recombined cells rather than holes in the
monolayer (see Figure 2.15). Scale bar = 400 µm.
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Figure 2.14. Claudin-5 is Present at the Tight Junctions of Recombined Cells.
Mouse BBB-ECs isolated from Ai14 mice were seeded at confluence onto glass-bottom
wells coated with collagen type IV. Following maturation, monolayers were incubated
for an hour with 5 µM TAT-HA2 and 50 U/cm2 TAT-Cre in serum-free media.
Following a media change and 48 hours of recovery, monolayers were fixed and
immunolabeled for claudin-5 expression. Monolayers were visualized with an
epifluorescent microscope. Note: the dark spaces in the TdTomato channel (left) reflect
non-recombined cells rather than holes in the monolayer as demonstrated by the
continuous staining in the claudin-5 channel (right). Scale bar = 200 µm.
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Figure 2.15. Principle of ECIS-TEER for Modeling Barrier Function.
A. Circuit diagram illustrating the relevant parameters for modeling ECIS-TEER. From
top to bottom, this includes the resistance of the media (Rm), the capacitance of the cell
membrane (Cc), the resistance of the cell (Rc), the resistance of the basal cleft (Rcleft), and
the capacitance of the gold electrode (Cel). B. The relative contributions of tight junctions
(Rb), cell-substrate interactions (α), and cell membrane composition (Cm) can be modeled
by varying the alternating current (AC) frequency. In general, lower frequencies like
4000 Hertz (Hz) are appropriate for assessing changes in Rb as current preferentially
flows via paracellular pathways rather than via transcellular pathways. Figure minimally
adapted from Robilliard et al.278 in Biosensors (2018, Vol. 8, Issue 3) under a Creative
Commons License (CC-BY).
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Figure 2.16. Loss of Decorin Expression Partially Rescues BBB Dysfunction.
A. Mouse BBB-ECs isolated from Dcn-floxed mice were seeded at confluence into
8W10E+ arrays coated with collagen type IV. Following maturation, monolayers were
incubated with TAT-HA2 in serum-free media alone (grey) or additionally with TAT-Cre
(orange) to ablate decorin gene expression. Following a media change and overnight
recovery, monolayers were incubated with PMN-ETcA-CM and data was continuously
collected at 4 kHz. Tracings were normalized to the zero-time point to determine the
relative change in TEER (n = 2 wells each). Error bars represent the standard deviation.
B. The peak change in TEER at 16 hours was significantly different between the two
groups (*p < 0.05, unpaired Student’s t-Test).
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Figure 2.17. Influence of Collagen Type on Permeability & Cldn5 Expression.
A. Mouse BBB-ECs were seeded at confluence into transwell inserts coated with
collagen type I (COL1 – orange) or collagen type IV (COL4 – blue). Following
maturation, the apparent permeability coefficient (P app) for the small solute tracer sodium
fluorescein (NaFluor) was used to assess barrier permeability for each collagen (n = 3
inserts each). Error bars represent the standard deviation of the mean. Groups marked
with different letters are statistically different from each other (p < 0.05, Student’s t-test).
B. Mouse BBB-ECs were seeded at confluence into wells coated with collagen type I
(COL1 – orange) or collagen type IV (COL4 – blue). Following maturation, cells were
lysed and assessed for expression of Cldn5 or Actb as a reference gene. Technical
duplicates were performed for each collagen (n = 3 wells each), and then 2 -ΔΔCq values
were calculated with the COL1 group arbitrarily set as the control group. Error bars
represent the standard deviation of the mean. Groups marked with different letters are
statistically different from each other (p < 0.05, Student’s t-test).
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Figure 2.18. Influence of Collagen Type on TEER.
Mouse BBB-ECs were seeded at confluence into 8W10E+ arrays coated with collagen
type IV (COL4 – blue) or collagen type I (COL1 – orange). Following maturation, data
was continuously collected over a range of frequencies (62.5 Hz to 64 kHz) for three
hours following an initial period of stabilization in the incubator (not shown). For this
figure, the mean resistance value (Ω) and standard deviations for each collagen type (n =
3 wells each) collected at 4 kHz are plotted as a function of time.
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Figure 2.19. Influence of Collagen Type on Rb & α.
A. The mean Rb value (Ω x cm2) and standard deviations for each collagen type (COL4 –
blue, COL1 – orange) for the data presented in Figure 2.7. B. The mean α value (Ω0.5 x
cm) and standard deviations for each collagen type (COL4 – blue, COL1 – orange) for
the data presented in Figure 2.7.
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Figure 2.20. Known Collagen Type IV-involved Pathways in Endothelial Cells.
A. Antibody (Ab)-mediated blockade of collagen type IV (COL4)-β1 integrin interactions
(orange – solid line) suppresses claudin-5 (CLDN5) expression (orange – dotted line)
through undetermined intermediaries.190,191 α?β1: Unknown α isoform. B. Silencing of
integrin-linked kinase (ILK; red – solid line), a putative pseudo-kinase kinase that
interacts with the cytoplasmic tail of β1, suppresses claudin-5 expression (red – dotted
line) through undetermined intermediaries.191 As the kinase Akt is a known downstream
target of ILK, it is possible that loss of ILK lowers Akt activity, in turn impairing its
ability to phosphorylate the transcription factor forkhead box protein O1 (FoxO1 orange) so as to prevent formation of a transcriptional repressor complex with betacatenin (βCAT - yellow) at the Cldn5 promotor. siILK: siRNA-mediated silencing of
ILK. Created with BioRender.com.

Figure 2.21. Known Collagen Type I-involved Pathways in Endothelial Cells.
A. Collagen type I (COL1) lowers cyclic AMP (cAMP) levels and protein kinase A (PKA) activity in an α 1β1- and α2β1-dependent
manner.230 As cAMP and PKA are positively associated barrier function and claudin-5 (CLDN5) expression,231 COL1 may impair a
cAMP-exchange protein directly activated by cAMP (EPAC)-CCAAT/enhancer-binding protein-α (C/EBPα) axis (red).232
Alternatively, COL1 may impair the ability of PKA to phosphorylate FoxO1 (orange).233 B. COL1 elevates the activities of the small
GTPase Ras homologue family member A (RhoA) and the kinase Src in a β1-dependent manner.234 Inhibition of either protein rescued
the destabilization of vascular endothelial-cadherin (CDH5).234 As CLDN5 is known to be phosphorylated by Rho-associated kinase
(ROCK), a known downstream target of RhoA, 58 COL1 may directly signal for the removal of CLDN5 from tight junctions.
Alternatively, destabilization of CDH5 liberates beta-catenin (βCAT – yellow) from the cell-cell contacts, in turn impairing a
phosphoinositide 3-kinase (PI3K)-Akt signaling pathway (green) that phosphorylates FoxO1 (orange). α?β1: Unknown α isoform. C.
COL1 impairs ILK in a β1-dependent manner.236 As the kinase Akt is a known downstream target of ILK, it is possible that loss of
ILK lowers Akt activity, impairing its ability to phosphorylate FoxO1 (orange). α?β1: Unknown α isoform. Created with
BioRender.com.
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Figure 2.22. Structural Features of Decorin.
A. Domain structure of the protein core. N: N-terminus. SP: signal peptide. PP:
Propeptide. GAG: Point of GAG chain attachment (Ser34). Cys: Cysteine-rich region.
LRR: Leucine-rich repeat. C: C-terminus. B. Solved crystal structure for the protein core
of bovine tissue-derived decorin (PDB: 1XCD). Each LRR is denoted by Roman
numerals (I-XII). The crystal structure was visualized using MolStar (M*) viewer 279 and
colored by sequence. Note: The first 21 residues of the mature protein, within which
resides the DEASGIG motif for GAGylation, are not shown due to conformational
disorder. Created with BioRender.com.
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Figure 2.23. Angiopoietin-Tie Signaling in Health & Disease.
A. Under healthy conditions, Ang-1 (blue) is the primary Ang member and binds to Tie2
receptors (red) enriched at cell-cell contacts which, in turn, suppresses FoxO1
transcriptional activity in a PI3K-AKT-dependent manner (yellow). Consequently,
claudin-5 gene expression is high, while decorin and Ang-2 expression are low. For
poorly understood reasons, basal Ang-2 (gold) expression also promotes Tie2 signaling
provided that the orphan receptor Tie1 is present (orange). B. Under inflammatory
conditions, Ang-2 predominates and the ectodomain of Tie1 is cleaved. These changes
shift Ang-2 to an antagonist of Tie2 signaling. This permits the nuclear accumulation of
FoxO1 which, in turn, suppresses claudin-5 gene expression and promotes decorin and
Ang-2 gene expression of decorin. Consequently, a positive feedback between FoxO1
and Ang-2 is formed. Note: Not illustrated is the fact that under inflammatory conditions,
Tie2 can be sequestered away from the cell-cell contacts, further impairing signaling.
Created with BioRender.com.
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Figure 2.24. Loss of SLRP Expression Partially Rescues Barrier Dysfunction.
A-D. Mouse BBB-ECs isolated from Dcnfl/fl mice (orange), Bgnfl/fl mice (blue), or Dcnfl/wt
x Bgnfl/fl mice (red) were seeded at confluence into 8W10E+ arrays coated with collagen
type IV. Following maturation, monolayers were incubated with TAT-HA2 and TAT-Cre
in serum-free media to ablate gene expression. To serve as a “wild-type” control, some
wells containing Dcnfl/fl BBB-ECs were incubated with TAT-HA2 alone in serum-free
media (grey). Following a media change and overnight recovery, monolayers were
incubated with PMN-ETcA-CM and data was continuously collected at 4 kHz. Tracings
were normalized to the zero-time point to determine the relative change in TEER (n = 2
wells each). Error bars represent the standard deviation. Note: The data presented for
decorin-knockout is the same as that shown in Figure 2.17. Additionally, at the time of
this experiment, a complete Dcnfl/fl x Bgnfl/fl genotype had not been achieved, so Dcnfl/wt x
Bgnfl/fl mice were used.
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Figure 2.25. No rescue in EAE with Bgn-floxed x Tie2-Cre Mice Post-Tamoxifen.
In a pilot study with Bgn-floxed x Tie2-Cre mice (blue; n = 5) and their Cre-negative
littermates (orange; n = 4), animals were injected i.p. with tamoxifen (50 mg/kg) every
12 hours for five consecutive days, then allowed to recover for 14 days. Subsequently,
active EAE was induced and clinical scoring was performed daily. Error bars represent
the standard error of the mean. Note: One Cre-negative animal reached a severity of
disease requiring humane euthanasia on 25 d.p.i. Per standard scoring procedure, a
clinical score of 5 was logged for the animal through the end of the experiment.
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Figure 2.26. Ai14 x Tie2-Cre Mice Exhibit Poor Recombination in vivo.
An Ai14 x Tie2-Cre mouse was injected i.p. with tamoxifen (50 mg/kg) every 12 hours
for five consecutive days, then allowed to recover for 14 days. Subsequently, the animal
was anesthetized and injected t.c. with TL-DyLight 649 to label the endothelium (red).
The animal was then flushed, decapitated, and its brain processed for confocal
microscopy to assess TdTomato (green) expression as a marker of recombination. A
representative micrograph is shown.
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Figure 2.27. Slco1c1-Cre Efficiently Recombines in vivo.
Bgn-floxed mice (Bfl/fl), Bgn-floxed x Tie2-Cre mice (TBfl/fl), or Bgn-floxed x Slco1c1Cre mice (SBfl/fl) were injected i.p. with tamoxifen (50 mg/kg) every 12 hours for five
consecutive days, then allowed to recover for 14 days. Microvessel-enriched pellets were
isolated from these three lines, then lysed for genomic DNA analysis. As an additional
control, wild-type (WT) animals were included. Note: Lanes represent the isolated
microvessels of a single animal.
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Figure 2.28. Principle of In-Cell Western Assay.
A. BBB-EC monolayers are cultured in a 96-well plate to a partially mature state, then
screened with compounds predicted to promote claudin-5 expression [1]. Following
fixation and permeabilization, monolayers are first labeled with a primary antibody
against claudin-5 [2], then a secondary antibody conjugated with IRDye ® 800CW [3]. To
normalize cell count between wells, CellTag 700™ is used [4]. B. When visualized using
a near-infrared (NIR) imaging system, compounds that promote claudin-5 expression can
be identified by increased signal in the 800 channel (middle) relative to the signal in the
700 channel (top) compared to wells administered vehicle controls (VEH). For
background correction, a subset of wells are incubated only with the secondary antibody
(BKGD). Created with BioRender.com.
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Figure 2.29. In-cell Western Assay for Screening pro-Claudin-5 Compounds.
A. Mouse BBB-ECs were seeded at confluence into a 96-well plate coated with collagen
type IV. Monolayers were allowed to partially mature (3 days), then were administered
methylprednisolone (MP; 10 µg/mL) with or without demethylasterriquinone B1
(DMAQ-B1; 5 mM), or neither. Six hours later, cells were fixed and analyzed via in-cell
western (ICW) assay for claudin-5 (orange). For normalization, monolayers were
counterstained with CellTag 700 (blue). B. Normalized and corrected mean claudin-5
signal value per µm2 for each group (n = 20 wells each). Error bars represent the standard
deviation of the mean. Groups marked with different letters are statistically different from
each other (p < 0.05, one-way ANOVA with post-hoc Tukey’s).
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APPENDIX A
Recent Transcriptional Studies Involving Claudin or TAMPs in Brain Microvessels.
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Summary of Recent Transcriptional Studies Involving Claudin or TAMP Expression in Brain MVs.

Mouse claudin-13 has no known human orthologue. Although there is a claudin-13-like gene in rats, no evidence exists that it is expressed.

LCM: Laser-capture microdissection. Dex-40 µm: Dextran-based sedimentation followed by the usage of a 40 µm filter. MACS: Magnetic-activated
cell sorting.

a

Note: Genes detected by qPCR-based assays are demarked by a check mark (✔) and those not detected by a cross mark (✘). Genes not tested are
demarked by two dashes (--). For relative expression, the mRNA amounts for all transcripts was summed, then the percentage for each gene calculated.
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Claudin-2
Claudin-3
Claudin-4
Claudin-5
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Claudin-7
Claudin-8
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Claudin-10
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a
Claudin-13
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Claudin-16

Table A.1.
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✔
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0.5%
✔
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✔
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Rat (Dex-40 µm)42
Exp. (% Overall)

LCM: Laser-capture microdissection. Dex-40 µm: Dextran-based sedimentation followed by the usage of a 40 µm filter. MACS: Magnetic-activated
cell sorting.

Claudins 22 and 24 are paralogues. Previously, they were designated singularly as claudin-21. There are no genes currently designated claudin-21 in
humans or rodents. cClaudin domain-containing protein 1 was previously designated claudin-25, and a separate gene is now designated as claudin-25 in
humans and rodents. 4Claudins 26 and 27 are putative members of the claudin family, but more recent phylogenetic analysis suggests they may actually
belong to the voltage-dependent calcium channel gamma subunit (CACNG) family.

b

Note: Genes detected by qPCR-based assays are demarked by a check mark (✔) and those not detected by a cross mark (✘). Genes not tested are
demarked by two dashes (--). For relative expression, the mRNA amounts for all transcripts was summed, then the percentage for each gene calculated.

Occludin
MarvelD2
MarvelD3

Gene
Claudin-17
Claudin-18
Claudin-19
Claudin-20
b
Claudin-21
b
Claudin-22
Claudin-23
b
Claudin-24
c
Claudin-25
d
Claudin-26
d
Claudin-27
c
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Mouse (LCM)39
Exp. (% Overall)

Human (LCM)39
Exp. (% Overall)
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APPENDIX B
Search Strategies Used to Identify Relevant Studies

Member

Gene

#0

Human
Mouse
Rat

Gene ID

KJD,

Search

Databases=WOS, BIOSIS,
SCIELO
Timespan=All years
Search language=Auto

TS=("keyword")

Search Strategy Parameters.

Search #

Table B.0.

MEDLINE,

RSCI,
--

Results

All searches used the same search settings
for databases, timespan, and language.

TS refers to a topic search which includes
the title, abstract, author-submitted
keywords, and Keywords Plus® (based on
the titles of the references of the article specific to Clarivate Analytics).

Notes

174

Member

Cldn1

Cldn2

Cldn3

Cldn4

Cldn5

Cldn6

Cldn7

Cldn8

Cldn9

Cldn10

#1

#2

#3

#4

#5

#6

#7

#8

#9

#10

603

1,092

TS=("claudin-6" OR "cldn6" OR "cldn-6" OR "cld6" OR
"cld-6" OR "cln6" OR "cln-6")
TS=("claudin-7" OR "cldn7" OR "cldn-7" OR "cld7" OR
"cld-7" OR "cln7" OR "cln-7")

TS=("claudin-10*" OR "cldn10*" OR "cldn-10*" OR
"cld10*" OR "cld-10*" OR "cln10*" OR "cln-10*")

2,926

TS=("claudin-5" OR "cldn5" OR "cldn-5" OR "cld5" OR
"cld-5" OR "cln5" OR "cln-5")

9071
58187
290485

2,439

TS=("claudin-4" OR "cldn4" OR "cldn-4" OR "cld4" OR
"cld-4" OR "cln4" OR "cln-4")

TS=("claudin-9" OR "cldn9" OR "cldn-9" OR "cld9" OR
"cld-9" OR "cln9" OR "cln-9")

3,209

TS=("claudin-3" OR "cldn3" OR "cldn-3" OR "cld3" OR
"cld-3" OR "cln3" OR "cln-3")

9080
56863
287099

3,096

TS=("claudin-2" OR "cldn2" OR "cldn-2" OR "cld2" OR
"cld-2" OR "cln2" OR "cln-2")

364

124

547

5,163

TS=("claudin-1" OR "cldn1" OR "cldn-1" OR "cld1" OR
"cld-1" OR "cln1" OR "cln-1")

TS=("claudin-8" OR "cldn8" OR "cldn-8" OR "cld8" OR
"cld-8" OR "cln8" OR "cln-8")

Results

Search

9073
54420
304124

Gene ID
9076
12737
65129
9075
12738
300920
1365
12739
65130
1364
12740
304407
7122
12741
65131
9074
54419
287098
1366
53624
65132

Search Strategy for the [CLAUDIN] data set.

Search #

Table B.1.

Two isoforms of claudin-10 (10a and 10b).

--

--

--

--

--

--

--

--

--

Notes
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Member

Cldn11

Cldn12

Cldn13

Cldn14

Cldn15

Cldn16

Cldn17

Cldn17

Cldn18

Cldn19

Search #

#11

#12

#13

#14

#15

#16

#17

#17

#18

#19

4,735

TS=("claudin-11" OR "cldn11" OR "cldn-11" OR "cld11"
OR "cld-11" OR "cln11" OR "cln-11" OR "oligodendrocytespecific protein" OR "OSP" OR "oligodendrocyte
transmembrane protein" OR "OTP")
TS=("claudin-12" OR "cldn12" OR "cldn-12" OR "cld12"
OR "cld-12" OR "cln12" OR "cln-12")
TS=("claudin-13" OR "cldn13" OR "cldn-13" OR "cld13"
OR "cld-13" OR "cln13" OR "cln-13")
TS=("claudin-14" OR "cldn14" OR "cldn-14" OR "cld14"
OR "cld-14" OR "cln14" OR "cln-14")
TS=("claudin-15" OR "cldn15" OR "cldn-15" OR "cld15"
OR "cld-15" OR "cln15" OR "cln-15")
TS=("claudin-16" OR "cldn16" OR "cldn-16" OR "cld16"
OR "cld-16" OR "cln16" OR "cln-16")
TS=("claudin-17" OR "cldn17" OR "cldn-17" OR "cld17"
OR "cld-17" OR "cln17" OR "cln-17")
TS=("claudin-17" OR "cldn17" OR "cldn-17" OR "cld17"
OR "cld-17" OR "cln17" OR "cln-17")
TS=("claudin-18" OR "cldn18" OR "cldn-18" OR "cld18"
OR "cld-18" OR "cln18" OR "cln-18")
TS=("claudin-19" OR "cldn19" OR "cldn-19" OR "cld19"
OR "cld-19" OR "cln19" OR "cln-19")

5010
18417
84588
9069
64945
500000
-57255
-23562
56173
304073
24146
60363
304388
10686
114141
155268
26285
239931
304125
26285
239931
304125
51208
56492
315953
149461
242653
298487

206

382

39

39

335

207

228

36

225

Results

Search

Gene ID

--

--

--

--

--

--

--

Claudin-13 is expressed in mice, but not
humans or rats.

--

Claudin-11 has historically been referred
to as OSP (oligodendrocyte-specific
protein).

Notes
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Member

Cldn20

Cldn21

Cldn22

Cldn23

Cldn24

Cldn25

Cldn26

Cldn27

Cldnd1

--

Search #

#20

#21

#22

#23

#24

#25

#26

#27

#28

#29

TS=("claudin-22" OR "cldn22" OR "cldn-22" OR "cld22"
OR "cld-22" OR "cln22" OR "cln-22")
TS=("claudin-23" OR "cldn23" OR "cldn-23" OR "cld23"
OR "cld-23" OR "cln23" OR "cln-23")
TS=("claudin-24" OR "cldn24" OR "cldn-24" OR "cld24"
OR "cld-24" OR "cln24" OR "cln-24")
TS=("claudin-25" OR "cldn25" OR "cldn-25" OR "cld25"
OR "cld-25" OR "cln25" OR "cln-25")

53842
75677
306454
137075
71908
290789
100132463
100039801
502083
644672
100042785
100360390

--

56650
224250
288182

283999
546519
688285

21

19,451

#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR
#9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR
#16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR
#23 OR #24 OR #25 OR #26 OR #27 OR #28

10

21

20

9

72

14

12

20

Results

TS=("claudin domain-containing protein 1" OR "claudin
domain-containing 1" OR "cldnd1")

TS=("claudin-26" OR "cldn26" OR "cldn-26" OR "cld26"
OR "cld-26" OR "cln26" OR "cln-26" OR "transmembrane
protein 114" OR "tmem114")
TS=("claudin-27" OR "cldn27" OR "cldn-27" OR "cld27"
OR "cld-27" OR "cln27" OR "cln-27" OR "transmembrane
protein 235" OR "tmem235")

TS=("claudin-21" OR "cldn21" OR "cldn-21" OR "cld21"
OR "cld-21" OR "cln21" OR "cln-21")

----

283953
74720
501675

TS=("claudin-20" OR "cldn20" OR "cldn-20" OR "cld20"
OR "cld-20" OR "cln20" OR "cln-20")

Search

49861
621628
680178

Gene ID

is

is

This represents the [CLAUDIN] data set.

Cldnd1 was formerly called claudin-25,
with a separate gene now designated
claudin-25.

The gene name for claudin-27
transmembrane protein 235.

The gene name for claudin-26
transmembrane protein 114.

The current gene designated claudin-25 is
different than the gene originally named
claudin-25 (see: Cldnd1).

--

--

--

No gene is currently designated Claudin21 in humans or rodents.

--

Notes
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Member

Ocln

MarvelD2

MarvelD3

--

#1

#2

#3

#4

#1 OR #2 OR #3

TS=("marvel domain-containing protein 3" OR "marvel
domain-containing 3" OR "marveld3")

91862
73608
498950
--

TS=("tricellulin" OR "tric" OR "marvel domain-containing
protein 2" OR "marvel domain-containing 2" OR
"marveld2")

TS=("occludin" OR "ocln")

Search

153562
218518
365657

100506658
18260
83497

Gene ID

Search Strategy for the [TAMP] data set.

Search #

Table B.2.

10,263

40

1,407

9,027

Results

This represents the [TAMP] data set.

--

The gene name for tricellulin is MarvelD2.

MarvelD1 is a different gene than
occludin.

Notes
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Ildr1

Ildr2

--

#2

#3

#4

#1

Search #

TS=("tight junction*")

Search

30,418

Results

TS=("Immunoglobulin Like Domain Containing Receptor
2" OR "ILDR2" OR "angulin-3")

387597
100039795
685277

#1 OR #2 OR #3

TS=("Immunoglobulin Like Domain Containing Receptor
1" OR "ILDR1" OR "angulin-2")

286676
106347
303914

--

2,797

TS=("angulin-1" OR "Lipolysis Stimulated Lipoprotein
Receptor" OR "lsr" OR "Immunoglobulin-Like Domain
Containing Receptor 3" OR "ildr3")

51599
54135
64355

Notes

This represents the [ANGULIN] data set.

--

--

--

Notes

Wildcard approach. This represents the [TJ] data set.

2,853

32

57

Results

Search

Gene ID

Search Strategy for the [TJ] data set.

Lsr

#1

Table B.4.

Member

Search Strategy for the [ANGULIN] data set.

Search #

Table B.3.
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[CLAUDIN]

[TAMP]

[ANGULIN]

[TJ]

#1 OR #2 OR #3 OR #4

#2

#3

#4

#5

Search

Search Strategy for the [UNIFIED] data set.

#1

Search #

Table B.5.

48,715

30,418

2,853

10,263

19,451

Results

This represents the [UNIFIED] data set.

Generic tight junction data set.

Angulin family data set.

TAMP family data set.

Claudin family data set.

Notes
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5,833

6,979

846

523

346

TS=("secondary-progressive MS" OR "SP-MS" OR "SPMS" OR "secondaryprogress*")

TS=("primary-progressive MS" OR "PP-MS" OR "PPMS" OR "primaryprogress*")

TS=("progressive-relapsing MS" OR "PR-MS" OR "PRMS" OR "progressiverelaps*")

TS=("acute multiple sclerosis" OR "acute MS" OR "Marburg's disease" OR
"Marbug disease" OR "Marburg's type" OR "Marburg type" OR "Marburg's
variant" OR "Marburg variant")

TS=("concentric sclerosis" OR "Balo's disease" OR "Balo disease" OR "Balo's
type" OR "Balo type" OR "Balo's variant" OR "Balo variant")

TS=("Tumefactive multiple sclerosis" OR "Tumefactive MS")

#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8

#3

#4

#5

#6

#7

#8

#9

165,410
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6,162

TS=("relapse-remitting MS" OR "RR-MS" OR "RRMS" OR "relapse-remit*")

#2

157,585

Results

TS=("multiple sclerosis")

Search

Search Strategy for the [MS] data set.

#1

Search #

Table B.6.

This represents the [MS] data set.

Atypical variant.

Atypical variant.

Atypical variant.

Least common of the main clinical forms.

Second-least common of the main clinical forms.

Second-most common of the main clinical forms.

Most common of the main clinical forms.

--

Notes
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#1 OR #2

#2

#3

Results

44,305

Search

TS=("experimental autoimmune encephalomyelitis" OR "experimental
autoimmune" OR "autoimmune encephalomyelitis" OR "EAE" OR
"experimental allergic encephalomyelitis" OR "experimental allergic" OR
"allergic encephalomyelitis")

Search #

#1

Search Strategy for the [EAE] data set.

3,572

TS=("acute hemorrhagic" OR "acute hemorrhagic leukoencephalitis" OR
"hemorrhagic leukoencephalitis" OR "AHLE" OR "acute hemorrhagic
encephalomyelitis" OR "hemorrhagic encephalomyelitis" OR "AHEM" OR
"Hurst's disease" OR "Hurst disease" OR "Weston-Hurst syndrome")

Table B.9.

5,380

TS=("acute disseminated" OR "acute disseminated encephalomyelitis" OR
"disseminated encephalomyelitis" OR "ADEM")

#1

8,836

Results

Search

Search #

Search Strategy for the [ADEM] data set.

20,611

TS=("neuromyelitis" OR "neuromyelitis optica" OR "NMO" OR
"neuromyelitis" OR "neuromyelitis optica spectrum" OR "neuromyelitis optica
spectrum disorder*" OR "NMOSD" OR "Devic's disease" OR "Devic disease")

#1

Table B.8.

Results

Search

Search Strategy for the [NMOSD] data set.

Search #

Table B.7.

This represents the [EAE] data set.

Notes

This represents the [ADEM] data set.

Rare variant of ADEM.

Common form.

Notes

This represents the [NMOSD] data set.

Notes
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Results

2,997

Search

TS=("experimental neuromyelitis" OR "experimental NMO*" OR "model of
neuromyelitis" OR "model of NMO*" OR "neuromyelitis optica model" OR
"neuromyelitis optica rodent model*" OR "neuromyelitis optica mouse
model*" OR "neuromyelitis optica rat model*" OR "NMO rodent model*" OR
"NMO mouse model*" OR "NMO rat model*" OR "neuromyelitis optica
spectrum disorder model*" OR "neuromyelitis optica spectrum disorder rodent
model*" OR "neuromyelitis optica spectrum disorder mouse model*" OR
"neuromyelitis optica spectrum disorder rat model*" OR "NMOSD rodent
model*" OR "NMOSD mouse model*" OR "NMOSD rat model*" OR
"neuromyelitis optica IgG" OR "NMO-IgG" OR "neuromyelitis optica
spectrum disorder IgG" OR "NMOSD-IgG" OR "neuromyelitis optica
recombinant antibod*" OR "neuromyelitis optica rAb*" OR "neuromyelitis
optica antibod*" OR "neuromyelitis optica Ab*" OR "NMO recombinant
antibod*" OR "NMO rAb*" OR "NMO antibod*" OR "NMO Ab*" OR
"neuromyelitis optica spectrum disorder recombinant antibod*" OR
"neuromyelitis optica spectrum disorder rAb*" OR "neuromyelitis optica
spectrum disorder antibod*" OR "neuromyelitis optica spectrum disorder Ab*"
OR "NMOSD recombinant antibod*" OR "NMOSD rAb*" OR "NMOSD
antibod*" OR "NMOSD Ab*" OR "Aquaporin-4-IgG" OR "AQP4-IgG" OR
"aquaporin-4 recombinant antibod*" OR "aquaporin-4 rAb*" OR "aquaporin4 antibod*" OR "aquaporin-4 Ab*" OR "AQP4 recombinant antibod*" OR
"AQP4 rAb*" OR "AQP4 antibod*" OR "AQP4 Ab*")

#1

Search Strategy for the [E-NMOSD] data set.

Search #

Table B.10.

This represents the [E-NMOSD] data set.

There is no set disease model name. Therefore, as
many phrases involving key words in different
orders were queried.

Notes
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#1 OR #2

#3

Results
1,588

Search

TS=("cuprizone" OR "oxalic acid bis(cyclohexylidene hydrazide)" OR "N,NOxalylbis(cyclohexanone
hydrazone)"
OR
"biscyclohexanone
oxaldihydrazone" OR "biscyclohexanoneoxalyhydrazone")

#1

5,360

536

4,831

Results

Search #

Table B.12.

Search Strategy for the [CUP] data set.

TS=("peptide-induced fatal syndrome" OR "PIFS" OR "peptide-induced fatal")

#2

#1

Search
TS=("Theiler's murine encephalomyelitis virus" OR "TMEV" OR "Theiler's
murine encephalomyelitis" OR "Theiler's murine" OR "Theiler's
encephalomyelitis virus" OR "Theiler's encephalomyelitis" OR "Theiler's
virus" OR "murine encephalomyelitis virus" OR "encephalomyelitis virus")

Search Strategy for the [TMEV] data set.

Search #

Table B.11.

Cuprizone model. This represents the [CUP] data
set.

Notes

This represents the [TMEV] data set.

Fulminant TMEV model

Classic TMEV model

Notes
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[MS]

[NMOSD]

[ADEM]

[EAE]

[E-NMOSD]

[TMEV]

[CUP]

#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7

#2

#3

#4

#

#6

#7

#8

Search

Search #

#1

Search Strategy for the [DISEASE] data set.

Table B.13.

205,981

1,588

5,360

2,997

44,305

8,836

10,611

165,410

Results

This represents the [DISEASE] data set.

Cuprizone data set.

TMEV data set.

E-NMOSD data set.

EAE data set.

ADEM data set.

NMOSD data set.

MS data set.

Notes
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[UNIFIED]

[DISEASE]

#1 AND #2

#2

#3

Search

Search #

#1

Search Strategy for the [OVERLAP] data set.

Table B.14.

657

205,981

48,715

Results

This represents the overlap between the [DISEASE] and
[UNIFIED] data sets.

Disease model set (all diseases and models).

Tight junction data set (all families and generic tight junction).

Notes

186

187

APPENDIX C
Summary Tables for Studies with CNS-IDDs.

Patients (n)@

Brain

• SP (10)
• Acute (2)
• OND (5)
• CD (2)

• ND (6)

Plumb
et al.83,b,c

Wosik
et al.85,d
White

White

White

White

Matter

Active

Active

• Demyelination
• Cellular Infiltration (H&E)

• Demyelination
• Activated microglia/macrophages
• Fibrinogen deposition
• CD45+ infiltrates

↓ OCLN intensity & strand thickness at tight junctions in
lesional vessels vs. NAWM.

↑ Proportion of abnormal tight junctions in lesional vessels vs.
ONDs or CDs based on altered OCLN & ZO-1 reactivity.

IHC-IF

IHC-IF

IHC-IF

↑ Proportion of abnormal tight junctions for pre-lesional
vessels in HLA-DR+ NAWM vs. HLA-DR- NAWM based on
altered OCLN & ZO-1 reactivity.

• Activated microglia/macrophages
• CD45+ infiltrates

Pre-Active

Disruption & loss of OCLN reactivity in lesional vessels near
HLA-DR+ macrophages, CD45+ infiltrates, or fibrinogen
deposition.

IHC-IF

Disruption & loss of CLDN5 & OCLN reactivity in prelesional vessels vs. NAWM. Also, ↓ CLDN5 & ↓ OCLN pixel
intensity.

•Activated microglia/macrophages
• Astrogliosis
• Fibrinogen & ApoBs deposition
• CD3+ infiltrates

IHC-IF

Methods

Pre-Active

Tight Junction Protein Alterations#
No apparent alteration of CLDN5 reactivity detected in prelesional vessels near HLA-DR+ microglial clusters.

Histology†
• Activated microglial clusters
• No astrogliosis
• No fibrinogen deposition

Pre-Active

Stage/Type†

PP: Primary-Progressive MS. SP: Secondary-Progressive MS. ND: Clinical form not determined or not provided. RR: Relapse-remitting MS. Acute: Acute MS (Marburg’s disease). OND: Other
neurological disease. CD: Control Donor. NP: Not provided. ApoB: Apolipoprotein B. CD3: Cluster of differentiation 3. CD45: Cluster of differentiation 45. HLA-DR: Human leukocyte antigen DR
isotype. NAWM: Normal-appearing white matter. CLDN5: claudin-5. OCLN: occludin. IHC-IF: Immunofluorescent-based immunohistochemistry.

Comparisons with HLA-DR- NAWM or control donors were not performed. bQuantification used a combination of occludin- and ZO-1-labeling. cMicrographs of occludin from HLA-DR+ NAWM or
control donors were not provided. dMicrographs were not provided.

a

Note: @When studies specified the patients involved in tight junction protein analyses, only those patients are listed and are marked by an asterisk (*). †Where available, lesion staging and histology are
included. #Unless otherwise noted, comparisons are between patients and control donors. Increases are marked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a leftright arrow (↔).

Brain

Brain

• SP (6)
• RR (4)

Alvarez
et al.9

Brain

Origin

CNS-EC-specific Alterations in MS.

• PP (2)*
Van Horssen
• SP (2)*
et al.82,a
• ND (1)*

Study

Table C.1.
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Brain

Brain &
Spine

• RR (6)
• CD (11)

• ND (2)
• CD (3)

Musolino
et al.90

Uchida
et al.40,g
NP

White

Grey

White

White

Matter

NP

NP

Pure Grey

Inactive

Inactive

Chronic
Active

Stage/Type†

• NP

• Demyelination

IHC-IF

IHC-IF

Disruption & loss of CLDN11 reactivity in patient brain &
spine vessels. Also, ↓ CLDN11 per GLUT1 intensity for brain
& spine.

IHC-IE

IHC-IE

qPCR

MA,
qPCR

Methods

Disruption & loss of CLDN5 reactivity in lesional vessels.

No apparent loss of CLDN5 reactivity detected in lesional
vessels vs. adjacent NAGM.

Sporadic loss of CLDN5+ in lesional vessels.

• Demyelination
• Sparse HLA-DR+ cell presence

• Demyelination
• No astrogliosis
• No fibrinogen or IgG deposition

↓ Ocln mRNA in BMVs isolated from patients vs. NAWM.

↑ Ocln mRNA in brain MVs isolated from patients vs. NAWM
using MA, but ↓ Ocln mRNA in BMVs isolated from patients
vs. NAWM using qPCR.

Tight Junction Protein Alterations#

• Demyelination
• No ORO+ cell presence

• Demyelination
• Sparse ORO+ cell presence
• HLA-DR+ presence at edge

Histology†

Statistics were not enumerated for the qPCR data. f Micrographs of control donors were not provided. fTissues were analyzed without distinction between matter type or lesion status.

PP: Primary-Progressive MS. SP: Secondary-Progressive MS. ND: Clinical form not determined or not provided. RR: Relapse-remitting MS. Prog: Progressive MS. CD: Control Donor. NP: Not
provided. MV: Microvessel. ORO: Oil Red O stain. HLA-DR: Human leukocyte antigen DR isotype. IgG: Immunoglobulin G. NAWM: Normal-appearing white matter. NAGM: Normal-appearing
grey matter. CLDN5: claudin-5. OCLN: occludin. CLDN11: claudin-11. GLUT1: Glucose transporter 1. MA: Microarray. qPCR: Quantitative Polymerase Chain Reaction. IHC-IE: Immunoenzymebased immunohistochemistry. IHC-IF: Immunofluorescent-based immunohistochemistry.

e

Note: @When studies specified the patients involved in tight junction protein analyses, only those patients are listed and are marked by an asterisk (*). †Where available, lesion staging and histology are
included. #Unless otherwise noted, comparisons are between patients and control donors. Increases are marked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a leftright arrow (↔).

Brain

Brain MVs

Origin

Van Horssen
et al.86,f

• PP (3)*
• SP (4)*

Patients (n)@

• ND (2)
• RR (1)
• PP (2)
• SP (14)
• Prog (2

Cunnea
et al.87,e

Study
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• Serum

• Plasma

• RR (20)
• CD (20)

• RR (29)*
• Gad+ (15)
• Gad- (14)
• CD (17)

CamaraLemarroy
et al.283

↑ OCLN protein concentration in RR-Gad+ plasma vs. RR-Gad- plasma.

↑ OCLN protein concentration.

↑ CLDN5 & ↑ OCLN protein concentration in RR serum at 6 & 12 months of treatment vs. 0 months.

↑ CLDN5 & ↑ OCLN protein concentration at 0, 6, and 12 months of treatment vs. control donor
serum.

↔ CLDN11 protein concentration.

↑ Cldn11 mRNA in PBLs.

ELISA

ELISA

ELISA

qPCR

qPCR

WB

↓ Total CLDN5 protein in PBLs isolated from RR-R patients after treatment vs. before.
↔ Cldn5 mRNA in PBLs isolated from RR-S patients after treatment vs. before.

qPCR

WB

qPCR

Methods

↓ Cldn5 mRNA in PBLs isolated from RR-R patients after treatment vs. before.

↑ Total CLDN1 & ↑ total CLDN5 protein in PBLs isolated from RR-R patients vs. RR-S patients or
control donors.

↑ Cldn5 mRNA in PBLs isolated from RR-R patients vs. RR-S patients or control donors.

Tight Junction Protein Alterations#

who positively responded to IFN-β treatment had lower initial claudin-5 mRNA levels than those who poorly responded to IFN-β treatment.

RR-R: Relapsing-remitting MS during relapse. RR-S: Relapse-remitting MS during remission (stable). CD: Control donor. Gad+/Gad-: Presence/absence of gadolinium-enhancing lesion at time of
blood draw. CLDN5: Claudin-5. PBLs: Peripheral blood leukocytes. CLDN1: Caudin-1. CLDN11: Claudin-11. OCLN: Occludin. qPCR: Quantitative polymerase chain reaction. WB: Western blotting.
ELISA: Enzyme-linked immunosorbent assay.

aPatients

Note: @When studies specified the patients involved in tight junction protein analyses, only those patients are listed and are marked by an asterisk (*). #Unless otherwise noted, comparisons are between
patients and control donors. Increases are marked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left-right arrow (↔).

--

• FTY720 for
12 months

--

• Plasma

Annunziata
et al.282

--

• Interferon-β for
3-6 months

• Glucocorticoids
for 7 days

--

Intervention(s)

• Peripheral Blood
Leukocytes

• RR-S (13)
• CD (15)

Hassanzadeh
et al.281

Origin

• Peripheral Blood
Leukocytes

Mandel
et al.280,a

Patients (n)@

Non-CNS-EC-specific Alterations in MS.

• RR-R (51)
• RR-S (53)
• CD (40)

Study

Table C.2.
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• Choroid Plexus

• PP (3)
• SP (10)
• CD (13)

• ND (NP)

Kooij
et al.285,c

Mora
et al.124
--

--

--

Intervention(s)

IHC-IF

qPCR

↔ Cldn1 & ↔ Cldn5 mRNA in homogenate.

CLDN4 reactivity detected at the glial limitans of astrocytes within active cortical lesions.

qPCR,
WB

IHC-IF

Disruption & loss of CLDN3 reactivity in tissue sections.

↓ Cldn3 mRNA & ↓ total CLDN3 protein in homogenate.

IHC-IE

Methods

Disruption & loss of CLDN11 reactivity in demyelinated rings vs. adjacent myelinated rings.

Tight Junction Protein Alterations#

is expressed by oligodendrocytes, hence its usage here as a myelin marker. cClinical form-specific analysis was not performed.

CS: Concentric sclerosis (Balo’s disease). PP: Primary-Progressive MS. SP: Secondary-Progressive MS. CD: Control donor. ND: Clinical form not determined or not provided. NP: Information not
provided. CLDN11: Claudin-11. CLDN3: Claudin-3. CLDN1: Caudin-1. CLDN5: Caudin-5. CLDN4: Caudin-4. IHC-IE: Immunoenzyme-based immunohistochemistry. IHC-IF: Immunofluorescentbased immunohistochemistry. qPCR: Quantitative polymerase chain reaction. WB: Western blotting.

bClaudin-11

Note: @When studies specified the patients involved in tight junction protein analyses, only those patients are listed and are marked by an asterisk (*). #Unless otherwise noted, comparisons are between
patients and control donors. Increases are marked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left-right arrow (↔).

• Cortical Astrocytes

• Brain Myelin

• CS (4)

Masaki
et al.284,b

Origin

Patients (n)@

Study
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• NMOSD (1)*
• CD (3)

• NMOSD (4)*
• CD (5)

Patients (n)@

• Spine

• Brain &
Spine

Origin

Sub-Acute‡

Early‡

Staging†

• Partial astrocyte repopulation
• Demyelination
• Activated macrophages/microglia
• No inflammatory infiltrates
• Focal fibrinogen deposition

• Completed astrocyte loss
• Demyelination
• Activated macrophages/microglia
• Inflammatory infiltrates
• No fibrinogen deposition

Histology†

CNS-EC-specific Alterations in NMOSD.

No apparent alteration of CLDN3 & OCLN reactivity in lesional vessels vs.
control donors.

No apparent alteration of CLDN5 reactivity in lesional vessels. Also, ↔
proportion of CLDN5+ lesional or perilesional vessels vs. control donors.

Tight Junction Protein Alterations#

IHC-IF

IHC-IF

Methods

autopsied after 2005 were seropositive for AQP4. Although the serostatus for patients autopsied prior to 2005 was not available, the patients all fulfilled at least two of the core NMOSD characteristics
of claudin-5 from control donors were not provided. cThe originals authors suggest that the fibrinogen in the sub-acute lesion may be old and not yet cleared, rather than freshly deposited.

CD: Control Donor. CLDN5: Claudin-5. CLDN3: Claudin-3. OCLN: Occludin. IHC-IF: Immunofluorescent-based immunohistochemistry.

bMicrographs

aPatients

Note: @When studies specified the patients involved in tight junction protein analyses, only those patients are listed and are marked by an asterisk (*). †Where available, lesion staging and histology are included.
Original author-reported staging marked by a double dagger (‡). # Increases are marked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left-right arrow (↔).

Winkler
et al.20,a,b,c

Study

Table C.3.
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• NMOSD (6)
• CD (5)

Patients (n)
• Sigmoid colon

Origin

--

Intervention(s)

Tight Junction Protein Alterations#
Disruption & loss of CLDN1 & OCLN reactivity in the colonic mucosa. Additionally, ↓ CLDN1 &
↓ OCLN average optical density.

Non-CNS-EC-specific Alterations in NMOSD.

patients were AQP4-seropositive.

CD: Control donor. CLDN1: Claudin-1. OCLN: Occludin. IHC-IF: Immunofluorescent-based immunohistochemistry.

aAll

Note: #Increases are demarked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left-right arrow (↔).

Cui et al.286,a

Study

Table C.4.

IHC-IF

Methods
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APPENDIX D
Summary Tables for Studies with Cell Culture Models of CNS-IDDs.

• ND-Acute (7)

• ND-Acute (10)

• RR-R (6)
• RR-S (9)
• SP (8)

Shimizu
et al.95,a,b

Tasaki
et al.96,a,b

Shimizu
et al.97,b

TY09

TY08

TY08

Cell Line

IgG

Serum

Serum

Serum

Sample

--

• MMP inhibition
(GM6001)

• Neutralizing Abs
(TNF-α, IFN-γ,
IL17, VEGF)

--

• MMP inhibition
(GM6001)

↑ Total CLDN5 for RR-R sera with VEGF Ab or GM6001 vs. without,
but ↔ total CLDN5 protein for RR-R sera with other Abs vs. without.

↓ Total OCLN protein for SP sera vs. FBS, but ↔ total OCLN protein
for either RR sera vs. FBS.

↓ Total CLDN5 protein for SP IgG vs. FBS IgG, but ↔ total CLDN5
protein for either RR patient IgG vs. FBS IgG.

↔ TEER for either RR IgG vs. FBS
IgG.
↔ Total OCLN protein for any patient IgG type vs. FBS IgG

↓ TEER for SP IgG vs. FBS IgG.

↔ Total CLDN5 & ↔ total OCLN protein for SP sera with Abs or
inhibitor vs. without.

↑ TEER for RR-R sera with VEGF
↔ Total OCLN protein for RR-R sera with Abs or inhibitor vs. without.
Ab or GM6001 vs. without.

↓ TEER for SP or RR-R sera vs. FBS.
↔ TEER for RR-S sera vs FBS.

↓ Total CLDN5 protein for RR-R or SP sera vs. FBS, but ↔ total
CLDN5 protein for RR-S sera vs. FBS.

↔ TEER or perm. to NaFl for patient
↔ Total CLDN5 protein for patient serum with GM6001 vs. without.
serum with GM6001 vs. without.

ND-Acute: Clinical form not determined or not provided during the acute phase of disease. RR-R: Relapsing-Remitting MS during relapse. RR-S: Relapse-Remitting MS in remission (stable). SP: SecondaryProgressive MS. IgG: Immunoglobulin G. TY08: Human brain endothelial cells (BECs) that express a temperature-sensitive SV40-T antigen variant. TY09/TY10: TY08-derived cells that additionally express
human telomerase reverse transcriptase (hTERT). Ab: Antibody. TNF-α: Tumor Necrosis Factor alpha. IFN-γ: Interferon gamma. IL17: Interleukin 17. VEGF: Vascular endothelial growth factor. MMP: Matrix
metalloproteinase. TEER: Transendothelial electrical resistance. NaFl: Sodium fluorescein. CLDN5: Claudin-5. OCLN: Occludin. FBS: Fetal bovine serum. WB: Western blotting.

aThese

patients fulfilled the 2010 revised McDonald diagnostic criteria. As the authors contrast patients during “acute phase” with those during “stable disease”, “acute phase” suggests following an episode of
neurologic symptoms. bAlthough control donor sera and IgG were used, only comparisons against FBS or FBS-derived IgG were performed.

WB

WB

WB

WB

WB

↔ TEER with patient serum vs. FBS. ↔ Total CLDN5 protein for patient serum vs. FBS.

--

Methods
WB

Tight Junction Protein Alterations#

↔ TEER with patient serum vs. FBS. ↔ Total CLDN5 & ↔ total OCLN protein for patient serum vs. FBS.

Barrier Alterations

--

Intervention(s)

Note: #Increases are marked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left-right arrow (↔).

Patients (n)

MS Sera/IgG-induced Alterations in Human CNS-EC Culture Models.

Study
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• RR (12-24)
• CD (12-24)

hCMEC/D3

Serum

Serum

Serum

Sample

--

• S1PR inhibition
(FTY720P)

• VDR Agonism
(Vitamin D3)

Intervention(s)

The exact TY cell line was not defined. dPatients were grouped into a single disease category for the qPCR data. eSerum samples were pooled and the exact number of patients was not enumerated.

RR-R: Relapsing-Remitting MS during relapse. RR-S: Relapse-Remitting MS in remission (stable). SP: Secondary-Progressive MS. CD: Control Donor. TY08: Human brain endothelial cells (BECs)
that express a temperature-sensitive SV40-T antigen variant. TY09/TY10: TY08-derived cells that additionally express human telomerase reverse transcriptase (hTERT). hCMEC/D3: Human BECs
that express SV40-T antigen and hTERT. S1PR: Sphingosine 1 phosphate receptor. TEER: Transendothelial electrical resistance. FITC: Fluorescein isothiocyanate. CLDN5: Claudin-5. OCLN: Occludin.
WB: Western blotting. qPCR: Quantitative polymerase chain reaction. FC: Flow cytometry.

c

FC

qPCR

WB

↑ Total CLDN5 & ↔ total OCLN protein for all patient serum types
with pre-treatment vs. without.

↑ Cldn5 mRNA for MS sera with pre-treatment vs. without.

WB

Methods

↑ Total CLDN5 protein for RR-R sera with pre-treatment vs. without,
but ↔ total CLDN5 protein for RR-S or SP sera under same conditions.

Tight Junction Protein Alterations#

↓ TEER & ↓ perm. to 70 kDa FITC↓ Mean intensity fluorescence of OCLN for RR sera vs. CD sera.
Dextran for RR sera vs. CD sera.

↑ TEER for all patient serum types
with FTY720P vs. without.

--

Barrier Alterations

Note: #Increases are marked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left-right arrow (↔).

Sheikh
et al.98,e

TY*

• RR-R (3)
Nishihara
• RR-S (3)
100,c,d
et al.
• SP (3)

Cell Line

TY10

Patients (n)

• RR-R (3)
Takahashi
• RR-S (3)
et al.101
• SP (3)

Study
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Serum

Serum

• SP (NP)
• CD (15)

• RR-R (NP)
• RR-S (NP)
• CD (3)

Proia
et al.229,b

Blecharz
et al.288
cEND

RBE4

SVEC4-10

Cell line

• Dex

↑ Cldn5 mRNA & ↔ Ocln mRNA for RR-R sera with Dex vs. without.

↑ Cldn5 & Ocln mRNA for RR-S sera with Dex vs. without.

↔ TEER for RR-R sera with Dex
vs. without.

↑ Total CLDN5 & ↑ total OCLN protein for RR-S sera with Dex vs. without.

↓ Cldn5 mRNA & ↔ Ocln mRNA for RR-S sera vs. CD sera.

↓ Cldn5 & ↓ Ocln mRNA for RR-R sera vs. CD sera.

qPCR

WB

qPCR

WB

↓ Total CLDN5 & ↓ total OCLN protein for both patient sera vs. CD sera.

↑ Total CLDN5 protein & ↓ total OCLN protein for RR-R sera with Dex vs.
without.

↓ TEER for both patient serum types
vs. CD sera.

--

IHC-IF,
WB

WB

Methods

Loss of OCLN reactivity & ↓ total OCLN protein for SP sera vs. CD sera.

↓ Total OCLN protein for ND-R sera vs. CD sera.

Tight Junction Protein Alterations#

↑ TEER for RR-S sera with Dex
vs. without.

↓ TEER for SP sera vs. CD sera.

--

Barrier Alterations

--

--

Intervention

ND-R: Clinical form not determined or provided during relapse. CD: Control donor. SP: Secondary-Progressive MS. NP: Information not provided. RR-R: Relapsing-Remitting MS during relapse. RRS: Relapse-Remitting MS in remission (stable). SVEC4-10: Mouse lymphatic endothelial cell line transformed by simian virus 40. RBE4: Rat brain endothelial cell (BEC) line that expresses the adenovirus
E1A gene. cEND: Mouse BEC line that expresses the murine polyoma middle T oncogene. Dex: Dexamethasone. TEER: Transendothelial electrical resistance. OCLN: Occludin. CLDN5: Claudin-5.
WB: Western blotting. IHC-IF: Immunofluorescent-based immunohistochemistry. qPCR: quantitative polymerase chain reaction.

patients met the 2001 McDonald diagnostic criteria. Additionally, patients in remission were recruited for the study, but their data was not shown. bA tri-culture model with rat astrocytes and rat
neurons was used. aAll patients were AQP4-seropositive.

aThese

Note: @When studies specified the patients involved in tight junction protein analyses, only those patients are listed and are marked by an asterisk (*). #Increases are demarked by an upwards arrow (↑),
decreases – by a downwards arrow (↓), and no change – by a left-right arrow (↔).

Serum

Sample

• ND-R (6)*
• CD (6)

Patients (n)@

MS Sera/IgG-induced Alterations in Non-human or Non-CNS EC Culture Models.

Minagar
et al.287,a
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TY08

Shimizu
et al.95,a,b

Serum

Sample

• Neutralizing Abs
(TNF-α, IFN-γ, IL6,
IL17, VEGF, TGFβ)

• Ab depletion
(Incubation with ACs
for 30 or 150 min)

• NMO-A (2)

• Plasma exchange

• NMO-A (2)

• NMO-A (8)
(+) α-BEC Abs (5)
(-) α-BEC Abs (3)

--

Intervention(s)

• NMO-A (14)

Patient (n)

↑ Total CLDN5 protein for patient serum after PE vs.
before PE.

↑ TEER with patient serum after TPE vs.
before TPE.

↑ TEER for patient serum following 30 or
150 minutes of depletion vs. none.

↔ TEER for patient serum containing αBEC Abs with IL17 Ab vs. without.

↑ TEER for patient serum containing αBEC Abs with VEGF Ab vs. without.

WB

WB

qPCR

TY08: Human brain endothelial cells (BECs) that express a temperature-sensitive SV40-T antigen variant. NMO-A: NMO during the acute phase of disease. Ab: Antibody. TPE: Therapeutic plasma
exchange. TNF-α: Tumor Necrosis Factor alpha. IFN-γ: Interferon gamma. IL6: Interleukin 6. IL17: Interleukin 17. VEGF: Vascular endothelial growth factor. TGFβ: Transforming growth factor beta.
AC: Astrocyte. TEER: Transendothelial electrical resistance. FBS: Fetal bovine serum. CLDN5: Claudin-5. OCLN: Occludin. WB: Western blotting. qPCR: Quantitative polymerase chain reaction.

the authors contrast patients during “acute phase” with those during “stable disease”, “acute phase” suggests following an episode of neurologic symptoms. bAlthough control donor sera and IgG
were used, only comparisons against FBS or FBS-derived IgG were performed.

aAs

↑ Total CLDN5 protein for patient serum following 30
or 150 minutes of depletion vs. none.

↔ Total CLDN5 & ↔ total OCLN protein for patient
serum containing α-BEC Abs with IL17 Ab vs. without.

↑ Total CLDN5 & ↔ total OCLN protein for patient
serum containing α-BEC Abs with VEGF Ab vs.
without.

↑ Ocln mRNA for patient serum, regardless of α-BEC
status, with IL17 Ab vs. without, but no alteration with
other Abs vs. without, regardless of α-BEC status.

↑ Cldn5 mRNA for patient serum containing α-BEC
Abs with VEGF Ab vs. without, but no alteration with
other Abs vs. without, regardless of α-BEC status.

WB

↓ Total CLDN5 protein for patient serum vs. FBS, but
↔ total OCLN protein for patient serum vs. FBS.

↓ TEER with patient serum vs. FBS.

WB

Methods

Tight Junction Protein Alterations#

Barrier Alterations

Note: #Increases are marked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left-right arrow (↔).

Cell Line

NMOSD Sera/IgG-induced Alterations in Human CNS-EC Culture Models.
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TY08

TY08

TY08

Tasaki
et al.96,a,b,c,d

Takeshita
et al.105

Shimizu
et al.106,e
• NMO (7)
• ICD (2)
--

--

• NMO (50 pooled)
• CD (NP pooled)

IgG

--

• NMOSD-A (5)
• NMO (4)
• LETM (1)
• AQP4 Expression
(Co-culture with AQP4+
or AQP4- ACs)

--

• NMO (50 pooled)
• CD (NP pooled)

rAb

↔ Total CLDN5 protein for patient serum vs. FBS.

WB

WB

Disruption & loss of CLDN5 reactivity with patient IgG
IHC-IF
vs. CD IgG. Also, ↓ CLDN5+ area fraction.

↑ Perm. to 10 kDa Dextran with patient rAb Disruption & loss of CLDN5 reactivity with patient rAb
IHC-IF
vs. ICD rAb.
vs. ICD rAb. Also, ↓ CLDN5+ area fraction.

--

Disruption & loss of CLDN5 reactivity with AQP4+
↑ Perm. to 10 kDa FITC-Dextran with
ACs & patient IgG vs. AQP4+ ACs & CD IgG or AQP4AQP4+ ACs & patient IgG vs. AQP4+ &
IHC-IF
ACs & patient IgG. Also, ↓ CLDN5+ area fraction vs.
CD IgG or AQP4- ACs & patient IgG.
both conditions.

↔ TEER and ↔ perm. to NaF with patient
↔ Total CLDN5 protein for patient IgG vs. FBS IgG.
IgG vs. FBS IgG.

--

WB

WB

Methods

TY08: Human brain endothelial cells (BECs) that express a temperature-sensitive SV40-T antigen variant. IgG: Immunoglobulin G. rAb: Recombinant antibody. NMOSD-A: NMOSD during the acute
phase of disease. NMOSD-S: NMOSD in remission (stable). LETM: Longitudinal extensive transverse myelitis. CD: Control Donor. ICD: Inflammatory control. MMP: Matrix metalloproteinase. AQP4:
Aquaporin 4. AC: Astrocyte. TEER: Transendothelial electrical resistance. FBS: Fetal bovine serum. NaF: Sodium fluorescein. FITC: Fluorescein isothiocyanate. kDa: Kilodalton. CLDN5: Claudin-5.
OCLN: Occludin. WB: Western blotting. qPCR: Quantitative polymerase chain reaction. IHC-IF: Immunofluorescent-based immunohistochemistry.

the authors contrast patients during “acute phase” with those during “stable disease”, “acute phase” suggests following an episode of neurologic symptoms. bAlthough control donor sera and IgG
were used, only comparisons against FBS or FBS-derived IgG were performed. cThe patients who donated stable disease serum also donated acute phase serum. dThe names of the MMP2 and MMP9
inhibitors were not defined. eThe patient-derived recombinant antibody recognizes glucose-regulated protein 78 (GRP78).

aAs

Tight Junction Protein Alterations#

↓ TEER and ↑ perm. to NaF with patient ↓ Total CLDN5 protein for patient serum vs. FBS, but
serum vs. FBS.
↔ total CLDN5 protein for NMO serum vs. LETM.

Barrier Alterations

↑ TEER & ↓ perm. to NaF for patient serum
• MMP inhibition
with GM6001 vs. without.
↑ Total CLDN5 protein for patient serum with any of the
(GM6001 or inhibitors
inhibitors vs. without.
specific to MMPs 2 or -9) ↑ TEER for patient serum with MMP-2 or
MMP-9 inhibitors vs. without.

--

Intervention(s)

• NMOSD-S (4)
• NMO (2)
• LETM (2)

• NMOSD-A (10)
• NMO (7)
• LETM (3)

Patient (n)

IgG

IgG

Serum

Sample

Note: #Increases are marked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left-right arrow (↔).

Cell Line

Study
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Patients (n)

--

--

Rat BMVs

Rat BECs

Intervention

Cell

↑ Perm. to sucrose for patient IgG vs. CD IgG.

--

Barrier Alterations

↓ Total CLDN5 & ↔ total OCLN protein for patient IgG vs.
CD IgG.

↓ Total CLDN5 & ↔ total OCLN protein for patient IgG vs.
CD IgG.

Tight Junction Protein Alterations#

WB

WB

Methods

patients were AQP4-seropositive.

NMOSD-R: NMOSD during relapse. CD: Control donor. IgG: Immunoglobulin G. BMV: Brain microvessel. Perm: Permeability. CLDN5: Claudin-5. OCLN: Occludin. WB: Western blotting.

aAll

Note: @When studies specified the patients involved in tight junction protein analyses, only those patients are listed and are marked by an asterisks (*). #Increases are demarked by an upwards arrow (↑),
decreases – by a downwards arrow (↓), and no change – by a left-right arrow (↔).

IgG

Sample

NMOSD Sera/IgG-induced Alterations in Non-human or Non-CNS EC Culture Models.

Cobo-Calvo • NMOSD-R (6)
et al.289,a
• CD (4)

Study
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APPENDIX E
Summary Tables for Studies with EAE-based Animal Models of CNS-IDDs.

Pre-onset: No CS
(9 dpi‡)

• Spine
(Thoraco-Lumbar)

• Brain MVs

• Spine
(Lumbar)

Paul
C57BL/6 Mice
et al.111,a

Beard
C57BL/6 Mice
et al.34

Argaw
C57BL/6 Mice
et al.112

Tight Junction Protein Alterations#

Methods

IHC-IF

IHC-IF

IHC-IF

WB

Disruption & loss of CLDN5 or OCLN reactivity in vessels with fibrinogen or albumin
IHC-IF
deposition, or with strong VEGFA reactivity.

Disruption & loss of CLDN5 in vessels with fibrinogen deposition.

↓ Total CLDN5 protein in isolated brain MVs.

Disruption & loss of CLDN5 reactivity in isolated brain MVs. Additionally, ↓ CLDN5 density
IHC-IF
at tight junctions.

Disruption & loss of CLDN5 reactivity in venules of diseased animals.

Disruption & loss of CLDN5 reactivity in the venules of diseased animals.

No apparent alteration of CLDN5 reactivity in venules or capillaries with focal IgG deposition
IHC-IF
in diseased animals.

Pre-onset to Early

Comparisons with naïve animals were not performed. bAlthough naïve wild-type animals were included, no comparisons for claudin-5 density were performed.

MV: Microvessel. dpi: Days post-induction. CS: Clinical score. T-L: Tail limpness. HL-W: Hind limb weakness. HL-PL: Hind limb paralysis. CLDN5: Claudin-5. OCLN: Occludin. VEGFA: Vascular
endothelial growth factor A. IHC-IF: Immunofluorescent-based immunohistochemistry. WB: Western blotting.

a

Note: †Where possible, the disease stage & clinical scores are provided. Otherwise, original author-reported staging marked by a double dagger (‡), with estimated staging marked by a tilde (~). #Unless
otherwise noted, comparisons are with respect to a healthy control animal. Increases are marked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left-right arrow (↔).

Early: HL-W/-PL

Onset: T-L

Pre-onset: No CS
(8 dpi‡)

Pre-onset: No CS
(9 dpi‡)

• Spine
(Thoraco-lumbar)

Paul
C57BL/6 Mice
et al.109,b

Stage & Severity
Pre-onset: No CS
(6 dpi‡)

Origin
• Spine
(Thoraco-lumbar)

Strain

†

CNS-EC-specific Alterations in MOG35-55-induced EAE Models (Base Disease).

Paul
C57BL/6 Mice
et al.110,a

Study
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C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

Errede
et al.113,c

Paul
et al.109,b

Welser
et al.114,d

Alt
et al.125,c

Sohet
et al.64,a,c,e

Mora
et al.124,c,e

Chapouly
et al.122,c

• Spine
(Lumbar)

• Spine MVs

• Spine

15-18 dpi: HL-PPS/-PL
(~Early-Peak)

‡

Disruption & loss of CLDN5 reactivity in vessels with fibrinogen deposition or near VEGFA
reactivity. Also, mean pixel intensity of CLDN5 negatively correlates with the mean pixel intensities IHC-IF
of VEGFA or TYMP, but not GFAP, in diseased mice.

qPCR

↓ Cldn5 mRNA in isolated spine MVs.

‡
13 dpi: NP
(~Early)

MA

IHC-IF

Loss of LSR reactivity in vessels within inflamed areas vs. adjacent non-inflamed areas. Also, ↓ LSR
IHC-IF
intensity per vessel within inflamed areas vs. adjacent non-inflamed areas.

↓ Cldn11 & ↓ Ocln mRNA in isolated BMVs.

↔ CLDN5+ per CD31+ area vs. diseased animals sacrificed on the same day as induction.

Disruption and loss of CLDN5 reactivity in inflamed venules of diseased animals. Also, ↓ CLDN5
IHC-IF
density at tight junctions vs. diseased animals at pre-onset (9 dpi).

Disruption & loss of OCLN reactivity in cortical vessels from animals with severe disability, but not
mild disability, vs. healthy controls.

IHC-IF

Methods

‡
4 dpo: NP
(~Early)

12 dpi: T-L
(~Onset-Early)

‡

Early: HL-PS

• Brain
(Medulla Oblongata)
• Brain MVs

Worsened disruption & loss of CLDN5 reactivity in cortical & subcortical vessels from diseased
animals with severe disability vs. those with mild disability or healthy controls.

Tight Junction Protein Alterations#

‡
Early-mild: T-L/HL-PS
Disruption & loss of CLDN5 reactivity in cortical vessels near demyelination.
Early-severe: HL-PL/FL-PS

Early: T-L/HL-W

‡

Stage & Severity

• Spine
(Thoraco-lumbar)

• Brain
(Cortex)

Origin

Onset to Early

Comparisons with naïve animals were not performed. bAlthough naïve wild-type animals were included, no comparisons for claudin-5 density were performed. cDisease course graphs were not provided.
Micrographs were not provided. eClinical scores were not provided.

MV: Microvessel. dpi: Days post-induction. dpo: Days post-onset. CS: Clinical score. T-L: Tail limpness. HL-W: Hind limb weakness. HL-PL: Hind limb paralysis. HL-PS: Hind limb paresis. FL-PS:
Forelimb paresis. NP: Not provided. HL-PPS: Hind limb paraparesis. CLDN5: Claudin-5. OCLN: Occludin. VEGFA: Vascular endothelial growth factor A. CD31: Cluster of differentiation 31. CLDN11:
Claudin-11. LSR: Lipolysis-stimulated lipoprotein receptor. TYMP: Thymidine phosphorylase. GFAP: Glial fibrillary acidic protein. IHC-IF: Immunofluorescent-based immunohistochemistry. WB:
Western blotting. MA: Microarray analysis. qPCR: Quantitative polymerase chain reaction.

d

a

Note: †Where possible, the disease stage & clinical scores are provided. Otherwise, original author-reported staging marked by a double dagger (‡), with estimated staging marked by a tilde (~). #Unless
otherwise noted, comparisons are with respect to a healthy control animal. Increases are marked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left-right arrow (↔).

Strain

Study

†
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C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

Wang
et al.117,a

Bittner
et al.118

Li
et al.116

Welser
et al.114,b

Uchida
et al.40

Niu
et al.115,c,d

Argaw
et al.112

Errede
et al.113

• Brain
(Cortex)

• Spine (Ventrolateral lumbar)

• Spine
NP

‡Late-severe:

‡Late-mild:

IHC-IF

Disruption & loss of CLDN5 or OCLN reactivity in vessels with fibrinogen or albumin leakage.

Loss of OCLN reactivity in vessels.

IHC-IF

IHC-IF

Disruption & loss of CLDN11 reactivity in brain & spinal cord vessels. Also, ↓ CLDN11+ per
IHC-IF
GLUT1+ intensity for both.

↓ CLDN5+ per CD31+ area vs. diseased animals sacrificed on the same day as induction.

IHC-IF,
IHC-IE

qPCR

↔ Cldn5 & ↔ Ocln mRNA in isolated BMVs from one set of experiments. However, ↔ Cldn5 & ↓
Ocln mRNA from a different set of experiments.
Disruption & loss of CLDN5 & OCLN reactivity in vessels.

IHC-IE,
IHC-IF

Methods

Disruption & loss of CLDN5 reactivity in in brain & spinal cord vessels.

Tight Junction Protein Alterations#

T-L/HL-PS
Worsened disruption & loss of CLDN5 & OCLN reactivity in cortical vessels from animals with
IHC-IF
HL-PL/FL-PS severe disability vs. those with mild disability.

Late: HL-W/-PL

‡Peak:

Peak: HL-PL

Peak: HL-PL

• Brain
(Medulla Oblongata)
• Brain & Spine

Peak: HL-W/-PL

• Spine

Peak: HL-PL

Peak: CS 2.5‡

• Brain & Spine
(Lumbar)
• Brain MVs

Stage & Severity

Origin

Peak-Late

MV: Microvessel. CS: Clinical score. HL-PL: Hind limb paralysis. HL-W: Hind limb weakness. NP: Not provided. T-L: Tail limpness. HL-PS: Hind limb paresis. FL-PS: Forelimb paresis. CLDN5:
Claudin-5. OCLN: Occludin. CD31: Cluster of differentiation 31. CLDN11: Claudin-11. GLUT1: Glucose transporter 1. FOV: Field of view. IHC-IE: Immunoenzyme-based immunohistochemistry.
IHC-IF: Immunofluorescent-based immunohistochemistry. qPCR: Quantitative polymerase chain reaction.

Scoring rubric was not provided. bMicrographs were not provided. cClinical scores were not provided. dDisease course graphs were not provided. e Although staging for the brain IHC-IF data was not
explicitly defined in either study, analysis of claudin-5 and occludin in the spine of knockout animals or bone marrow chimera animals were stated as 40 dpi. fStaging information was not provided.

a

Note: †Where possible, the disease stage & clinical scores are provided. Otherwise, original author-reported staging marked by a double dagger (‡), with estimated staging marked by a tilde (~). #Unless
otherwise noted, comparisons are between the diseased animal vs. a healthy control. Increases are marked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left-right
arrow (↔).

Strain

Study

†
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C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

Paul
et al.110,c,d

Bénardais
et al.120

Eilam
et al.121

Zhang
et al.119

Ferrara
et al.126,e

Girolamo
et al.127,d,e

Becker
et al.123,c,f
NP

Disruption & loss of CLDN5 reactivity in vessels.

Unclear: HL-PS/FL-PS
Disruption & loss of CLDN5 & OCLN reactivity in vessels.
(Likely Late)

• Brain
(Cortex)

Disruption & loss of CLDN5 & OCLN reactivity in vessels.

Unclear: HL-PS
(Likely Late)

Late: HL-PL/FL-PL Loss of CLDN5 reactivity in vessels. Also, ↓ CLDN5 fluorescence intensity.

• Spine
(Lumbar)
• Brain
(Cortex)

Late: HL-PL/FL-PL Disruption & loss of CLDN5 reactivity in vessels. Also, ↓ CLDN5 mean optical density.

↓ CLDN5+ vessels per FOV in vehicle-treated diseased animals vs. healthy controls.

• Brain
(Cortex)

• Spine

Methods

IHC-IF

IHC-IF

IHC-IF

IHC-IF

IHC-IF

IHC-IE

Disruption & loss of CLDN5 reactivity in the venules, but not the capillaries. Also, ↓ CLDN5 density
IHC-IF
in the venules, but not the capillaries.

Tight Junction Protein Alterations#

Late: HL-A/-PS

Late: NP

Stage & Severity

• Spine

• Spine
(Thoraco-lumbar)

Origin

Peak-Late

CS: Clinical score. HL-PL: Hind limb paralysis. NP: Not provided. HL-PS: Hind limb paresis. FL-PS: Forelimb paresis. HL-A: Hind limb ataxia. FL-PL: Forelimb paralysis. CLDN5: Claudin-5. OCLN:
Occludin. CD31: Cluster of differentiation 31. CLDN11: Claudin-11. FOV: Field of view. IHC-IF: Immunofluorescent-based immunohistochemistry.

Clinical scores were not provided. dDisease course graphs were not provided. eAlthough staging for the brain IHC-IF data was not explicitly defined in either study, analysis of claudin-5 and occludin
in the spine of knockout animals or bone marrow chimera animals were stated as 40 dpi. fStaging information was not provided.

c

Note: †Where possible, the disease stage & clinical scores are provided. Otherwise, original author-reported staging marked by a double dagger (‡), with estimated staging marked by a tilde (~). # Unless
otherwise noted, comparisons are between the diseased animal vs. a healthy control. Increases are marked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left-right
arrow (↔).

Strain

Study

†
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C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

Beard
et al.34

Wang
et al.290,a

Wang
et al.291

Lengfeld
et al.74

Wang
et al.117,b

Choi
et al.292

Liu
et al.293
• Spinal Cord

• Spinal Cord

• Spinal Cord

• Spinal Cord

• Brain

• Brain

• Brain

Origin

↓ Cldn3 & ↓ Cldn5 mRNA.

↓ Cldn5 mRNA & ↓ total CLDN5 protein.

↓ Total CLDN5 & ↓ total OCLN protein, with a greater loss in animals with worsened disability.

Peak: HL-PL/FL-W ↓ Total OCLN protein.

Peak: PPS

Peak: CS 2.5‡

CS 1 ~ Early: T-L
CS 3 ~ Peak: HL-PL

‡

‡

↓ Total CLDN5 & ↓ total OCLN protein.

↓ Total CLDN5 protein.

Tight Junction Protein Alterations#

Peak: HL-PL/FL-PL ↓ Total CLDN5 & ↓ total OCLN protein.

Peak: CS 5‡

Pre-onset: No CS
(8 dpi‡)

Stage & Severity

CNS Homogenate-specific Analyses

WB

qPCR

qPCR,
WB

WB

WB

WB

WB

Methods

grading rubric was based off the sum of disability for tail and individual limbs, complicating direct assignment of disea se severity to clinical score. bClinical scores were not provided.

CS: Clinical score. dpi: Days post-induction. HL-PL: Hind limb paralysis. FL-PL: Forelimb paralysis. T-L: Tail limpness. PPS: Paraparesis. FL-W: Forelimb weakness. CLDN5: Claudin-5. OCLN:
Occludin. CLDN3: Claudin-3. WB: Western blotting. qPCR: Quantitative polymerase chain reaction.

aThe

Note: †Where possible, the disease stage & clinical scores are listed. When partial information was available, estimated staging is demarked by a tilde (~), while author-reported information is demarked
by a double dagger (‡). When neither staging, nor clinical scores were provided for tight junction analyses, but were available for associated data sets, estimated staging is in parentheses. #Unless
otherwise noted, comparisons are between the diseased animal and healthy control. Increases are demarked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left-right
arrow (↔).

Strain/Genotype

†

Non-CNS-EC-specific Alterations in MOG35-55-induced EAE Models (Base Disease).

Study

Table E.2.

206

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

Niu
et al.115,b,c

Horng
et al.294,c

Kebir
et al.295c,d

Souza
et al.296

Zhang
et al.119

Kim
et al.297,e,f

• Unclear
(Brain or Spine)

• Spinal Cord

• Spinal Cord

• Spinal Cord

• Spinal Cord

• Spinal Cord

Origin

‡

Peak: NP

↓ Total CLDN4 & ↓ total OCLN protein.

↓ Total OCLN protein.

↓ Total CLDN1 & ↓ total CLDN4 protein, with degradation products detected for both.

↓ Ocln mRNA.

Tight Junction Protein Alterations#

Insufficient Information

↓ Total OCLN protein, but ↔ total CLDN5 protein.

Late: HL-PL/FL-PL ↓ Total CLDN5 & ↓ total OCLN protein.

Late: HL-W

Unclear: Grade 4‡
(Likely Peak)

18-21 dpi ~ Peak: HL-W/-PL

‡

Stage & Severity†

WB

WB

WB

WB

WB

qPCR

Methods

NP: Not provided. dpi: Days post-induction. HL-W: Hind limb weakness. HL-PL: Hind limb paralysis. FL-PL: Forelimb paralysis. OCLN: Occludin. CLDN1: Claudin-1. CLDN4: Claudin-4. CLDN5:
Claudin-5. qPCR: Quantitative polymerase chain reaction. WB: Western blotting.

Clinical scores were not provided. cDisease course graphs were not provided. dThe grading rubric was not provided. eThe tissue homogenate analyzed was not explicitly defined. fNo staging was
provided.

b

Note: †Where possible, the disease stage & clinical scores are listed. When partial information was available, estimated staging is demarked by a tilde (~), while author-reported information is demarked
by a double dagger (‡). When neither staging, nor clinical scores were provided for tight junction analyses, but were available for associated data sets, estimated staging is in parentheses. #Unless
otherwise noted, comparisons are between the diseased animal and healthy control. Increases are demarked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left-right
arrow (↔).

Strain/Genotype

Study

CNS Homogenate-specific Analyses

207

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

Horng
et al.294,b,c

Shrestha
et al.298,c

Uchida
et al.40

Paul
et al.111,b,c

• Peripheral Blood
Leukocytes
‡

‡

8 dpi ~ Pre-onset: No CS
‡
13 dpi ~ Early: NP

9 dpi ~ Pre-onset: No CS

8 dpi ~ Pre-onset: No CS

Peak: HL-PL

Peak: HL-PL

15 dpi ~ Early: HL-W/PL

• BA & SCA
Epithelium

‡

6 dpi ~ Pre-onset: No CS
‡
9 dpi ~ Onset: No CS/T-L
‡
15 dpi ~ Early: HL-W/PL

21 dpi ~ Peak: NP

Peak: HL-PL

‡

‡

‡

Stage & Severity

•CP Homogenate

• CP Epithelium

• CP Epithelium

• SC Astrocytes

Origin

Tight Junction Protein Alterations#

IHC-IF

Methods

↑ Cldn5 mRNA in isolated PBLs of diseased mice at 8 dpi vs. healthy controls , with subsequent
↓ Cldn5 mRNA at 13 dpi vs 8 dpi.

CLDN5 reactivity & total CLDN5 protein detected in isolated PBLs of diseased mice.

CLDN5 reactivity detected in extravasated leukocytes by venules of diseased mice.

Disruption & loss of CLDN11 reactivity in both tissues.

↔ Total CLDN3 & ↔ total CLDN11 protein.

No apparent alteration of CLDN3 & CLDN11 reactivity.

Disruption & loss of CLDN3 reactivity.

qPCR

IHC-IF,
FC, WB

IHC-IF

IHC-IF

WB

IHC-IF

IHC-IF

Disruption & loss of CLDN2 reactivity following onset of disease, but not pre-onset. Also, ↓
IHC-IF
total CLDN2+ area per nuclei.

CLDN4 reactivity detected at the glia limitans of diseased mice.

Non-CNS Homogenate-specific Analyses

SC: Spinal cord. CP: Choroid plexus. BA: Brain arachnoid. SCA: Spinal cord arachnoid. dpi: days post-induction. NP: Not provided. CS: Clinical score. T-L: Tail limpness. HL-W: Hind limb weakness.
HL-PL: Hind limb paralysis. CLDN4: Claudin-4. CLDN2: Claudin-2. CLDN3: Claudin-3. CLDN11: Claudin-11. CLDN5: Claudin-5. IHC-IF: Immunofluorescent-based immunohistochemistry. WB:
Western blotting. FC: Flow cytometry. qPCR: Quantitative polymerase chain reaction.

Clinical scores were not provided. cDisease course graphs were not provided.

b

Note: †Where possible, the disease stage & clinical scores are listed. When partial information was available, estimated staging is demarked by a tilde (~), while author-reported information is demarked
by a double dagger (‡). When neither staging, nor clinical scores were provided for tight junction analyses, but were available for associated data sets, estimated staging is in parentheses. #Unless
otherwise noted, comparisons are between the diseased animal and healthy control. Increases are demarked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left-right
arrow (↔).

Strain/Genotype

Study

†

208

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

Argaw
et al.128

Chapouly
et al.122

Niu
et al.115,a

Li
et al.116

Bénardais
et al.120

Hou
et al.130

Eilam
et al.121

Zhang
et al.119

Bittner
et al.118,b

Late-VEH: HL-PL/FL-PL
Rescue of CLDN5 reactivity in vessels. Also, ↑ CLDN5 mean optical density. IHC-IF
Late-TX: T-L

• Brain
• Immunomodulatory
(Cortex) (GA early→ peak)

• Brain
MVs

• Glutamate Blocker
(Riluzole – unclear→ peak)

• NF-κB Inhibition
• Spine
(TMP or IKK-16 post(Lumbar)
onset→ late)
Peak-VEH: Mild PPS
Peak-TX: HL-W/-PL

↑ Ocln mRNA in isolated BMVs, but ↔ Cldn5 mRNA when compared by
treatment or disease.

qPCR

Late-VEH: HL-PL/FL-PL
Rescue of CLDN5 reactivity in vessels for both treatment groups. Also, ↑
Late-TMP: T-L/HL-PL
IHC-IF
CLDN5 intensity for both treatment groups.
Late-IKK-16: T-L/HL-PL

Rescue of OCLN reactivity in all treatment groups. Also, ↑ OCLN intensity
IHC-IF
for all treatment groups, with the greatest increase in the dual treatment group.

Late-VEH: HL-PL
Late-Mino: T-L/HL-PL
Late-MSC: T-L/HL-PL
Late-Dual: No CS/T-L

• Immunomodulatory
• Spine
(Minocycline, MSC-IFN-β,
(Lumbar)
or both post-onset→ late)

IHC-IF,
IHC-IE

IHC-IF

No rescue of CLDN5 reactivity in vessels. Also, ↔ number of CLDN5+
IHC-IE
vessels per FOV.

• Spine

• Spine

Rescue of CLDN5 & OCLN reactivity in vessels.

Rescue of OCLN reactivity in vessels.

Late-VEH: Mod. PPS
Late-TX: AT/Mild PPS

NP

• Nrf2 Activation
(DMF post-induction→ late)

‡Peak:

Peak-VEH: HL-W/-PL
Peak-TX: T-L

• Nrf2 Activation
(NGN pre-induction→ peak)
• Nrf2 Activation
(SFN post-onset→ peak)

• Spine

Peak-VEH: HL-PL/FL-PL
Rescue of CLDN5 reactivity in vessels & fibrinogen leakage for all treatment
Peak-CAV: T-L/HL-W
groups. Additionally, ↑ CLDN5+ area per FOV for all treatment groups, with IHC-IF
Peak-2LDR: T-L/HL-W
the greatest increase in the dual treatment group.
Peak-Dual: T-L/HL-W

Methods

Rescue of CLDN5 reactivity in vessels & fibrinogen leakage. Also, ↑ CLDN5+
IHC-IF
area per FOV.

Tight Junction Protein Alterations#

• AC Signaling Inhibition
• Spine
(Cavtratin, 2DLR, or both
(Lumbar)
post-onset → early)

Stage & Severity†
Peak-VEH: HL-PL
Peak-TX: T-L/HL-W

Intervention(s)

• Spine
• AC Signaling Inhibition
(Lumbar) (Cavtratin post-onset → early)

Origin

Clinical scores were not provided. bTwo separate interventions were performed – one post-induction, the other post-onset. However, the treatment group analyzed was not explicitly defined.

MV: Microvessels. AC: Astrocyte. 2DLR: 2-deoxy-L-ribose. Nrf2: Nuclear factor erythroid 2–related factor 2. NGN: Naringenin. SFN: Sulforaphane. DMF: Dimethyl fumarate. MSC-IFN-β: Interferon
beta-expressing mesenchymal stem cells. GA: Glatiramer acetate. NF-κB: Nuclear factor kappa beta. TMP: Tetramethylpyrazine. VEH: Vehicle group. TX: Treatment group. CAV: Cavtratin. Combo:
Dual treatment group. Mino: Minocycline. HL-PL: Hind limb paralysis. T-L: Tail limpness. FL-PL: Forelimb paralysis. HL-W: Hind limb weakness. Mod: Moderate. PPS: Paraparesis. AT: Ataxia. CS:
Clinical score. CLDN5: Claudin-5. FOV: Field of view. OCLN: Occludin. IHC-IF: Immunofluorescence-based immunohistochemistry. IHC-IF: Immunoenzyme-based Immunohistochemistry. qPCR:
Quantitative polymerase chain reaction.

a

Note: †Where possible, the disease stage & respective clinical scores are provided. Otherwise, author-reported staging marked by a double dagger (‡). #Unless otherwise noted, comparisons are with
respect to the control group. Increases are marked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left-right arrow (↔).

Strain/Genotype

CNS-EC-specific Alterations in MOG35-55-induced EAE Models (Therapeutic Interventions).

Study

Table E.3.

209

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

Beard
et al.34

Wang
et al.290

Wang
et al.291

Choi
et al.292

Liu
et al.293
• Spinal Cord

• Spinal Cord

• Brain

• Brain

• Brain

Origin

Peak-VEH: PPS
Peak-TX T-PL

Peak-VEH: HL-PL
Peak-MSC: HL-W

• Immunomodulatory
(HBPDS post-onset → peak)
• Mesenchymal Stem Cells
(Single injection post-onset)

↑ Total CLDN5 protein.

↑ Cldn3 mRNA, but ↔ Cldn5 mRNA.

Peak-VEH: HL-PL/FL-PL
Peak-LOW: HL-PL/FL-PL ↑ Total CLDN5 & ↑ total OCLN protein for the medium and high dosage
Peak-MED: HL-PL (full) treatment groups, but not the low dosage treatment group.
Peak-HIGH: HL-PL (partial)

• Anti-oxidant/-inflammatory
(RSV post-induction → peak)

↑ Total CLDN5 protein, but ↔ total OCLN protein.

↑ Total CLDN5 protein.

Tight Junction Protein Alterations#

Peak-VEH: CS 5
Peak-TX: CS 2

Pre-onset-VEH: NP
Pre-onset-TX: NP

Stage & Severity†

• I2R Antagonist
(IDZ post-induction → early)

• IR Agonist
(DMAQ-B1 24 hours prior)

Intervention(s)

WB

qPCR

WB

WB

WB

Methods

IR: Insulin receptor. DMAQ-B1: Demethylasterriquinone B1. I2R: Imidazoline I2 receptor. IDZ: Idazoxan. RSV: Resveratrol. HBPDS: Hyungbangpaedok-San. VEH: Vehicle group. TX: Treatment
group. LOW: Low dosage. MED: Medium dosage. HIGH: High dosage. MSC: Mesenchymal stem cells. NP: Not provided. CS: Clinical score. HL-PL: Hind limb paralysis. FL-PL: Forelimb paralysis.
PPS: Paraparesis. T-PL: Tail paralysis. HL-W: Hind limb weakness. NP: Not provided. T-W: Tail-weakness. T-L: Tail limpness. CLDN5: Claudin-5. OCLN: Occludin. CLDN4: Claudin-4. WB:
Western blotting. qPCR: Quantitative polymerase chain reaction.

Note: †Where possible, the disease stage & clinical scores are listed. When partial information was available, estimated staging is demarked by a tilde (~), while author-reported information is demarked
by a double dagger (‡). When neither staging, nor clinical scores were provided for tight junction analyses, but were available for associated data sets, estimated staging is in parentheses. #Unless
otherwise noted, comparisons are between the treatment group and control group. Increases are demarked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left-right
arrow (↔).

Strain/Genotype

CNS Homogenate-specific Analyses

Non-CNS-EC-specific Alterations in MOG35-55-induced EAE Models (Therapeutic Interventions).

Study

Table E.4.

210

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice

Niu
et al.115,a,b

Souza
et al.296

Zhang
et al.119

Giacoppo
et al.299,c

Kim
et al.297

Insufficient information

Insufficient Information

• PAR1 Antagonists
(VOR or KC post-induction
→ unclear)

• Unclear
(Brain/Spine)

↑ Total OCLN protein for either treatment group vs. vehicle. However,
↔ total CLDN5 protein when compared by disease or treatment.

↑ Total CLDN1, ↑ total CLDN3, & ↑ total CLDN5 protein.

WB

WB

WB

Late-VEH: HL-PL/FL-PL
↑ Total CLDN5 & ↑ total OCLN protein for either treatment group vs.
Late-TMP: T-L/HL-PL
vehicle.
Late-IKK: T-L/HL-PL

• NF-κB Inhibition
(TMP or IKK-16 early → late)
• Nrf2 Activation
(GRA pre-induction → unclear)

WB

↑ CLDN4 & ↑ total OCLN protein with either physical exercise strategy.

Late-CTL: HL-W
Late-STR: T-W
Late-END: No CS/T-W

qPCR

Methods

• Strength or Endurance Train.
(Pre-induction → ~onset)

Tight Junction Protein Alterations#
↑ Ocln mRNA.

‡

Stage & Severity†
Peak-VEH: NP
‡
Peak-TX: NP

• Nrf2 activation
(NGN pre-induction → peak)

Intervention(s)

• Brain

• Spinal Cord

• Spinal Cord

• Spinal Cord

Origin

The staging in the Methods section contradicts the staging in the figure legend.

Nrf2: nuclear factor erythroid 2–related factor 2. NGN: Naringenin. NF-κB: Nuclear factor kappa B. TMP: Tetramethylpyrazine. GRA: Glucoraphanin. PAR1: Protease-activated receptor-1. VOR:
Vorapaxar (SCH-530348). KC: KC-A0590. NP: Not provided. VEH: Vehicle group. TX: Treatment group. CTL: Control group. STR: Strength group. END: Endurance group. CS: Clinical score. HLW: Hind limb weakness. T-W: Tail-weakness. HL-PL: Hind limb paralysis. FL-PL: Forelimb paralysis. OCLN: Occludin. CLDN4: Claudin-4. CLDN5: Claudin-5. CLDN1: Claudin-1. qPCR:
Quantitative polymerase chain reaction. WB: Western blotting.

c

Note: †Where possible, the disease stage & clinical scores are listed. When partial information was available, estimated staging is demarked by a tilde (~), while author-reported information is demarked
by a double dagger (‡). When neither staging, nor clinical scores were provided for tight junction analyses, but were available for associated data sets, estimated staging is in parentheses. #Unless
otherwise noted, comparisons are between the treatment group and control group. Increases are demarked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left-right
arrow (↔).

Strain/Genotype

Study

CNS Homogenate-specific Analyses

211

C57BL/6 Mice
• B1R-/C57BL/6 Mice
• Irgm1-/-

C57BL/6 Mice
• Kcnk2-/-

C57BL/6 Mice
• NG2-/-

C57BL/6 Mice
• NG2-/-

C57BL/6 Mice
• LXRα-/C57BL/6 Mice
• Asm-/-

Göbel
et al.132,a
Wang
et al.117,b

Bittner
et al.118,c

Ferrara
et al.126,d

Girolamo
et al.127,e

Wouters
et al.133,f
Becker
et al.123,g

• B1R-KO

Manipulation(s)

• LXRα-KO
• Asm-KO

• Spine

• NG2-KO

• Brain
(Cortex)
• Brain

• NG2-KO

• BM chimeras
(W→W, K→W,
W→K, K→K)

• Spine

• Brain
(Cortex)

• Knck2-KO

• BMVs
• NG2-KO

• Knck2-KO

• Spine

• Brain & Spine
• Irgm1-KO
(Lumbar)

• Brain MVs

Origin

NP

Rescue of CLDN5 reactivity in vessels.

IHC-IF

IHC-IF

IHC-IF

Rescue of CLDN5 & OCLN reactivity in vessels of diseased NG2-KO animals vs.
IHC-IF
healthy NG2-KO animals.

Late-WT: HL-PS
Late-KO: T-L

Unclear: Likely Peak
Rescue of CLDN5 & OCLN reactivity in vessels.
WT: HL-PS/TPL
KO: T-L/FL-PS
Late-WT: HL-PL
↓ CLDN5+ area fraction.
Late-KO: T-PL/HL-PPS

Worsened disruption & loss of CLDN5 & OCLN reactivity in wild-type recipients
IHC-IF
vs. NG2-KO recipients, regardless of donor genotype.

IHC-IF

qPCR

↔ Cldn5 & ↔ Ocln mRNA in isolated BMVS from diseased Kcnk2-KO mice vs.
diseased wild-type mice, naïve Kcnk2-KO mice, or naïve wild-type mice.
Rescue of CLDN5 & OCLN reactivity in vessels.

IHC-IF

IHC-IE,
IHC-IF

qPCR

Method

No rescue of OCLN reactivity in vessels. Also, ↔ OCLN intensity.

Rescue of CLDN5 reactivity in vessels.

↑ Ocln mRNA, but ↔ Cldn5 mRNA, in isolated BMVs.

Tight Junction Protein Alterations#

Late-WW: HL-PL
Late-KW: HL-PS/-A
Late-WK: HL-PL
Late-KK: HL-PS/-A

Unclear: Likely Late

Peak-WT: HL-PL
Peak-KO: PPS

Unclear: Likely Peak

Peak-WT: PPS
Peak-KO: T-L
Peak-WT: CS 2.5
Peak-KO: CS 1.0

Stage & Severity†

B1R: Bradykinin B1 receptor. Irgm1: Immunity-related GTPase family M protein 1. Knck2: Potassium channel subfamily K member 2. NG2: Neural/glial antigen 2. LXRα: Liver X receptor alpha.
Asm: Acid sphingomyelinase. MV: Microvessel. KO: Knockout. BM: Bone marrow. WW: Wild-type BM into wild-type recipients. KW: Knockout BM into wild-type recipients. KW: Knockout BM
into wild-type recipients. KK: Knockout BM into knockout recipients. WT: Wild-type. NP: Not provided. PPS: Paraparesis. T-L: Tail limpness. HL-PL: Hind limb paralysis. HL-PS: Hind limb paresis.
HL-A: Hind limb ataxia. T-PL: Tail paralysis. TPL: Tetraplegia. OCLN: Occludin. CLDN5: Claudin-5. qPCR: Quantitative polymerase chain reaction. IHC-IF: Immunofluorescent-based
immunohistochemistry.

Although naïve animals were included, no statistical comparisons were performed. bNo scoring rubric was provided. cStaging for the IHC-IF data was not explicitly defined, but related qPCR experiments
were performed at peak. dStaging for the brain IHC-IF data was not explicitly defined, but related IHC-IF experiments were stated as 40 dpi. eStaging for the brain IHC-IF data was not explicitly defined,
but related permeability experiments were stated as 20 dpi. f Micrographs were not provided. gNeither clinical score, nor staging were provided.

a

Note: †Where possible, the disease stage & clinical scores are provided. Otherwise, original author-reported staging marked by a double dagger (‡), with estimated staging marked by a tilde (~). # Unless
otherwise noted, comparisons are with respect to a genotype control or wild-type animal. Increases are marked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left right arrow (↔).

Strain/Genotype

Non-Claudin-involved Genetic Manipulations

CNS-EC-specific Alterations in MOG35-55-induced EAE Models (Genetic Manipulations).

Study

Table E.5.

212

Origin

•

• Ccl2-ECKO
• Ccl2-ACKO

• Spine
(Thoracolumbar)

C57BL/6 Mice
• Gfap-Cre x Ccl2fl/fll
• Tie2-Cre x Ccl2fl/fll

C57BL/6 Mice
• Gfap-Cre x Vegfafl/fll

C57BL/6 Mice
• Gfap-IκBα-dn

Paul
et al.109,c

Argaw
et al.128

Brambilla
et al.136,d

• NF-κB inhibition
(AC-specific)

• Spine
(Thoracic)

dpi-ACKO: No CS
dpi-ACKO: No CS/T-L

‡16

Peak-WT: HL-W/-PL
Peak-KO: LT
Late (x2)-WT: T-L/HL-PL
Late (x2)-DN: T-W/-L

‡9

No rescue of CLDN5 optical density in GFAP-IκBα-dn mice vs. wild-type mice
IHC-IE
at either two analyzed time points (both post-peak).

Rescue of CLDN5 reactivity, plus fibrinogen deposition, in vessels. Also,
IHC-IF
rescue of CLDN5+ area per FOV.

↑ CLDN5 density in venules of Ccl2-ACKO mice at both time points vs. wildtype mice. Also, ↓ CLDN5 density between time points for Ccl2-ACKO mice.

dpi-WT: T-L/HL-W
dpi-ECKO: No CS

dpi-WT: No CS
dpi-ECKO: No CS

‡16

‡9

‡9

‡16

Disruption & loss of CLDN5 reactivity in vessels. Also, ↓ CLDN5+ per CD31+
IHC-IF
area.
↑ CLDN5 density in venules at tight junctions of Ccl2-ECKO mice at both time
points vs wild-type mice. Also, ↔ CLDN5 density between time points for
Ccl2-ECKO mice.
↓ CLDN5 density in venules at tight junctions of Ccl2-ECKO mice at 9 dpi vs IHC-IF
Ccl2-ACKO mice. However, ↑ CLDN5 density vs. Ccl2-ACKO mice at 16 dpi.

Peak-WT: HL-PL
Peak-KO: QPL

IHC-IF

↔ CLDN5+ per CD31+ area.

Early-WT: HL-PS
Early-KO: HL-PS

IHC-IF

Method

qPCR

Rescue of CLDN5 reactivity in vessels for IFNγR-EC-only mice vs. IFNγR-KO
mice. Also, ↑ CLDN5+ per Tie2+ intensity.

Loss of CLDN5 reactivity in vessels for IFNγR-KO mice vs. wild-type mice.
Also, ↓ CLDN5+ per Tie2+ intensity.

Tight Junction Protein Alterations#

Peak-WT: HL-uPL/-bPL ↑ Ocln mRNA, but ↔ Cldn1, ↔ Cldn2, ↔ Cldn3, & ↔ Cldn5 mRNA, in
Peak-KO: T-L/HL-uPL isolated SCMVs.

Peak-WT: T-L/HL-PS
Peak-KO: HL-PS
Peak-EC-only: HL-PL

Stage & Severity†

IFNγR: Interferon gamma receptor. Tie2: Tyrosine kinase with Ig and EGF homology domains 2. Cre: Cyclic recombinase. LR: Leptin receptor. fl: Floxed allele. Itgb4: Integrin subunit beta 4. Gfap:
Glial fibrillary acidic protein. Ccl2: Chemokine (C-C motif) ligand 2. Vegfa: Vascular endothelial growth factor A. IκBα-dn: Dominant-negative mutant of inhibitor of nuclear factor kappa B. SCMV:
Spinal cord microvessel. KO: Knockout. EC-only: Endothelial cell-restricted expression. ECKO: Endothelial-restricted knockout. ACKO: Astrocyte-restricted knockout. NF-κB: Nuclear factor kappa B.
AC: astrocyte. WT: Wild-type or genotype control. dpi: Days posts-induction. x2: Two time points. DN: Dominant-negative mutant. T-L: Tail limpness. HL-PS: Hind limb paresis. HL-PL: Hind limb
paralysis. HL-uPL: Hind limb unilateral paralysis. HL-bPL: Hind limb bilateral paralysis. QPL: Quadriplegia. CS: Clinical score. HL-W: Hind limb weakness. T-W: Tail weakness. CLDN5: Claudin5. Ocln: Occludin. CLDN1: Claudin-1. CLDN2: Claudin-2. CLDN3: Claudin-3. CD31: Cluster of differentiation 31. FOV: Field of view. IHC-IF: Immunofluorescent-based immunohistochemistry.
qPCR: Quantitative polymerase chain reaction. IHC-IE: Immunoenzyme-based immunohistochemistry.

Although naïve animals were included, no statistical comparisons by disease were performed. bMicrographs were only provided for the peak stage. cOnset of disease was delayed in Ccl2-KO mice,
complicating direct comparison of animals by stage. dThe two time points were approximately 1- and 3-weeks post-peak.

a

Note: †Where possible, the disease stage & respective clinical scores are provided. Otherwise, author-reported staging marked by a double dagger (‡). #Unless otherwise noted, comparisons are with
respect to a genotype control or wild-type animal. Increases are marked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left-right arrow (↔).

• Vegfa-ACKO

• Spine

Itgb4-ECKO

• Brain
(Medulla
Oblongata)

C57BL/6 Mice
• Tie2-Cre x Itgb4fl/fll

Welser
et al.114,b

• LR-ECKO

• IFNγR-KO
• IFNγR-EC-only

Manipulation(s)

• SCMVs

C57BL/6 Mice
•Tie2-Cre x LRfl/fll

C57BL/6 Mice
• Brain
• IFNγR-/(Cerebellum)
• IFNγR-/- x Tie2-IFNγR

Strain/Genotype

Ouyang
et al.135,a

Ni
et al.134

Study

Non-Claudin-involved Genetic Manipulations

213

C57BL/6 Mice
• Cldn12LacZ/LacZ
• Cldn12LacZ/+
• Cldn12-KO

• Brain (Cortex
• Cldn12-LacZ
& Cerebellum)

• Brain
‡CS

‡CS

‡CS

0: No CS
2: HL-PL

2: HL-PL

Induction → Late

Pre-onset: No CS

• eGFP-Cldn5- ECKI
& Cav1-KO
• Cldn12-KO

Pre-onset: No CS
Early: T-PL
Peak: HL-W/-PL

• eGFP-Cldn5- ECKI

Pre-onset: No CS
(9 dpi‡)

Late-CTL: HL-PPS/-PL
Late-ECKI: T-L

Induction → Late

Stage & Severity†

--

Method

No apparent difference in LacZ activity in the cortex or cerebellum of diseased
Cldn12-LacZ animals at CS 2 vs. those at CS 0.

No apparent difference in leakage of fibronectin or IgG.

↔ Day of onset & ↔ overall disease severity.

X-Gal

IHC-IF

--

↔ % of EGFP-CLDN5+ tight junctions in venules with protrusions, gaps, or
IV-2PM
tortuosity in eGFP-Cldn5-ECKI x Cav1-KO mice vs. eGFP-Cldn5-ECKI mice.

Disruption & loss of eGFP-CLDN5 reactivity in areas with fibrinogen leakage
in all diseased groups, with worsened alterations in areas with greater leakage.

↑ % of eGFP-CLDN5+ tight junctions in venules with gaps or tortuosity in the
IV-2PM
early & peak diseased groups only.

↑ % of eGFP-CLDN5+ tight junctions in venules with static or dynamic
protrusions in all diseased groups.

Disruption of eGFP-CLDN5 reactivity in inflamed venules near dual
IHC-IF
DRAQ5+/eGFP-CLDN5+ inflammatory cuffs.

↔ Number of CD45+ inflammatory cuffs, but ↓ % of cuffs with Hoechst or
IHC-IF
fibronectin leakage.

↔ Day of onset & ↔ peak CS, but rescue of chronic CS.

Phenotype or Tight Junction Protein Alterations #

~30% of Tie2+ vessels exhibited detectable claudin-1 expression before induction. bStaging information was not provided.

Tie2: Tyrosine kinase with Ig and EGF homology domains 2. tTA: Tetracycline transactivator. TRE: Tetracycline-responsive promoter element. CLDN1: Claudin-1. CLDN3: Claudin-3. eGFP: Enhanced
green fluorescent protein. CLDN5: Claudin-5. CAV1: Caveolin-1. CLDN12: Claudin-12. LacZ: β-galactosidase reporter gene replacing the encoding exon of Cldn12. ECKI: Endothelial-specific
knockout. KO: Knockout. CTL: Genotype control. CS: Clinical score. HL-PPS: Hind limb paraparesis. HL-PL: Hind limb paralysis. T-L: Tail limpness. NS: No score. T-PL: Tail paralysis. HL-W: Hind
limb weakness. CD45: Cluster of differentiation 45. DRAQ5: Deep red anthraquinone 5. IHC-IF: Immunofluorescent-based immunohistochemistry. IV-2PM: Intravital two-photon microscopy. X-Gal:
5-bromo-4-chloro-3-indolyl β-d-galactopyranoside.

aOnly

Note: †Where possible, the disease stage and respective clinical score are provided. Otherwise, author-reported staging marked by a double dagger (‡). #Unless otherwise noted, comparisons are with
respect to the genotype control or wild-type animal. Increases are marked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left -right arrow (↔).

Castro-Dias
et al.48,b

Lutz
et al.137

--

C57BL/6 Mice
• Tie2-eGFP-Cldn5+/- • Spine
• Tie2-eGFP-Cldn5+/- (Lumbar)
x Cav1-/-

• Cldn1-ECKI

• Brain
• eGFP-Cldn5- ECKI

• Cldn1-ECKI

Manipulation(s)

--

• Spine
C57BL/6 Mice
(Thoraco• Tie2-eGFP-Cldn5+/Lumbar)

C57BL/6 Mice
• Tie2-tTA x
[TRE]-Cldn1

Pfeiffer
et al.45,a

Origin

Paul
et al.111

Strain/Genotype

Study
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C57BL/6 Mice
• Igrm1-/-

C57BL/6 Mice
• ApoE-/-

C57BL/6 Mice
• Cdh5-tTA x [TRE]Axin-IRES-eGFP

C57BL/6
• Cdh5-Cre x Dhhfl/fl

Wang
et al.117,a

Zheng
et al.300

Lengfeld
et al.74,b

Mora
et al.124
• Spinal Cord

• Spinal Cord

• Brain

• Spinal Cord

Origin

• Dhh-ECKO

• Axin-ECKI

• ApoE-KO

• Igrm1-KO

Manipulation(s)

‡

Late-CTL: HL-PL
Late-KO: HL-W/-PL

Peak-CTL: LT/HL-PS
‡
Peak-EC: HL-PS

Late-WT: T-LT
Late-KO: T-F

Peak-WT: CS 2.5‡
Peak-KO: CS 1.0‡

Stage & Severity†

↑ Total CLDN4 protein.

↔ Total CLDN5 & ↔ total OCLN protein.

WB

WB

WB

qPCR

↓ Cldn5 & ↓ Ocln mRNA vs. diseased wild-type, healthy ApoE-KO, or healthy
wild-type animals.
↓ Total CLDN5 protein & ↓ total OCLN protein vs. diseased wild-type, healthy
ApoE-KO, or healthy wild-type animals.

qPCR,
WB

Method

↑ Cldn5 mRNA & ↑ total CLDN5 protein.

Tight Junction Protein Alterations#

Irgm1: Immunity-related GTPase M protein 1. ApoE: Apolipoprotein E. Cdh5: Cadherin-5. tTA: Tetracycline-controlled transactivator. TRE: Tetracycline-responsive promotor element. IRES: internal
ribosome entry site. eGFP: Enhanced green fluorescent protein. Cre: Cyclic recombinase. Dhh: Desert hedgehog. fl: Flanked by loxP. KO: Knockout. ECKI: Endothelial-restricted knockin. ECKO:
Endothelial-restricted KO. WT: Wild-type. CTL: Genotype control. CLDN5: Claudin-5. OCLN: Occludin. CLDN4: Claudin-4. qPCR: Quantitative polymerase chain reaction. WB: Western blotting.

scoring rubric was not provided. bWhen the animals that died are included, there was a significant increase in disability for Axin-ECKI mice. However, when these mice are excluded, there was no
difference.

aThe

Note: †Where possible, the disease stage & clinical scores are listed. When partial information was available, estimated staging is demarked by a tilde (~), while author-reported information is demarked
by a double dagger (‡). When neither staging, nor clinical scores were provided for tight junction analyses, but were available for associated data sets, estimated staging is in parentheses. #Unless
otherwise noted, comparisons are between the genetically manipulated animal and the wild-type or genotype control. Increases are demarked by an upwards arrow (↑), decreases by a downwards arrow
(↓), and no change by a left-right arrow (↔).

Strain/Genotype

Non-Claudin-involved Genetic Manipulations (CNS Homogenates)

Non-CNS-EC-specific Alterations in MOG35-55-induced EAE Models (Genetic Manipulations).
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C57BL/6 Mice
• Cldn3-/-

Castro-Dias
et al.47

• Cldn4-ACKO

Worsened peak disability, total average disability, and mortality.

No difference in onset or overall disease severity.

Earlier onset, worsened peak disability, & worsened chronic disability.

Phenotype & Tight Junction Protein Alterations #

--

--

--

Method

Unclear: NP
(Likely Peak)

CLDN1 reactivity in astrocytes from spinal cord lesions of diseased
IHC-IF
Cldn4-ACKO mice.

Peak-CTL: HL-W/-PL
Worsened CD4+ infiltration, fibrinogen & IgG leakage, & demyelination. IHC-IF
Peak-KO: HL-PL/FL-PL

Induction →
Peak

Induction → Late

Induction → Late

Stage &
Severity†

Cldn3-KO mice were independently generated, rather than two publications characterizing the same line.

CLDN3: Claudin-3. GFAP: Glial fibrillary acidic protein. Cre: Cyclic recombinase. CLDN4: Claudin-4. fl: flanked by loxP. CTL: Genotype control. HL-W: Hind limb weakness. HL-PL: Hind limb
paralysis. FL-PL: Forelimb paralysis. NP: Not provided. CD4: Cluster of differentiation 4. CLDN1: Claudin-1. IHC-IF: Immunofluorescent-based immunohistochemistry.

aThe

Note: †Where possible, the disease stage & clinical scores are listed. When partial information was available, estimated staging is demarked by a tilde (~), while author-reported information is demarked
by a double dagger (‡). When neither staging, nor clinical scores were provided for tight junction analyses, but were available for associated data sets, estimated staging is in parentheses. #Unless
otherwise noted, comparisons are between the genetically manipulated animal and the wild-type or genotype control. Increases are demarked by an upwards arrow (↑), decreases by a downwards arrow
(↓), and no change by a left-right arrow (↔).

• Spinal Astrocytes

• Cldn4-ACKO

--

• Cldn4-ACKO

• Cldn3-KO

• Cldn3-KO

Manipulation(s)

--

--

Origin

C57BL/6 Mice
fl/fl • Spine
• Gfap-Cre x Cldn4

C57BL/6 Mice
• Cldn3-/-

Kooij
et al.285

Horng
et al.294

Strain/Genotype

Study
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Strain/Genotype

• BP-EVs

• PBLs

Origin

• eGFP-Cldn5-ECKI

• BM Chimeras
CD45.1/CD45.2
→ eGFP-Cldn5-ECKI

• eGFP-Cldn5-ECKI

Manipulation(s)

‡

‡

‡

‡

‡

8 dpi ~ Pre-onset: No CS

8 dpi ~ Pre-onset: No CS

9 dpi ~ Pre-onset: No CS

8 dpi ~ Pre-onset: No CS

9 dpi ~ Pre-onset: No CS

Stage & Severity†

Method

FC

FC

FC

eGFP-CLDN5 in PBLs isolated from diseased chimeric mice.
eGFP-CLDN5+ in blood plasma-derived EVs from diseased eGFP-Cldn5ECKI mice.

eGFP-CLDN5 detected in extravasated leukocytes near eGFP-CLDN5+
IHC-IF
venules in diseased chimeric mice.

eGFP-CLDN5 in PBLs isolated from diseased eGFP-Cldn5-ECKI mice

eGFP-CLDN5 reactivity in extravasated leukocytes near venules of diseased
IHC-IF
eGFP-Cldn5-ECKI mice.

Phenotype & Tight Junction Protein Alterations#

disease course graph was provided.

Tie2: Tyrosine kinase with Ig and EGF homology domains 2. eGFP: Enhanced green fluorescent protein. CLDN5: Claudin-5. CD45.1: Cluster of differentiation 45.1 allele. CD45.2: Cluster of
differentiation 45.2 allele. PBL: Peripheral blood leukocyte. BP-EV: Blood plasma-derived extracellular vesicle. ECKI: Endothelial-restricted knockin. BM: Bone marrow. dpi: Days post-induction. CS:
Clinical score. IHC-IF: Immunofluorescent-based immunohistochemistry. FC: Flow cytometry.

aNo

Note: †Where possible, the disease stage & clinical scores are listed. When partial information was available, estimated staging is demarked by a tilde (~), while author-reported information is demarked
by a double dagger (‡). When neither staging, nor clinical scores were provided for tight junction analyses, but were available for associated data sets, estimated staging is in parentheses. #Unless
otherwise noted, comparisons are between the genetically manipulated animal and the wild-type or genotype control. Increases are demarked by an upwards arrow (↑), decreases by a downwards arrow
(↓), and no change by a left-right arrow (↔).

C57BL/6 Mice
Paul
• Tie2-eGFP-Cldn5+/et al.111,a
• CD45.1/CD45.2

Study
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Lewis Rats

CBA/H Mice
• iNOS-/-

Morgan
et al.140

Ninkovic
et al.141,a

• Brain
(Forebrain)

• Spine
(Lumbar)

Origin

• iNOS-KO

Late-WT/VH: HL-W
Late-WT/TX: HL-W
Late-KO/VH: T-L/HL-W
Late-KO/TX: T-L

Late: HL-W

--

• NO Synthase Inhibition
(AG post-induction → late)

Peak: HL-PL

Stage & Severity†

--

Intervention(s)

Method

Rescue of OCLN reactivity in agmatine-treated diseased wild-type & iNOSKO mice vs. respective vehicle-treated diseased counterparts or healthy
counterparts.

Comparable loss of OCLN reactivity in vehicle-treated wild-type or iNOS-KO
mice vs. healthy wild-type or iNOS-KO mice.

Loss of OCLN reactivity.

IHC-IE

IHC-IE

Disruption & loss of CLDN5 & OCLN reactivity in vessels with Hoechst+
IHC-IF
inflammatory cuffs.

Tight Junction Protein Alterations#

has multiple putative mechanisms of action.

iNOS: Inducible nitric oxide synthase. AG: Agmatine. KO: Knockout. WT: Wild-type. VH: Vehicle group. TX: Treatment group. HL-PL: Hind limb paralysis. HL-W: Hind limb weakness. T-L: Tail
limpness. CLDN5: Claudin-5. OCLN: Occludin. IHC-IF: Immunofluorescent-based immunohistochemistry. IHC-IE: Immunoenzyme-based immunohistochemistry.

aAgmatine

Note: †Where possible, the disease stage and respective clinical score are provided. Otherwise, author-reported staging marked by a double dagger (‡). #Unless otherwise noted, comparisons are made
for the diseased animal vs. a healthy control, the treatment group vs. the control group, or the genetically manipulated animal vs. the wild-type control. Increases are marked by an upwards arrow (↑),
decreases by a downwards arrow (↓), and no change by a left-right arrow (↔).

Strain/Genotype

CNS-EC-specific Alterations in MBP-induced EAE Models.

Study

Table E.7.
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Lewis Rats

Morgan
et al.140,a
• SCH

Origin

Pre-onset: No CS
Onset-Early: T-L → HL-W
Peak: HL-PL
Late (x3): T-L → No CS

Peak: HL-PL

Stage & Severity†

↑ OCLN protein dephosphorylation at all stages.

↑ OCLN protein dephosphorylation.
↑ OCLN protein in TX100-soluble fractions.

↔ Total CLDN5 protein.

Tight Junction Protein Alterations#

IP-WB

IP-WB

WB

Method

electrophoretic mobility of higher molecular weight occludin bands was interpreted as dephosphorylation rather than the usage of an anti-phospho-OCLN antibody..

SCH: Spinal cord homogenate. x3: Three time points. HL-PL: Hind limb paralysis. CS: Clinical score. T-L: Tail limpness. HL-W: Hind limb weakness. CLDN5: Claudin-5. OCLN: Occludin. WB:
Western blotting. IP-WB: Immunoprecipitation WB.

aIncreased

Note: †Where possible, the disease stage & clinical scores are listed. When partial information was available, estimated staging is demarked by a tilde (~), while author-reported information is demarked
by a double dagger (‡). When neither staging, nor clinical scores were provided for tight junction analyses, but were available for associated data sets, estimated staging is in parentheses. #Unless
otherwise noted, comparisons are between the diseased animal and healthy control. Increases are demarked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left-right
arrow (↔).

Strain/Genotype

Non-CNS-EC-specific Alterations in MBP-induced EAE Models.

Study

Table E.8.
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DA Rats
• Eae18b

Adzemovic
et al.139,b
• Spine

Origin
• EAE Resistance

Intervention(s)
Early-WT: No CS/T-L
Early-EAE18b: No CS/T-L

Stage & Severity†
Rescue of OCLN reactivity in vessels of diseased Eae18b animals vs. wild-type.
Also, ↑ number of OCLN+ vessels per tissue cross section.

Tight Junction Protein Alterations#

IHC-IE

Method

Eae18 locus, which contains C-C motif chemokine ligands (CCLs) 1, 2, 7, 11, and 12, was introduced into the EAE-susceptible DA strain by breeding with the EAE-resistant PVG.av1 rat strain.

WT: Wild-type. CS: Clinical score. HL-PL: Hind limb paralysis. HL-W: Hind limb weakness. T-L: Tail limpness. HL-PS: Hind limb paresis. CLDN5: Claudin-5. OCLN: Occludin. FOV: Field of view.
CD31: Cluster of differentiation 31. IHC-IF: Immunofluorescent-based immunohistochemistry. IHC-IE: Immunoenzyme-based immunohistochemistry.

aThe

Note: †Where possible, the disease stage and respective clinical score are provided. Otherwise, author-reported staging marked by a double dagger (‡). #Unless otherwise noted, comparisons are made
for the diseased animal vs. a healthy control, the treatment group vs. the control group, or the genetically manipulated animal vs. the wild-type control. Increases are marked by an upwards arrow (↑),
decreases by a downwards arrow (↓), and no change by a left-right arrow (↔).

Strain/Genotype

CNS-EC-specific Alterations in MOG1-125-induced EAE Models.

Study

Table E.9.
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Various Rats

BN Rats

Becanovics
et al.301

Fairless
et al.302
• Optic nerve head

• Thymus, Spleen,
Lymph node,
Spine, Brain

• gDNA

Origin

Onset: CS > 0.

Pre-onset: No CS.
Onset: CS > 0.

--

Stage & Severity†

Disruption of OCLN reactivity in vessels at both stages.

↑ Cldn4 mRNA in spleen, thymus, spine and brain homogenates, but not lymph node homogenate, in
strains resistant to EAE vs. susceptible to EAE.

A polymorphism in the Cldn4 gene (K191E) segregates with susceptibility to EAE.

Tight Junction Protein Alterations#

IHC-IF

qPCR

DNA-Seq

Method

gDNA: Genomic DNA. CS: Clinical score. CLDN4: Claudin-4. OCLN: Occludin. DNA-Seq: DNA sequencing. qPCR: Quantitative polymerase chain reaction. IHC-IF: Immunofluorescent-based
immunohistochemistry.

Note: †Where possible, the disease stage & clinical scores are listed. When partial information was available, estimated staging is demarked by a tilde (~), while author-reported information is demarked
by a double dagger (‡). When neither staging, nor clinical scores were provided for tight junction analyses, but were available for associated data sets, estimated staging is in parentheses. #Unless
otherwise noted, comparisons are between the diseased animal and healthy control. Increases are demarked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left-right
arrow (↔).

Strain/Genotype

Non-CNS-EC-specific Alterations in MOG1-125-induced EAE Models.

Study

Table E.10.
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SJL Mice

Stevens
et al.303,a
• SC Myelin

Origin
‡

Peak: NP

Stage & Severity†
Disruption & loss of CLDN11 reactivity in demyelinated areas with Cresyl Violet+ infiltrates.

Tight Junction Protein Alterations#

IHC-IE

Method

(previously named OSP) is expressed by oligodendrocytes as a component of the myelin sheath, hence its usages as a demyeli nation marker rather than a vascular marker here.

SC: Spinal cord. NP: Not provided. CLDN11: Claudin-11. IHC-IE: Immunoenzyme-based immunohistochemistry.

aClaudin-11

Note: †Where possible, the disease stage & clinical scores are listed. When partial information was available, estimated staging is demarked by a tilde (~), while author-reported information is demarked
by a double dagger (‡). When neither staging, nor clinical scores were provided for tight junction analyses, but were available for associated data sets, estimated staging is in parentheses. #Unless
otherwise noted, comparisons are between the diseased animal and healthy control. Increases are demarked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left-right
arrow (↔).

Strain/Genotype

Non-CNS-EC-specific Alterations in OSP/CLDN11-induced EAE Models.

Study

Table E.11.
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SJL/L Mice

SJL/L Mice

SJL Mice

Halder
et al.142

Halder
et al.143,a

Lanz
et al.144,b
• Spine

• Spine
(Lumbar)

• Spine
(Lumbar)

Origin

• PKCβ Inhibition
(ENZ unclear → unclear)

• CMH (10% O2)
(Post-onset → late)

--

Unclear – Likely Late

Peak-Norm: HL-PL
Peak-CMH: HL-PL
Late (x3)-Norm: HL-PS
Late (x3)-CMH: T-L

Peak: HL-PL

Peak: HL-PL
Late: HL-PS

Peak-Norm: HL-PL
Peak-CMH: T-L

Peak: HL-PL

-• CMH (10% O2)
(Post-induction → peak)

Stage & Severity†

Intervention(s)

Method

Rescue of CLDN5 reactivity in vessels.

↑ Proportion of OCLN+ per CD31+ vessels per FOV at the late stage (1-, 2-,
& 3-weeks post-peak), but not at peak.

Rescue of OCLN reactivity in vessels at a late stage (1-week post-peak), but
not at peak.

↓ Proportion of OCLN+ per CD31+ vessels per FOV.

Disruption & loss of OCLN reactivity in vessels at both stages.

Rescue of OCLN reactivity in vessels. Also, ↑ OCLN signal per FOV.

IHC-IF

IHC-IF

IHC-IF

IHC-IF

Disruption & loss of OCLN reactivity in vessels. Also, ↓ OCLN signal per
IHC-IF
FOV.

Tight Junction Protein Alterations#

CMH: Chronic mild hypoxia. O2: Oxygen. PKCβ: Protein kinase C-beta type. ENZ: Enzastaurin (LY-317615). WT: Wild-type. Norm: Normoxia. x3: Three time points analyzed. HL-PL: Hind limb
paralysis. T-L: Tail limpness. HL-PS: Hind limb paresis. OCLN: Occludin. CLDN5: Claudin-5. FOV: Field of view. CD31: Cluster of differentiation 31. IHC-IF: Immunofluorescent-based
immunohistochemistry. IHC-IE: Immunoenzyme-based immunohistochemistry.

comparisons between diseased animals at the late-stage time points and healthy controls were not provided. bNeither clinical scores, nor staging information were provided for the IHC-IF
data. For other data sets, treatment was initiated at peak disability and continued through an unspecified late stage.

aStatistical

Note: †Where possible, the disease stage and respective clinical score are provided. Otherwise, author-reported staging marked by a double dagger (‡). #Unless otherwise noted, comparisons are made
for the diseased animal vs. a healthy control, the treatment group vs. the control group, or the genetically manipulated animal vs. the wild-type control. Increases are marked by an upwards arrow (↑),
decreases by a downwards arrow (↓), and no change by a left-right arrow (↔).

Strain/Genotype

CNS-EC-specific Alterations in PLP139-159-induced EAE Models.

Study

Table E.12.
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SJL/N Mice

SD Rats

Wolburg
et al.44,a

Huang
et al.145

• Brain
(Cerebellum)

• Brain

Origin

• Kv1 blocker
(ImKTx88 post-induction
or post-onset → peak)

--

--

Intervention(s)

Method

Loss of CLDN1 & CLDN3 reactivity, but not CLDN5 or OCLN reactivity, in
IHC-IF
vessels near CD45+ inflammatory cuffs.

Tight Junction Protein Alterations#

Rescue of CLDN5 reactivity for either treatment group.

IHC-IF

1:T-L
Worsened disruption & loss of CLDN5 reactivity in rats with more severe
IHC-IF
4:HL-PL/FL-PL disability vs. those with milder disability.

Peak-VEH:HL-PL
Peak-TX-PI:No CS/T-L
Peak-TX-PO:T-L/HL-W

‡CS

‡CS

Paraplegic‡

Stage & Severity†

Although claudin-5 & occludin reactivity was detected in inflamed vessels, the vessels exhibited tortuous morphology. The authors stated that this confounded assessment about subcellular localization.

KV1: Voltage-gated potassium channel. CS: Clinical score. VEH: Vehicle group. TX: Treatment group. PI: Post-induction. PO: Post-onset. T-L: Tail limpness. HL-PL: Hind limb paralysis. FL-PL:
Forelimb paralysis. HL-W: Hind limb weakness. CLDN1: Claudin-1. CLDN3: Claudin-3. CD45: Cluster of differentiation 45. CLDN5: Claudin-5. OCLN: Occludin. IHC-IF: Immunofluorescent-based
immunohistochemistry.

a

Note: †Where possible, the disease stage and respective clinical score are provided. Otherwise, author-reported staging marked by a double dagger (‡). #Unless otherwise noted, comparisons are with
respect to healthy or vehicle controls. Increases are marked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left-right arrow (↔).

Strain/Genotype

Syngeneic Homogenates

CNS-EC-specific Alterations in CNS Homogenate-induced EAE Models.

Study

Table E.13.
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Wistar Rats

Lewis Rats

Lewis Rats

Lewis Rats

Shou
et al.146

Yang
et al.147,b

Grygorowicz
et al.148,c

Viñuela-Berni
et al.149,d

• P2X7R antagonist
(BBG post-induction →
pre-onset)

--

• Immunomodulatory
(TIIA post-onset → early)

Peak-VEH: HL-PL/-A
Peak-TX: No CS/L-T

Peak: HL-PL/-A

dpi-VEH: HL-PL
dpi-TX: > No CS.

‡12

‡12

Pre-onset-VEH: No CS
Pre-onset-TX: No CS

Pre-onset (x2): No CS
Peak: HL-PL

Pre-onset (x4): No CS
Peak: HL-PL

Peak-VEH: HL-PL/PPL
Peak-LOW: HL-W/-PL
Peak-HIGH: T-L/HL-W

WB

WB

↓ Total CLDN5 in isolated BMVs & SCMVs.

WB

WB

↑ Total CLDN5 protein in isolated BMVs from the treatment group vs. the
vehicle group, but not healthy controls.

Intermediate rescue of total CLDN5 protein.

WB

↑ Total CLDN5 protein in isolated BMVs from the treatment group vs. the
vehicle group or healthy controls.

Disruption & loss of CLDN5 reactivity in isolated BMVs at two times points
IHC-IF
pre-onset, but no apparent alteration at peak disability.

↓ Total CLDN5 protein in isolated BMVs at four time points pre-onset, and at
peak disability.

Rescue of CLDN5 & OCLN reactivity for both treatment groups. Additionally,
↑ CLDN5 & ↑ OCLN IOD for both treatment groups, with a greater increase IHC-IE
at the higher dosage.

IHC-IE

Loss of CLDN5 & OCLN reactivity. Also, ↓ CLDN5 & ↓ OCLN IOD.

HL-PL/PPL

‡Peak:

--

Method

Loss of CLDN5 reactivity in vessels at all stages. Also, ↓ CLDN5 AOD
IHC-IF
between onset and peak, with modest ↑ CLDN5 AOD at remission.

Tight Junction Protein Alterations#

Onset: T-L
Peak: FL-PL
Late: HL-W

Stage & Severity†

--

Intervention(s)

-• BMVs,
SCMVs • AVPR antagonist
(CO pre-induction → peak)

• BMVs
(GM)

• Brain

• Brain

Origin

BMV: Brain microvessel. GM: Grey Matter. SCMV: spinal cord microvessel. TIIA: Tanshinone IIA. P2X7R: Purinergic Receptor P2X 7. BBG: Brilliant Blue G. AVPR: Arginine vasopressin receptor.
CO: Conivaptan. CS: Clinical score. VEH: Vehicle group. LOW: Low dosage. HIGH: High dosage. TX: Treatment group. x4: Four time points. x2: Two time points. T-L: Tail limpness. FL-PL:
Forelimb paralysis. HL-W: Hind limb weakness. HL-PL: Hind limb paralysis. PPL: Paraplegia. HL-A: Hind limb ataxia. CLDN5: Claudin-5. AOD: Average optical density (OD). OCLN: Occludin.
IOD: Integrated OD. IHC-IF: Immunofluorescent-based immunohistochemistry (IHC). IHC-IE: Immunoenzyme-based IHC. WB: Western blotting.

The drug was considered at two dosages. cOnset of disease was delayed in the treatment group, complicating direct comparison of groups. dThere was no significant difference between the treatment
group and the vehicle group or healthy controls, but there was a significant difference between the vehicle group and healthy controls.

b

Note: †Where possible, the disease stage and respective clinical score are provided. Otherwise, author-reported staging marked by a double dagger (‡). #Unless otherwise noted, comparisons are with
respect to healthy or vehicle controls. Increases are marked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left-right arrow (↔).
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SJL/N Mice

SD Rats

Wolburg
et al.304,a,b

Huang
et al.145,c
• BH

• CP Epithelium

Origin

• Kv1 Blocker
(ImKTx88 post-induction
or post-onset → unclear)
VEH:HL-PL
TX-PI:T-L
TX-PO:T-L

Unclear – Likely Peak

↑ Total CLDN5 & total ↑ OCLN protein for either intervention strategy
vs. vehicle.

↑ Cldn5 & ↑ Ocln mRNA for either intervention strategy vs. vehicle
qPCR

qPCR,
WB

↓ Cldn5 & ↓ Ocln mRNA. Also, ↓ Total CLDN5 & ↓ total OCLN protein.

Unclear: HL-PL
(Likely Peak)

--

Method

Disruption & loss of CLDN1, CLDN2, & CLDN11 reactivity, but not
IHC-IF
OCLN reactivity.

Tight Junction Protein Alterations#

Insufficient Information

Stage & Severity†

--

Intervention(s)

was not provided. bClinical scores were not provided. cNeither the staging, nor the clinical scores were explicitly defined. However, for associated data sets, the staging was defined

CP: Choroid plexus. BH: Brain homogenate. KV1: Voltage-gated potassium channel subfamily A. VEH: Vehicle group. TX: Treatment group. PI: Post-induction. PO: Post-onset. HL-PL: Hind limb
paralysis. T-L: Tail limpness. CLDN1: Claudin-1. CLDN2: Claudin-2. CLDN11: Claudin-11. OCLN: Occludin. CLDN5: Claudin-5. IHC-IF: Immunofluorescence-based immunohistochemistry. qPCR:
Quantitative polymerase chain reaction. WB: Western blotting.

as peak.

aStaging information

Note: †Where possible, the disease stage & clinical scores are listed. When partial information was available, estimated staging is demarked by a tilde (~), while author-reported information is demarked
by a double dagger (‡). When neither staging, nor clinical scores were provided for tight junction analyses, but were available for associated data sets, estimated staging is in parentheses. #Unless
otherwise noted, comparisons are between the diseased animal and healthy control, or treatment group and vehicle. Increases are demarked by an upwards arrow (↑), decreases by a downwards arrow
(↓), and no change by a left-right arrow (↔).

Strain/Genotype

Syngeneic Homogenates

Non-CNS-EC-specific Alterations in CNS Homogenate-induced EAE Models.

Study

Table E.14.
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Lewis Rats

Lewis Rats

Lewis Rats

Huang
et al.305

Huang
et al.306

Yang
et al.147
• BH

• BH (Cerebellum)
• SCH (Lumbar)

• BH (Cerebellum)
• SCH (Lumbar)

Origin

• Anti-Inflamm./Immunomod.
(TIIA post-induction → peak)

--

• ROCK Inhibitor
(FSD post-induction → peak)

Peak-VEH:HL-PL/PPL
Peak-LOW:HL-W/-PL
Peak-HIGH:T-L/HL-W

Peak:HL-PL/PPL

Peak-VEH:HL-PL
Peak-TX:HL-W

WB

WB

↓ Total CLDN5 & ↓ total OCLN protein.
↑ Total CLDN5 & ↑ total OCLN protein for either dosage vs.
vehicle.

WB

↑ Total OCLN protein in BH & SCH.

WB

↓ Total OCLN protein in BH & SCH.

Peak:HL-PL

--

Method

WB

Tight Junction Protein Alterations#

Pre-onset (x2): No CS
↓ Total OCLN protein in BH & SCH at all stages vs. animals
Onset:HL-W/PL
sacrificed at 0 dpi.
Peak:HL-PL/FL-PL

Stage & Severity†

--

Intervention(s)

BH: Brain homogenate. SCH: Spinal cord homogenate. ROCK: Rho-associated kinase. TIIA: Tanshinone IIA. x2: Two time points. VEH: Vehicle group. TX: Treatment group. LOW: Low dosage.
HIGH: High dosage. CS: Clinical score. HL-W: Hind limb weakness. HL-PL: Hind limb paralysis. FL-PL: Forelimb paralysis. PPL: Paraplegia. T-L: Tail limpness. OCLN: Occludin. CLDN5: Claudin5. dpi: Days post-induction. WB: Western blotting.

Note: †Where possible, the disease stage & clinical scores are listed. When partial information was available, estimated staging is demarked by a tilde (~), while author-reported information is demarked
by a double dagger (‡). When neither staging, nor clinical scores were provided for tight junction analyses, but were available for associated data sets, estimated staging is in parentheses. #Unless
otherwise noted, comparisons are between the diseased animal and healthy control, or treatment group and vehicle. Increases are demarked by an upwards arrow (↑), decreases by a downwards arrow
(↓), and no change by a left-right arrow (↔).
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SJL/J Mice
• TCR-1640

Alvarez
et al.9

• Brain
(Cerebellum)

Origin

Pre-onset: 45, 50, & 55 dpn‡

Pre-onset: 30 & 35 dpn‡

Stage†

Method

Disruption of OCLN & CLDN3 reactivity in vessels near astrogliosis & fibrinogen deposition.
Additionally, ↓ OCLN pixel intensity at 45-55 dpn vs. 30-35 dpn, but ↔ CLDN3 & ↔ CLDN5 pixel IHC-IF
intensity at same time points.

OCLN & CLDN3 reactivity detected in vessels at 35 dpn. Also, ↔ OCLN, ↔ CLDN3, & ↔ CLDN5
IHC-IF
pixel intensity between 30 and 35 dpn.

Tight Junction Protein Alterations#

TCR-1640: T cell receptor reactive to residues 92-106 of myelin oligodendrocyte glycoprotein. dpn: Days post-natal. OCLN: Occludin. CLDN3: Claudin-3. CLDN5: Claudin-5. IHC-IF:
Immunofluorescent-based immunohistochemistry.

this model, astrogliosis and barrier dysfunction is observed ~45 dpn onwards, while onset of disability is generally ~65 dpn. In females, the disease generally follows a relapse-remission course.
However, in males, the disease generally follows a primary-progressive course.

aIn

Note: †Where possible, the disease stage and respective clinical score are provided. Otherwise, author-reported staging marked by a double dagger (‡). #Increases are marked by an upwards arrow (↑),
decreases by a downwards arrow (↓), and no change by a left-right arrow (↔).

Strain/Genotype

TCR-1640 Modela

CNS-EC-specific Alterations in Transgenic EAE Models.

Study

Table E.15.
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APPENDIX F
Summary Tables for Studies with Other Animal Models of CNS-IDDs

Lewis Rats

Winkler
et al.20,b,c

• Brain
(Cortex)

Origin

6, 10, 24 hpi,
3 & 6 dpi

↑ Proportion of OCLN+ lesional vessels from immune cell-depleted animals vs. control seruminjected animals. However, ↔ proportion of CLDN3+ or CLDN5+ lesional vessels with respect IHC-IF
to disease or intervention.

↓ Proportion of OCLN+ lesional vessels over the first 24 hpi, with partial and complete recovery
at 3 & 6 dpi, respectively. However, ↔ proportion of CLDN3+ or CLDN5+ lesional vessels
over the same timeframe.

No apparent alteration of CLDN3 & CLDN5 reactivity detected in lesional vessels vs. control
IHC-IF
Ab-injected animals.

10 hpi

AQP4: Aquaporin-4. hpi: Hours post-injection. OCLN: Occludin. CLDN3: Claudin-3. CLDN5: Claudin-5. IHC-IF: Immunofluorescent-based immunohistochemistry.

b

In this model, barrier dysfunction, neutrophil infiltration, and astrocyte loss occurred by 6 hpi. Barrier function was restored by 24 hpi, but astrocyte loss and neutrophil infiltration persisted over 3 dpi.
Micrographs were not provided for every time point measured, nor were micrographs were provided for the intervention experiments. cInjection of an anti-PMN antiserum depleted multiple immune
cell types by ~90%, including neutrophils, T cells, and B cells.

a

Method

Loss of OCLN reactivity in lesional vessels at 10 & 24 hpi vs. control Ab-injected animals, with
recovery of OCLN reactivity by 3 dpi.

Tight Junction Protein Alterations#

10, 24 hpi,
& 3 dpi

Staging†

• Immune cell Depletion
6 hpi
(Antiserum pre-induction)

--

Intervention

Note: #Increases are marked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left-right arrow (↔).

Strain/Genotype

Intracortical Injection of Patient-derived Recombinant AQP4 Antibody & Complementa

CNS-EC-specific Alterations in Experimental NMOSD Models.

Study

Table F.1.
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C57BL/6 Mice
• Prf1-/-

C57BL/6 Mice

C57BL/6 Mice

C57BL/6 Mice
• Prf1-/-

C57BL/6 Mice
• Prf1+/- or Prf1-/-

Suidan
et al.159,b

Suidan
et al.163

Johnson
et al.161

Johnson
et al.164

Willenbring
et al.162
Brain

Brain

Brain

BMVs

BMVs

Origin

24 hpp

24 hpp

24 hpp

24 hpp

• No immune cell depletion
(Rat serum days 5-7 post-infection)
• Neutrophil depletion
(anti-Ly6G days 5-7 post-infection)
• CD8+ T cell depletion
(anti-GR-1 days 5-7 post-infection)
• Prf1-KO mice restored with
Prf1-competent CD8+ T cells

12 hpp

12 hpp

• Peptide-based NRP-1 inhibitor
(-0.5, +3, +6, & +9 hpp)

• Prf1-KO (hemi- or homozygous)

24 hpp

0, 4, 12,
& 24 hpp

--

• Prf1-KO

Stage

Intervention

WB

WB

WB

Method

Disruption & loss of CLDN5 reactivity in vessels, plus severity of fibrinogen
leakage, increases with the number of Prf1 alleles in VP2-injected animals vs. IHC-IF
respective E7-injected counterparts.

Disruption & loss of CLDN5 and OCLN reactivity in vessels with FITC-albumin
IHC-IF
leakage in VP2-injected animals vs. E7-injected counterparts.

Rescue of CLDN5 & OCLN reactivity, plus FITC-albumin leakage, in CD8IHC-IF
depleted VP2-injected animals vs. non-depleted counterparts.

No rescue in CLDN5 and OCLN reactivity in vessels near FITC-albumin leakage in
IHC-IF
neutrophil-depleted VP2-injected mice vs. non-depleted counterparts.

Disruption & loss of CLDN5 and OCLN reactivity in vessels near FITC-albumin
IHC-IF
leakage in non-depleted VP2-injected mice vs. E7-injected counterparts.

↑ Total OCLN in NRP-1-treated VP2-injected animals vs. vehicle-treated
counterparts.

↔ Total CLDN5 & ↔ total OCLN in VP2-injected Prf1-KO animals vs. E7-injected
counterparts.

↓ Total OCLN over first 12 hpp, with recovery at 24 hpp in VP2-injected wild-type
animals.

↔ Total CLDN5 over first 12 hpp, but increase at 24 hpp, in VP2-injected wild-type
animals.

Tight Junction Protein Alterations#

In this model, detectable astrogliosis and barrier dysfunction is observed by 4 hpi, peaking at ~12 hpi for both. bStatistics were not enumerated for the WB experiments using wild-type mice.

Prf1: Perforin. BMVs: Brain microvessels. KO: Knockout. NRP-1: Neurpilin-1. Ly6G: Lymphocyte antigen 6 complex, locus G. CD8: Cluster of differentiation 8. GR-1: Granulocyte receptor-1. hpp:
Hours post-injection of the VP2 or E7 peptides. CLDN5: Claudin-5. VP2: Peptide encoding the immunodominant epitope of the VP2 capsid protein (VP2121-130). OCLN: occludin. E7: Control peptide.
FITC: Fluorescein isothiocyanate. WB: Western blotting. IHC-IF: Immunofluorescent-based immunohistochemistry.

a

Note: No studies that characterized members of the claudin, TAMP, or angulin families using the classic TMEV model were found. #Increases are marked by an upwards arrow (↑), decreases by a
downwards arrow (↓), and no change by a left-right arrow (↔).

Strain/Genotype

Peptide-induced Fatal Syndromea

CNS-EC-specific Alterations in TMEV Models.

Study

Table F.2.
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C57BL/6 mice

Berghoff
et al.172,a
• Brain
(Cortex)

• Brain
(Corpus Callosum)

Origin

--

--

Intervention

5 weeks of feeding

5 weeks of feeding

Stage

No apparent alteration of OCLN reactivity in vessels. Also, ↔ OCLN+ area fraction.

Disruption & loss of OCLN reactivity in vessels. Also, ↓ OCLN+ area fraction.

Tight Junction Protein Alteration#

IHC-IF

IHC-IF

Method

5 weeks of feeding was chosen by the authors as it corresponded to peak demyelination and barrier dysfunction in the corpus callosum, but not for the cortex.

OCLN: Occludin. IHC-IF: Immunofluorescent-based immunohistochemistry.

a

Note: #Comparisons are between cuprizone-fed mice and control chow-fed mice. Increases are marked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no change by a left-right arrow
(↔).

Strain/Genotype

CNS-EC-specific Alterations in Cuprizone Models.

Study

Table F.3.
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C57BL/6 mice
• Cxcr3-/-

C57BL/6 mice

Berghoff
et al.172

Shelestak
et al.174

5 days of feeding

• Cxcr3-KO

--

--

• BH (Corpus
Callosum)
3 days of feeding

5 weeks of feeding

5 days of feeding

5 weeks of feeding

5 days of feeding

--

--

Stage

Manipulation(s)

• BH (Cortex)

• BH (Corpus
Callosum)

Origin

↓ Total OCLN protein in homogenate.

WB

WB

qPCR

↓ Cldn5 & ↓ Ocln mRNA in homogenate.

↔ Total CLDN5 protein in homogenate.

WB

↓ Total CLDN5 protein in homogenate.

qPCR

qPCR

Rescue of Cldn5 & Ocln mRNA in homogenate from cuprizone-fed Cxcr3-KO mice vs.
cuprizone-fed wild-type mice.
↓ Cldn5 & ↓ Ocln mRNA in homogenate.

qPCR

Method

↓ Cldn5 & ↓ Ocln mRNA in homogenate.

Tight Junction Protein Alterations#

CXCR3: C-X-C Motif Chemokine Receptor 3. BH: Brain homogenate. KO: Knockout. CLDN5: Claudin-5. OCLN: Occludin. qPCR: Quantitative polymerase chain reaction. WB: Western blotting.

Note: #Unless otherwise noted, comparisons are between cuprizone-fed mice and control chow-fed mice. Increases are demarked by an upwards arrow (↑), decreases by a downwards arrow (↓), and no
change by a left-right arrow (↔).

Strain/Genotype

Non-CNS-EC-specific Alterations in Cuprizone Models.

Study

Table F.4.
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APPENDIX G
Reagents, Primers, Antibodies, & Software Used in These Studies.

BBB-EC Isolation

Immunohistochemistry

Cellbiologics
ThermoFisher Scientific
R&D Systems

Complete Endothelial Cell Medium with Kit
Gibco™ Puromycin Dihydrochloride
R&D Systems™ Cultrex Rat Collagen I, Lower Viscosity

ThermoFisher Scientific

Gibco™ DMEM, high glucose, HEPES, no phenol red

Spectrum

Sigma-Aldrich

Bovine Serum Albumin

DNAse

Fisher Bioreagents

HEPES

Sigma-Aldrich

ThermoFisher Scientific

Gibco™ HBSS, no calcium, no magnesium, no phenol red

Collagenase/Dispase

Electron Microscopy Services

PFTE Printed Slides

Acros Organics

Triton X-100

Vector Laboratories

Sigma-Aldrich

Paraformaldehyde

Vectashield Antifade Mounting Medium

Vector Laboratories

Lycopersicon Esculentum (Tomato) Lectin, DyLight 649

Sigma-Aldrich

Sigma-Aldrich

Trichloroacetic Acid

Bovine Serum Albumin

Sigma-Aldrich

Boric Acid

Sigma-Aldrich

Sodium Fluorescein Salt

Barrier Function
(in vivo)

Hooke Laboratories

MOG35-55/CFA Emulsion PTX

Active EAE Induction

Manufacturer

Reagent

List of Reagents Used in These Studies.

Purpose

Table G.1.

3443-100-01

A1113803

M1168-Kit

D348910MG

11097113001

21063029

A1470

BP310-100

14175095

63419-14

H-1000-10

A1470

327371000

P6148

DL-1178-1

T6399

B6768

F6377

EK-2110

Catalogue
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RNA Isolation &
Analysis

Conditioned Media

T Cell Activation

Purpose

Bio-Rad
Bio-Rad

SsoAdvanced Universal SYBR Green Supermix

ThermoFisher Scientific

Gibco™ DMEM, High Glucose, L-Glutamine, Phenol Red

iScript cDNA Synthesis Kit

ATCC

C8-D1A Mouse Astrocyte Line

Molecular Research Center

BioLegend

Ultra-Leaf Purified anti-mouse IFN-γ

4-Bromoanisole (BAN)

BioLegend

Recombinant Mouse IL-12 p70

Molecular Research Center

Hooke Laboratories

MOG35-55 Peptide in TC Media (100X)

RNAzol RT

Alfa Aesar

2-Mercaptoethanol

Miltenyi Biotec

ThermoFisher Scientific

Gibco™ Sodium Pyruvate (100 mM)

Neutrophil Isolation Kit, mouse

ThermoFisher Scientific

Gibco™ MEM Non-Essential Amino Acids Solution (100X)

Hooke Laboratories

Sigma-Aldrich

L-Glutamine–Penicillin–Streptomycin solution (100X)

Naïve C57BL/6 Spleen Cells & Lymph Node Cells

ThermoFisher Scientific

Gibco™ Fetal Bovine Serum, One Shot™

ThermoFisher Scientific

Fisher Bioreagents

HEPES

Gibco™ Penicillin-Streptomycin (100X)

Gibco

RPMI 1640

Atlanta Biologicals

Hooke Laboratories

C57BL/6 MOG35-55 Spleen & Lymph Node Cells

Fetal Bovine Serum

Manufacturer

Reagent

1725271

1708891

BN 191

RN 190

130-097-658

CF-1203

15140122

S11150

11965092

CRL-2541

505847

577002

DS-0111

A1589030

11360070

11140050

G6784

A3160401

BP310-100

11875085

CF-1003

Catalogue
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Tamoxifen-induced
Recombination in vivo

Barrier Function
(Cell Culture)

TAT-Cre-mediated
Recombination

Purpose

Manufacturer
Sigma-Aldrich
AnaSpec
Cellbiologics
ThermoFisher Scientific
Sigma-Aldrich
Acros Organics
Sigma-Aldrich
ThermoFisher Scientific
Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich
Corning
Applied Biophysics
R&D Systems
Advanced BioMatrix
R&D Systems
Sigma-Aldrich
Thermo Scientific Chemicals

Reagent
TAT-Cre Recombinase Protein
TAT-HA2 Fusion Peptide
Complete Endothelial Cell Medium
Live Cell Imaging Solution
Paraformaldehyde
Triton X-100
Bovine Serum Albumin
Tween-20
Sodium Fluorescein Salt
Boric Acid
Trichloroacetic Acid
6.5 mm Transwell® with 0.4 µm Pore Polyester Membrane Insert
8W10E+ PET Array
R&D Systems™ Cultrex Rat Collagen I, Lower Viscosity
Type IV Collagen, Lyophilized, Human
R&D Systems™ Mouse Decorin Recombinant Protein
Tamoxifen (Free base)
Corn Oil

405435000

T5648

1060-DE

5022

3443-100-01

8W10E+

3470

T6399

B6768

F6377

BP337-100

A1470

327371000

P6148

A14291DJ

M1168

AS-64876

SCR508

Catalogue
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In-Cell Western

Genomic DNA
Isolation & Analysis

Purpose

Sigma-Aldrich
Acros Organics

Paraformaldehyde
Triton X-100

LI-COR

LI-COR

Odyssey Blocking Buffer (TBS)

CellTag™ 700 Stain

Advanced BioMatrix

Type IV Collagen, Lyophilized, Human

Tocris

Corning

96-well Flat Clear Bottom Black Polystyrene TC-treated Microplates

Demethylasterriquinone B1

ThermoFisher Scientific

GeneRuler 50 bp DNA Ladder

Tocris

ThermoFisher Scientific

Promega Molecular Grade Ethidium Bromide Solution

Methylprednisolone

ThermoFisher Scientific

UltraPureTM Agarose

ThermoFisher Scientific

ThermoFisher Scientific

Phire Hot Start II PCR Master Mix

Tween-20

Atlanta Biologicals

Fetal Bovine Serum

Sigma-Aldrich

Sigma-Aldrich

Dextran from Leuconostoc spp. (Mr ~70,000)

Bovine Serum Albumin

Manufacturer

Reagent

926-41090

1819

4819/50

BP337-100

A1470

327371000

P6148

927-50000

5022

3904

SM0373

H5041

16500-100

F125S

S11150

31390

Catalogue
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2.15
2.31
2.31

Claudin-5-AF488

Claudin-5

Donkey anti-Mouse IgG-IRDye® 800CW

Version
1.2.215.0
5.2
9.2.0

Software

ECIS

Image Studio Lite

Prism

List of Software Used in These Studies.

2.5, 2.6

Decorin-AF488

Table G.4.

Figure

List of Antibodies Used in These Studies.
Catalogue

RRID

Excised: 414

Floxed: 1195

Wild-type: 978

ThermoFisher Scientific

GraphPad

LI-COR

Applied Biophysics

Manufacturer

926-32212

35-2500

352588

--

--

--

Size (bp)

AB_621847

AB_2533200

AB_2532189

A kind gift from Dr. David E. Birk (Clone: LF-113)
ThermoFisher Scientific

LI-COR

--

--

--

GAG CCA GGA GGA GTT TGA TG
CTC AGT CCA GTC GGT GTC CT

Sequence (5’ to 3’)

Manufacturer

--

qMmuCED0027505

qMmuCID0039628

qMmuCED0001017

PrimePCR Assay ID

Antibody

Table G.3.

Bgn

Actb

Beta Actin

Biglycan

Dcn

Cldn5

Claudin-5

Decorin

Gene Symbol

Gene Name

List of Primers Used in These Studies.

Recombination of
Floxed Alleles

qPCR

Purpose

Table G.2.
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APPENDIX H
Clinical Scoring Rubric According to Hooke Labs
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Table H.
Score

EAE Scoring Rubric for Mice at Onset & Peak Disease.
Clinical observations
No obvious changes in motor function compared to non-immunized mice.

0.0

When picked up by base of tail, the tail has tension and is erect. Hind legs are usually spread
apart. When the mouse is walking, there is no gait or head tilting.
Tip of tail is limp.

0.5

When picked up by base of tail, the tail has tension except for the tip. Muscle straining is felt
in the tail, while the tail continues to move.
Limp tail.

1.0

When picked up by base of tail, instead of being erect, the whole tail drapes over finger. Hind
legs are usually spread apart. No signs of tail movement are observed.
Limp tail and hind leg inhibition.

1.5

When picked up by base of tail, the whole tail drapes over finger. When the mouse is dropped
on a wire rack, at least one hind leg falls through consistently. Walking is very slightly
wobbly.
Limp tail and weakness of hind legs.

2.0

When picked up by base of tail, the legs are not spread apart, but held closer together. When
the mouse is observed walking, it has a clearly apparent wobbly walk. One foot may have
toes dragging, but the other leg has no apparent inhibitions of movement.
- OR Mouse appears to be at score 0.0, but there are obvious signs of head tilting when the walk is
observed. The balance is poor.
Limp tail and dragging of hind legs.
Both hind legs have some movement, but both are dragging at the feet (mouse trips on hind
feet).
- OR -

2.5
No movement in one leg/completely dragging one leg, but movement in the other leg.
- OR EAE severity appears mild when picked up (as score 0.0-1.5), but there is a strong head tilt
that causes the mouse to occasionally fall over.
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Score

Clinical observations
Limp tail and complete paralysis of hind legs (most common).
- OR Limp tail and almost complete paralysis of hind legs. One or both hind legs are able to paddle,
but neither hind leg is able to move forward of the hind hip.
- OR -

3.0

Limp tail with paralysis of one front and one hind leg.
- OR ALL of:
Severe head tilting,
Walking only along the edges of the cage,
Pushing against the cage wall,
Spinning when picked up by base of tail.
Limp tail and complete paralysis of hind legs. In addition to:
Mouse is moving around the cage, but when placed on its side, is unable to right itself. Hind
legs are together on one side of body.

3.5
- OR Mouse is moving around the cage, but the hind quarters are flat like a pancake, giving the
appearance of a hump in the front quarters of the mouse.
Limp tail, complete hind leg and partial front leg paralysis.
Mouse is minimally moving around the cage but appears alert and feeding.
4.0

Often euthanasia is recommended after the mouse scores 4.0 for 2 days. However, with daily
s.c. fluids most C57BL/6 mice may recover to 3.5 or 3.0, while SJL mice may fully recover
even if they reach score 4.0 at the peak of disease. When the mouse is euthanized because of
severe paralysis, a score of 5.0 is entered for that mouse for the rest of the experiment.
Complete hind and partial front leg paralysis, no movement around the cage. Mouse is not
alert.

4.5

Mouse has minimal movement in the front legs. The mouse barely responds to contact.
Euthanasia is recommended. When the mouse is euthanized because of severe paralysis, a
score of 5.0 is entered for that mouse for the rest of the experiment.
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Score

Clinical observations
Mouse is spontaneously rolling in the cage (euthanasia is recommended).
- OR -

5.0

Mouse is found dead due to paralysis.
- OR Mouse is euthanized due to severe paralysis.
Table reproduced with permission by Hooke Laboratories Inc., https://hookelabs.com
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APPENDIX I
Brain-related RNA-Seq Data Sets for Alpha Integrin Isoform Expression
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Figure I.1.

Integrin Expression in Cells Isolated from the Mouse Cortex.

A publicly available bulk RNA-Seq data set31 for various cell types isolated from the
cortex of mice was queried for the expression of Itga1 (upper) and Itga2 (lower) through
its web portal (http://www.brainrnaseq.org/). FPKM: Fragments per kilobase million.
OPC: Oligodendrocyte precursor cell.
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Figure I.2.

Integrin Expression in Cells Isolated from the Human Cortex.

A publicly available bulk RNA-Seq data set32 for various cell types isolated from the
cortex of human patients was queried for the expression of Itga1 (upper) and Itga2
(lower) through its web portal (http://www.brainrnaseq.org/). FPKM: Fragments per
kilobase million.
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Figure I.3.

Integrin Expression Across Mouse Endothelial Cell Types.

A publicly available bulk RNA-Seq data set33 for brain and peripheral endothelial cell
types isolated from Tie2-GFP mice was queried for the expression of Itga1 (upper) and
Itga2 (lower) through its web portal (https://markfsabbagh.shinyapps.io/vectrdb/). NonEC: GFP-negative cells. EC: GFP-positive cells. TPM: Transcripts per million. Brain:
Cells derived from one-week-old animals. Cultured: Cultured primary mouse BBB-ECs.
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Figure I.4.

Integrin Expression in Cells Isolated from the Mouse Brain.

A publicly available single-cell RNA-Seq data set34 for CNS cell types isolated from
fluorescent reporter mice was queried for the expression of Itga1 (upper) and Itga2
(lower) through its web portal
(http://betsholtzlab.org/VascularSingleCells/database.html). PC: Pericyte. vSMC:
Vascular smooth muscle cell. aaSMC: Arteriolar smooth muscle cell. aSMC: Arterial
smooth muscle cell. MG: Microglia. FB: Fibroblast-like. OL: Oligodendrocyte. EC:
Endothelial cell. vEC: Venous endothelial cell. capilEC: Capillary endothelial cell. aEC:
Arterial endothelial cells. AC: Astrocyte.
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Figure I.5.

Integrin Expression in Across Mouse Brain Endothelial Cell Types.

A publicly available single-cell RNA-Seq data set33 for brain endothelial cell types
isolated from Tie2-GFP mice was queried for the expression of Itga1 (upper) and Itga2
(lower) through its web portal (https://markfsabbagh.shinyapps.io/vectrdb/). UMI:
Unique molecular identifier. Capillary-V: Capillary (venous-side). Capillary-A: Capillary
(arterial-side).
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APPENDIX J
AKT2 Maintains Brain Endothelial Claudin-5 Expression and Selective Activation
of IR/AKT2/FOXO1-signaling Reverses Barrier Dysfunction
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Abstract
Inflammation-induced blood–brain barrier (BBB) dysfunction and microvascular
leakage are associated with a host of neurological disorders. The tight junction protein
claudin-5 (CLDN5) is a crucial protein necessary for BBB integrity and maintenance.
CLDN5 is negatively regulated by the transcriptional repressor FOXO1, whose activity
increases during impaired insulin/AKT signaling. Owing to an incomplete understanding
of the mechanisms that regulate CLDN5 expression in BBB maintenance and dysfunction,
therapeutic interventions remain underdeveloped. Here, we show a novel isoform-specific
function for AKT2 in maintenance of BBB integrity. We identified that AKT2 during
homeostasis specifically regulates CLDN5-dependent barrier integrity in brain
microvascular endothelial cells (BMVECs) and that intervention with a selective insulinreceptor (IR) agonist, demethylasterriquinone B1 (DMAQ-B1), rescued IL-1β-induced
AKT2 inactivation, FOXO1 nuclear accumulation, and loss of CLDN5-dependent barrier
integrity. Moreover, DMAQ-B1 attenuated preclinical CLDN5-dependent BBB
dysfunction in mice subjected to experimental autoimmune encephalomyelitis. Taken
together, the data suggest a regulatory role for IR/AKT2/FOXO1-signaling in CLDN5
expression and BBB integrity during neuroinflammation.
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Introduction
Blood–brain barrier (BBB) dysfunction is a pathological hallmark in inflammationassociated diseases of the central nervous system (CNS), including multiple sclerosis,
stroke, dementia, traumatic brain injuries, encephalopathies, and brain metastases. 1–4
Under homeostasis, local cues promote BBB maintenance by fostering highly restrictive
brain endothelial cell–cell contacts.5–7 During an aberrant inflammatory response,
however, BBB dysfunction can be triggered by mediators from circulation or the CNS,
which act upon endothelial cells (ECs) to reduce their cell–cell adhesive forces. Loss of
this adhesion results in barrier hyperpermeability, leading to edema, poor nutrient
exchange, neuronal toxicity, and CNS dysfunction. 8,9
This compromise in BBB integrity is a direct result of inflammatory-mediated
disruption of the adherens and tight junction complexes at endothelial cell–cell
contacts.10,11 Although the establishment of the BBB interface requires the involvement of
various junctional proteins, the tight junction protein claudin-5 (CLDN5) is known to play
an indispensable role in restricting small molecule flux through paracellular
passageways.12–14 In vitro BBB models have demonstrated that CLDN5 is a common target
of inflammatory mediators such as interleukin-1β (IL-1β),15 homocysteine,16,17 and tumor
necrosis factor alpha,18 while multiple animal models of CNS diseases have shown loss of
CLDN5 is a common phenomenon associated with BBB dysfunction. 16,18–23
Maturation of endothelial tight junctions produced by high levels of CLDN5 is
known to require AKT-dependent inactivation and dissociation of the transcription factor
FOXO1 from a silencer region within the Cldn5 promoter.13,15 Under certain
proinflammatory conditions, FOXO1 can re-occupy this silencer, resulting in CLDN5
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downregulation and endothelial barrier dysfunction. 15,24,25 Moreover, we have shown in
vitro that siRNA-mediated knockdown of FoxO1 prevents loss of CLDN5 during IL-1βmediated barrier dysfunction,15 suggesting that targeting FOXO1 inactivation directly or
through upstream regulators, such as AKT, could be an effective means for therapeutic
preservation of CLDN5 during inflammation.
Given the complexity and extensiveness of the AKT signaling network, it is not
surprising that the outcome of AKT signaling on endothelial barrier maintenance appears
to be highly context-dependent. This convolution is, in part, due to AKT isoforms that can
have both overlapping and distinct functions, 26 of which both AKT1 and AKT2 have been
shown to have unique regulatory roles in vascular endothelium. While much remains
undetermined about these isoform-specific functions, AKT1 is known to be involved in the
proinflammatory-mediated loss of endothelial barrier integrity, while its deficiency
protects against endothelial hyperpermeability in a λ-carrageenan-induced edema model.27
By way of contrast, AKT2 is known to distinctly regulate endothelial insulin signaling,28
but it remains largely unknown whether AKT2 is involved in any modulation of barrier
integrity.
The role of vascular insulin signaling in endothelial barrier maintenance is even
more complicated, as some groups have shown insulin-mediated barrier enhancement,
while others have shown negligible effects. 29–31 Although vascular insulin signaling
canonically acts through the insulin receptor (IR), insulin is well-known to be crossreactive with the insulin-like growth factor 1 receptor (IGF1R) and vice versa with insulinlike growth factors (IGFs) cross-reacting with the IR. Despite a high degree of homology
between these two receptors, knockout studies have demonstrated that these pathways
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mediate very distinct cellular and physiological processes. Namely, the IGF1R primarily
mediates mitogenic pathways, while the IR regulates metabolic effects. Due to insulin’s
receptor promiscuity and conflicting information regarding the effects of insulin on BBB
integrity, identifying selective agonists would undoubtedly aid in clarifying the role for IRspecific signaling in endothelial barrier modulation.
Given that FOXO1 inactivation is a known metabolic target for IR signaling, 32 we
explored a novel role for IR/AKT/FOXO1-signaling to regulate CLDN5-dependent BBB
integrity. First, we establish a pathophysiological relevance for studying this pathway by
analyzing brain microvessels isolated from mice with neuroinflammation-induced BBB
disruption and demonstrate increased FOXO1 concurrent with decreased CLDN5. We next
show that AKT-mediated regulation of CLDN5 and brain microvascular endothelial cell
(BMVEC) integrity is distinct to the AKT2 isoform. Furthermore, the selective IR agonist
demethylasterriquinone B1 (DMAQ-B1), unlike insulin or IGF-1, preferentially induces
IR signaling, decreases FOXO1 nuclear accumulation, upregulates CLDN5, and enhances
barrier function in cultured BMVECs. Finally, and most importantly, we demonstrate that
DMAQ-B1-dependent

IR/AKT2/FOXO1-signaling

reverses

inflammation-mediated

CLDN5 loss and BBB dysfunction. The results from these experiments establish that
selective activation of the IR can reverse the aberrant loss of BBB integrity during
inflammation. We suggest targeting the IR/AKT2/FOXO1/CLDN5-axis as a potential
therapy in CNS diseases associated with BBB dysfunction.
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Materials and Methods
Reagents and Supplies
A complete list of reagents and supplies including purchasing information can be
found in Supplementary Tables 1 and 2.
Animal Use
Mice used in these studies were C57BL/6 J purchased from Jackson Laboratory.
Animals were maintained under a 12-h light/dark schedule with food and water ad libitum.
All animal use was approved by the Institutional Animal Care and Use Committees at the
University of South Florida and Boise State University and was performed in accordance
with the Guide for the Care and Use of Laboratory Animals. All experiments have been
reported in compliance with the ARRIVE guidelines.
Experimental Autoimmune Encephalomyelitis and DMAQ-B1 Pharmacotherapy
Ten-week-old male mice were immunized with experimental autoimmune
encephalomyelitis (EAE)-inducing kits per the manufacturer’s instructions (Hooke Labs,
MA) and standardized protocols.33,34 All analyses and treatments were performed during
the preclinical stage at seven to eight days post-induction (d.p.i.), which is a time frame
well-established for the onset of EAE-induced BBB dysfunction.35 For pharmacologic
studies, EAE mice (7 d.p.i.) or controls were randomly assigned to receive a single dose of
DMAQ-B1 (5 mg/kg) or vehicle (0.5% methylcellulose). 36 Methylcellulose and DMAQB1 were prepared fresh daily and administered via oral-gavage with a stainless-steel curved
gavage needle (18 G, 5 cm length, 2.4 mm tip; Kent Scientific). Mice were monitored for
signs of distress or hypoglycemia for 24 h. Pilot studies revealed that a single-dose of
5 mg/kg did not result in any hypoglycemic episodes.
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Analyses of BBB Integrity
As previously described with minor modifications, Evans blue (EB) extravasation
assays were used to determine EAE-induced BBB dysfunction.37,38 Briefly, for EB leakage
studies in Figure 1(a), animals (n = 3; EAE – 7 d.p.i.) were injected I.P. with 100 µL of 2%
EB in PBS, or PBS alone as a ‘no EB’ control for autofluorescence, 24 h prior to Lactated
Ringer’s (LR) flushes via transcardial perfusion and perfusion fixation with 4%
paraformaldehyde (PFA). Brains were excised and sectioned into 1 mm slices from rostral
to caudal using a coronal Adult Mouse Brain Slicer (Zivic Instruments). Slices were
arranged and imaged at 700 and 800 nm with a near-infrared imaging system (Odyssey
CLx; LI-COR Biosciences). For EB leakage studies in Figure 7(e) and (f) (n = 5–6), blood
was collected via cardiac puncture and brains were removed after LR flushes and divided
into right and left halves. The right half was post-fixed for 24 h in 4% PFA and a sagittal
image was obtained with the Odyssey CLx, as shown in Figure 1(a). The left half was
homogenized in 1 mL of PBS. EB from the homogenates and plasma was extracted into
formamide (2 mL at 60 ℃ for 24 h) and supernatants (5000 × g for 30 min) were compared
against an EB standard curve. As an indicator of BBB protein leakage, brain/serum EB
concentrations were normalized per brain weight (mg), and values are represented as fold
change from control.
In an additional set of experiments (Figure 7(g)), sodium fluorescein extravasation
assays were used as an indicator of small solute (376 Da; Stokes' radius ≈ 0.45 nm)
leakage.16,39 Mice (n = 3; EAE – 8 d.p.i) were injected I.P. with 5 µL/g of 10% sodium
fluorescein in saline solution. After 2 h, blood was collected by cardiac puncture, the
remaining blood in the cerebrovasculature was flushed with LR, and brains were rapidly
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excised. Diluted blood-serum (1:10 in PBS) and supernatants (12,000 × g for 15 min at
4℃) from brain homogenates (6 strokes with loose-fitting Dounce homogenizer) were
diluted 1:10 in 20% trichloroacetic acid (TCA). After incubation at 4℃ for 24 h,
supernatants (12,000 × g for 15 min) were removed and diluted with equal volumes of
borate buffer (0.05 M, pH 10). Fluorescence (ex. 480 nm, em. 538 nm) from sample
supernatants containing solubilized sodium fluorescein in 10% TCA and 0.025 M borate
buffer was quantified, brain/serum sodium fluorescein concentration values were
normalized per brain weight (mg), and values are represented as fold change from control.
Microvessel Isolation and Characterization
Microvessel isolations were performed as previously described.40 Whole brains
were excised, meninges and pial vessels were carefully removed, and the remaining tissue
was homogenized (six strokes with a loose-fitting Dounce homogenizer) in phenol-free
DMEM + 2% FBS (DMEM-S). Homogenates were then mixed 1:1 with 36% dextran
(∼70 kDa; Sigma), and centrifuged for 10 min at 10,000 × g. Pellets were resuspended in
DMEM-S and sieved through a 70 µm strainer to retain large vessels and allow
microvessels to pass through. To reduce RBC contamination, microvessel pellets were
layered over Percoll and centrifuged at 1700 × g for 10 min. The microvessel enriched
pellet was rinsed twice with DMEM and used for further analyses.
For immunostaining and confocal fluorescence microscopy experiments, isolated
microvessels from three mice were pooled (n = 27; 9 pools of 3), fixed with 4% PFA and
permeabilized with 10% donkey serum containing 0.05% Triton X-100. Microvessels were
immunostained per standard protocols with appropriate primary and secondary antibodies
in microfuge tubes with end-over-end rotation (see Supplementary Table 2). Stained
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vessels were adhered to slides via cytocentrifugation (Cytospin, Thermo Shandon), then
mounted in Vectashield containing DAPI to coverslips. Confocal micrographs were taken
with an Olympus FLUOVIEW FV1000 confocal laser scanning microscope (Olympus),
and image stacks were analyzed and processed with Imaris (Bitplane). For Figure 1(b) to
((f),f), Imaris ‘Surface’ rendering (thresholding) was used to define regions showing
positive fluorescence intensity and then the average intensity per voxel in those regions, or
volumes of interest (VOI), was determined. For Figure 1(d), nuclei were defined by
thresholding and FOXO1 intensities only within these nuclear VOIs were measured.
For Western blotting, microvessels were isolated as above, except that mice were
perfused (transcardial) with PBS containing protease and phosphatase inhibitors before
excising the brain. Microvessel pellets from three mice were pooled (n = 9; 3 pools of 3),
resuspended in ice-cold RIPA with protease and phosphatase inhibitors, homogenized (20
strokes with tight-fitting Dounce homogenizer) and incubated on ice for 20 min. Samples
were centrifuged at 12,000 × g for 10 min at 4℃, supernatants were collected, protein
concentrations were determined by BCA assay, and sample protein was normalized in
Laemmli sample buffer.
Primary BMVEC Isolation
As we have previously described,15 primary BMVECs were obtained from isolated
microvessels (described above) of C57BL/6 J pups between P7 and P10 (∼10 pups for a
confluent 25 cm2 monolayer). The resultant microvessel pellets were resuspended in HBSS
with collagenase/dispase, DNase I, and Na-tosyl-L-lysine chloromethyl ketone (TLCK) for
40 min at 37℃. BMVECs were pelleted, washed with DMEM-S, seeded at confluence,
and grown on collagen type IV-coated plates in endothelial growth medium (Cell
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Biologics) at 37℃ with 5% CO2 in a humidified incubator. Unless otherwise stated in
figure legends, only initially plated cells (P0) or cells passaged once (P1) at a 1:1 ratio were
used in these experiments. Additionally, before use in experiments, BMVECs were grown
for two to seven days post-confluence (P.C.) to allow for proper maturation of tight
junctions.
BMVEC Barrier Function Assays
Endothelial cell barrier functional assays were conducted as we have previously
demonstrated.15 For solute permeability and transwell transendothelial electrical
resistance (TEER) assays, BMVEC monolayers were grown seven days P.C. in collagen
type IV-coated, 0.4 µm PTFE transwell inserts prior to inflammatory injury and/or
treatment with pharmacologic and molecular interventions. Before adding sodium
fluorescein (0.5 mg/mL) to the luminal chamber, stable measurements of TEER (Ω × cm2)
were obtained with a Millicell-ERS voltohmmeter (EMD Millipore). Then, 30 min after
luminal addition of sodium fluorescein, samples were collected from both the upper
(luminal) and lower (abluminal) chambers for fluorescence analyses. Sodium fluorescein
concentrations were determined using a standard curve and the sodium fluorescein
permeability coefficient (Ps) was calculated as follows: PS = [A]/t×1/A×V/[L] where [A]
is the abluminal concentration; t is the time in seconds; A is the area of the membrane in
cm2; V is the volume of the abluminal chamber; and [L] is the luminal concentration. For
electric cell-substrate impedance (ECIS)-based TEER assays, an indicator of cell-cell
adhesive barrier resistance, the barrier function of cultured BMVEC monolayers was
determined by measuring real-time TEER using an ECIS sensor (ECIS Zθ, Applied
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BioPhysics). ECIS tracings are presented as normalized TEER, and peak changes are
quantified for statistical analyses.
Gene Silencing
Introduction of siRNA duplexes was achieved using a Nucleofector® Kit from
Amaxa Biosystems (MD, USA), as we have previously described. 15 BMVECs (1 × 106)
were resuspended in 100 µL of transfection solution, mixed to final concentration of 2 μM
siRNA, and transfected with program T-011 on the Nucleofector IIb™ device. Cells were
plated onto collagen type IV-coated ECIS arrays, transwell inserts and/or culture flasks.
BMVEC Immunocytochemistry
Tight junction proteins were immunostained in BMVEC monolayers per standard
immunohistochemistry (ICC) protocols and as we have shown before. 15,41,42 BMVECs
were grown to 48 h P.C. on glass coverslips and treated with various doses of DMAQ-B1
for 6 h. Cell monolayers were fixed with 4% PFA, permeabilized with 0.05% Triton X100, blocked with 2% BSA in PBS, and probed with anti-CLDN5 (AF 488) and anti-ZO1 (AF 594) primary conjugated antibodies overnight at 4℃. Coverslips were mounted with
Vectashield containing DAPI, confocal micrographs were obtained with Olympus
FLUOVIEW FV1000 confocal laser-scanning microscope, and images were analyzed and
processed with Imaris (Bitplane). For Figure 5, ZO-1+ areas at endothelial cell–cell borders
were defined by thresholding with Surface rendering in Imaris software. Then the total
CLDN5 intensity in these ZO-1+ areas was measured and divided by ZO-1+ areas to
provide average CLDN5. For representative 3D images, a 3D-colocalization channel
(yellow) was used to highlight the increased density of CLDN5 in tight junction complexes.
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Sandwich FLISAs
Three separate sandwich fluorescent-linked immunosorbent assays (FLISAs) were
used per standard protocols and adapted for detection with the Odyssey CLx. Briefly,
microtiter plates were coated with capture antibodies (5 µg/mL) in carbonate/bicarbonate
buffer (pH 9.6) overnight at 4℃, and blocked at RT for 1 h. Protein concentrations of
BMVEC lysates were normalized (BCA assay) and incubated in capture antibody-coated
wells for 90 min at 37℃. Plates were washed with TBS + 0.05% Tween-20 (TBST) and
then incubated with detection antibodies for 2 h at RT. Plates were either imaged
immediately on Odyssey CLx (IRDye® 800CW-conjugated primary antibodies) or
incubated with IRDye® 800CW-conjugated secondary antibody for 1 h at RT before
imaging. As an indicator of IR and IGFR1 activity, a sandwich FLISA was developed to
determine tyrosine phosphorylation on insulin receptor substrate 1 (IRS-1). A mouse antiIRS-1 antibody was used as the capture antibody, and a primary rabbit antiphosphotyrosine followed by a secondary IRDye® 800CW-conjugated donkey anti-rabbit
was used as the detection antibody. In order to identify the isoform-specificity of AKT
activation loop phosphorylation at T308 (pT308 on AKT), isoform-specific rabbit
monoclonal antibodies against either AKT1 or AKT2 were used as capture antibodies and
an IRDye® 800CW-conjugated rabbit anti-pAKT(T308) was used as the detection
antibody. An IRDye® 800CW Labeling Kit (LI-COR Biosciences) was used for primary
conjugation to the rabbit anti-pAKT(T308), as per the manufacturer’s instructions.
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High-Salt Nuclear Extraction
Nuclear isolation and protein extraction was performed as previously described. 15
Following treatments, BMVECs were collected into non-nuclear extraction buffer (Buffer
A: 10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.05% NP40, pH 7.9) with
protease and phosphatase inhibitors. Nuclei were pelleted and washed. Pellets were
resuspended in Buffer B (5 mM HEPES, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT,
26% glycerol (v/v), 300 mM NaCl, pH 7.9). Samples were homogenized (20 strokes tightfitting Dounce homogenizer), incubated on ice for 30 min, centrifuged at 24,000 × g for 20
min at 4℃, and the supernatant was collected as nuclear extract. Protein from nuclear
extract was quantified (BCA assay) and normalized in Laemmli sample buffer.
mRNA and Protein Analyses
For real-time quantitative PCR (qPCR) assays, mRNA was isolated from BMVEC
monolayers with RNAzol® following manufacturer’s procedures. RNA was normalized,
and reverse transcription was completed with iScript™ cDNA Synthesis Kit according to
the manufacturer’s procedures. Quantification cycle (Cq) values were determined with
quantitative real-time PCR in accordance with the PrimePCR™ assay. The 2 −ΔΔCq method
was used as a relative quantification strategy with the results presented as the fold change
of target gene expression in a target sample relative to a control sample, normalized to βactin as the reference gene. For Western blotting, two-color near-infrared immunoblotting
was completed per standardized protocols and imaged with an Odyssey CLx scanner.
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Statistical Analyses
All statistical analyses were performed with Prism (Version 7.0 e; Graphpad
Software, Inc.). α was set at 0.05 a priori for statistical significance. No specific blinding
was performed in these studies. A detailed list of statistical analyses is provided in
Supplementary Table 3.
Results
Endothelial FOXO1 is Activated and CLDN5 is Downregulated During
Neuroinflammation
EAE-induced BBB dysfunction precedes the onset of CNS damage, demyelination,
and paralysis.43 Accordingly, CLDN5 loss from BBB has also been reported during
EAE.20,35,45 Using this model, we analyzed EB leakage to confirm neuroinflammatorymediated BBB dysfunction (Figure 1(a)). Given the knowledge, albeit primarily based on
cell culture studies, that CLDN5 is regulated by FOXO1-mediated transcriptional
repression,13,15,25 we then sought out evidence for this mechanism in microvessels isolated
from mice with EAE-induced BBB dysfunction. As hypothesized, microvessels from EAE
mice have significantly total and nuclear-localized FOXO1 (tFOXO1 and nFOXO1,
respectively) staining (Figure 1(b) to (d)). At BBB tight junctions, ZO-1 expression
remained unchanged and served as a volume of interest (VOI) to analyze changes in
CLDN5 density (Figure 1(b), (e) and (f)). Expressional changes were also confirmed by
immunoblotting microvessel homogenates (Figure 1(g) and (h)).
BMVEC Regulation of CLDN5 by AKT is Isoform-Specific
Next, we investigated AKT isoform-specific regulation of CLDN5-dependent
BMVEC barrier function. We tested several conditions where CLDN5 expression is known
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to change and evaluated relative differences in the most likely AKT isoforms to be involved
in CLDN5 regulation, AKT1 and AKT2 (Figure 2). BBB endothelial cells are known to
lose their barrier properties in culture, especially with subsequent passaging. Here we
demonstrate by immunoblotting BMVEC lysates that CLDN5 and AKT2, but not AKT1,
are significantly decreased after passaging freshly isolated BMVECs (P0) (Figure 2(a)).
Knowing that BMVEC CLDN5 expression levels continue to incrementally increase for
several days after confluence, we compared the daily changes in expression levels of Akt1,
Akt2, and Cldn5 in BMVEC monolayers relative to the levels in subconfluent BMVECs
(Figure 2(b)). While relative mRNA for all of these genes increased after confluence (1
day P.C.), only Akt2 and Cldn5 continued over the following days. To determine the direct
isoform-specific effect of AKT on CLDN5, we silenced Akt1 and Akt2 with siRNA and
evaluated CLDN5 expression and TEER. Knockdown efficiency was ∼50% for both
AKT1 and AKT2. However, immunoblotting the same lysates for CLDN5 revealed that
only knockdown of AKT2 had any detectable effect on CLDN5 expression (Figure 2(c)
and ((d)). Simultaneously, the effects of Akt1 and Akt2 silencing on BMVEC monolayers
revealed that loss of AKT2 causes significant barrier dysfunction (Figure 2(e)).
Interestingly, AKT1 knockdown produced a nominal increase in barrier integrity, which is
consistent with the findings that suggest AKT1 activation may be involved in
hyperpermeability.27
We previously reported that exposing BMVECs to elevated IL-1β for 1.5 h causes
AKT inactivation (decreased pT308 on AKT), FOXO1 activation (increased pT24 on
FOXO1, nuclear accumulation, and occupancy on Cldn5 silencer), and CLDN5 loss
(decreased mRNA and protein) sustained for at least 24 h. 15 Here, we found that exposing

265
BMVECs to IL-1β for 24 h also leads to loss of AKT2 expression, but not AKT1 (Figure
2(f)). Since we have shown in this work that nuclear accumulation of FOXO1 and
downregulation of CLDN5 are present in brain microvessels of EAE mice (Figure 1), we
immunoblotted those same lysates for expression levels of AKT1 and AKT2 (Figure 2(g)).
As with IL-1β-mediated loss of AKT2, microvessels from EAE mice have decreased AKT2
with no loss of AKT1.
Selective Activation of IR Signaling in BMVECs Enhances Barrier Integrity
While the role of AKT1 in endothelial cells has been well-studied, the only known
function in endothelium for which AKT2 may be the predominant mediator is insulin
signaling. Although the insulin signaling pathway is well-known to regulate FOXO
transcription factors,46 there is a scarcity of knowledge regarding insulin signaling in the
regulation of CLDN5-dependent BBB integrity. This lack of information is likely because
of multiple confounders that make it difficult to study insulin-receptor signaling, such as
receptor promiscuity and overlapping functions of insulin and IGFs, heterogeneous IR and
IGFR expression, heterodimerization of the IR and IGFR subunits, insulin resistance, and
multiple intracellular targets. Thus, in these studies, we used the IR-selective agonist
DMAQ-B1 and compared it to insulin- and IGF-signaling in BMVECs. Since IRS-1 can
be a common substrate for both IR and IGFR tyrosine kinases47 and may be upstream of
AKT2/FOXO1-signaling,46 we used sandwich FLISAs to identify the EC50 of insulin
(Figure 3(a)), IGF-1 (Figure 3(b)), and DMAQ-B1 (Figure 3(c)), on tyrosine
phosphorylation of IRS-1. The EC50 for insulin and IGF-1 was within the physiological
response ranges,48 and the EC50 for DMAQ-B1 was similar to previous reports.36
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As one of several small-molecule IR agonists that have been tested for their utility
as oral anti-diabetics, DMAQ-B1 was discovered to preferentially trigger IR-dependent
activation of PI3K/AKT signaling at low concentrations, without activating the IGF1R or
its canonical downstream ERK1/2 pathway.53 Using the EC50 for pIRS-1, we found that
treating BMVECs with insulin [2 nM], IGF-1 [20 nM], and DMAQ-B1 [5 μM] all led to a
similar increase in active AKT; however, only insulin and IGF-1 increased ERK activity
(Figure 3(d)). Interestingly, even though all three agonists induced comparable
phosphorylation of IRS-1 and AKT phosphorylation, only DMAQ-B1 led to decreased
nuclear localization of FOXO1, upregulation of CLDN5, and enhancement of BMVEC
barrier function (Figure 3(e) to ((h)). To confirm that the presence of DMAQ-B1 had no
confounding impact on BMVEC proliferation or viability in our cell culture studies, a stainbased cell cycle assay (DAPI) and a stain-based viability assay (calcein AM and propidium
iodide) were conducted on BMVEC monolayers (P3; two days P.C.) following 6 h of
incubation with DMAQ-B1 [5 μM] or a vehicle control and no differences were observed
in either cell cycle distribution or ratio of viable to nonviable cells (Figure S1).
DMAQ-B1 Promotes AKT2/FOXO1-Signaling and Increases Cldn5 mRNA
Upregulation
Further analyses of DMAQ-B1 revealed that DMAQ-B1 dose-dependently
promotes AKT2-specific activation (pT308 on AKT2; Figure 4(a) and ((b)), FOXO1
inactivation (decreased nuclear accumulation; Figure 4(c)), and transcriptional-mediated
upregulation of Cldn5 (qRT-PCR/mRNA – Figure 4(d); ICC/protein – Figure 5; and
WB/protein – Figure S2). Compared to vehicle (0 μM), treating BMVECs with 2.5, 5, and
10 μM of DMAQ-B1 increased total active AKT (pT308) after 45 min. However, sandwich
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FLISAs revealed that DMAQ-B1 [10 μM] significantly increased pT308 on AKT2, but not
AKT1 (Figure 4(b)). Additionally, we found that Cldn5 mRNA is increased concurrently
with decreased nFOXO1 following 45 min of treatment with DMAQ-B1. DMAQ-B1 also
dose-dependently increased CLDN5 protein levels after 6 h (WB – Figure S1; ICC – Figure
5). Confocal analysis of fixed BMVECs demonstrated that increased CLDN5 levels were
indeed localized to the EC–EC tight junctions demarcated by ZO-1, which was unchanged
with DMAQ-B1 treatment. Furthermore, 3D rendering of a CLDN5 at ZO-1 colocalization
channel highlights how upregulation of CLDN5 does not just increase its turnover, but
significantly increases its density at EC–EC junctions (Figure 5).
DMAQ-B1-Mediated BMVEC Barrier Enhancement is Dependent upon CLDN5
Upregulation
Using three separate techniques to measure BMVEC barrier function, we found in
all cases that DMAQ-B1 dose-dependently increases ECIS-TEER (Figure 6(a)), transwellfluorescein permeability (Figure 6(b)), and transwell-TEER (Figure 6(c)). To determine a
causal role for CLDN5 in DMAQ-B1-mediated BMVEC barrier enhancement, we silenced
Cldn5 with siRNA (Figure 6(d)) and analyzed TEER (Figure 6(e)) or transwell
permeability assays (Figure 6(f)). Efficiency of CLDN5 knockdown was determined by
immunoblotting 24 h after transfection (Figure 6(d)). Cldn5-silenced monolayers
abrogated the barrier-enhancing effects of DMAQ-B1 [5 μM; 6 h] compared to controls
(Figure 6(e) and ((f)).
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DMAQ-B1 Reverses Inflammation-Induced BMVEC Barrier Disruption in vitro and in
vivo
Given that inflammation is well known to mediate insulin resistance,49,71 we sought
to determine if DMAQ-B1 could attenuate inflammation-mediated BMVEC barrier
dysfunction in vitro and in vivo. We first found that DMAQ-B1 can attenuate IL-1βmediated AKT activation, FOXO1 inactivation, and CLDN5 downregulation (Figure 7(a)).
Next, we treated IL-1β-stimulated [100 ng/mL] BMVECs on ECIS after 1 h with DMAQB1 and followed TEER tracings for an additional 5 h. DMAQ-B1 [5 μM] not only
increased baseline TEER, but also increased TEER of IL-1β-treated BMVECs (Figure 7(b)
and ((c)). Additionally, IL-1β-mediated sodium fluorescein hyperpermeability was rescued
with co-treatment of DMAQ-B1 (Figure 7(d)). Since we have observed significant BBB
dysfunction eight days post-induction of EAE mice, 24 h prior (7 d.p.i.) we gave one single
dose of DMAQ-B1 [5 mg/kg; via oral gavage] to both control and EAE mice. Both EB and
sodium fluorescein extravasation assays revealed significantly less leakage from brain
microvessels in EAE mice treated with DMAQ-B1 compared to those untreated (Fig. 7(f)
to (g)). Concomitantly, EAE-induced loss of CLDN5 was abrogated with DMAQ-B1
(Figure 7(h)).
Discussion
The key finding presented in this study is that isoform-specific activation of AKT2
by the selective IR agonist, DMAQ-B1, rescued loss of CLDN5-dependent BBB integrity.
We applied a step-wise approach to demonstrate the involvement of the AKT2/FOXO1signaling pathway in maintaining high CLDN5 expression, and determined the potential of
DMAQ-B1 to reverse diminished CLDN5 levels. First, we detected significant nuclear
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accumulation of FOXO1 and loss of CLDN5 in microvessels isolated from mice with EAEinduced BBB dysfunction. Second, by determining the correlation of AKT2 and CLDN5
expression and conducting AKT2-specific knockdown experiments, we identified the
importance of AKT2 in maintaining high levels of CLDN5. Third, by evaluating the
canonical IR/AKT2/FOXO1 signaling pathway, we determined the novel capacity of
DMAQ-B1 to reduce FOXO1 nuclear accumulation, increase CLDN5 density at tight
junctions, and strengthen barrier function of primary BMVEC monolayers. Fourth, siRNAmediated silencing of BMVEC Cldn5 confirmed that CLDN5 is necessary for enhanced
barrier function induced by DMAQ-B1. Lastly, DMAQ-B1 reversed BMVEC barrier
dysfunction in vitro and in vivo following inflammatory challenge.
Contemporaneous

with

inflammation-induced

microvascular

leakage,

a

quantitative loss of CLDN5 from the BBB has been reported in multiple neurological
diseases, which at least in part suggests that CLDN5 is transcriptionally downregulated.
Hence, preventing or reversing this downregulation is key to therapeutic preservation of
BBB integrity. FOXO1-mediated transcriptional repression of Cldn5 was first identified in
cell culture studies for its role in AJ-dependent upregulation of CLDN5 following
endothelial confluency,13 and Morini et al.25 recently extended their findings to include that
FOXO1 also recruits a polycomb repressor complex to the same Cldn5 silencer occupied
by FOXO1 in subconfluent endothelial cells. We recapitulate this data as a proof-ofprinciple for our culture model, but also demonstrate that Cldn5 mRNA levels continue to
increase beyond endothelial confluency. Elevated levels of FOXO1, along with the loss of
CLDN5, were also observed in an acrolein-induced lung injury model.24 Our results here
extend our previous in vitro findings to an in vivo model of neuroinflammatory-mediated
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CNS injury. In this model, BBB dysfunction precedes EAE-induced paralysis, and CLDN5
downregulation concomitant with BBB dysfunction has been reported multiple
times.20,35,45 However, the precise onset and regulatory mechanisms governing CLDN5
downregulation during EAE was not well-resolved, and to the best of our knowledge, this
is the first report of EAE-induced FOXO1 activation in brain microvessels associated with
a loss of CLDN5-dependent BBB integrity.
Most literature devoted to FOXO1 in endothelial cells has been focused on
angiogenesis and postnatal neovascularization. 31,50–53 However, the role of FOXO1 in
highly mature endothelial cells, such as those of the BBB, remains unclear. Our studies,
therefore, were intentionally conducted on adult mice in vivo (> 90 d.p.n.), and mature
BMVEC monolayers. In addition to our previous FOXO1 knockdown studies, 15 we found
enhanced barrier properties of BMVEC monolayers with no signs of overgrowth or
apparent problems. Similarly, Park et al. 54 demonstrated inactive FOXO1 in the blood–
retinal barrier (BRB) of adult mice, which was reactivated in diabetic retinopathy leading
to loss of BRB integrity.54 Our finding of inflammation-mediated FOXO1 activation and
diminished endothelial cell–cell integrity is in line with this finding, as well as another in
vivo study demonstrating the atheroprotective effects of endothelial-specific FOXO1
depletion from aortic endothelial cells. 55 Interestingly, this study also reported that
upregulation of ICAM-1 and increased monocyte-endothelial adhesion is dependent on
FOXO1 activation. Taken as a whole, it would appear that FOXO1 lies dormant in mature
endothelium, especially at the BBB, yet serves as an inflammatory response element that
may couple leukocyte transmigration with disassembly of endothelial cell–cell junctional
complexes.
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FOXO1 inactivation by AKT is a canonical target of insulin signaling in endothelial
cells, which is well-known to be impaired during inflammation. 56 Nevertheless, tightly
controlled insulin therapy to maintain normoglycemia has been shown to counteract
inflammation-mediated endothelial dysfunction,57–59 suggesting that at least some level of
IR activation is intact. A role for insulin-signaling in BBB function remains controversial,
as some have shown insulin-mediated barrier enhancement and others have shown no
effect.29–31,60–63 Our results demonstrate that exposing BMVECs to physiologically relevant
concentrations of insulin and IGF-1 produced equal levels of IRS-1 phosphorylation
compared with DMAQ-B1, but unlike DMAQ-B1-mediated IR agonism they did not
reduce nuclear accumulation of FOXO1, alter CLDN5 expression, or enhance BMVEC
barrier function. How then do we explain the barrier-enhancing effects of DMAQ-B1,
given that all three agonists produced equal levels of not just IRS-1, but AKT
phosphorylation too? AKT is well-known to simultaneously both proangiogenic and
antiangiogenic, which may be related to isoform-specificity. Thus, one plausible
explanation is that insulin and IGF-1 trigger IRS-1 and AKT1 phosphorylation through the
IGF1R or hybrid IR/IGF1R receptors,63 whereas DMAQ-B1 is selective for IR agonism
that is known to result in phosphorylation of AKT2. This is additionally supported by our
finding that insulin and IGF-1 uniquely trigger the canonical IGF1R target, ERK1/2, which
is also known for its proangiogenic and hyperpermeability-inducing roles in microvessels.
Indeed, we did find a nominal decrease in barrier function following IGF-1, but we did not
observe the same for insulin. This discrepancy may be due to insulin promiscuity
counterbalancing both the positive and negative effects on barrier regulation.
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While certain aspects of endothelial AKT remain poorly elucidated, there is
consensus that specificity of these isozymes is highly context-dependent owing to factors
such as tissue distribution, cellular localization, temporal regulation, and different
signaling pathways.64–67 Based upon gene ablation studies, only AKT1 and AKT2 appear
to have physiological relevance in endothelial cells, although their roles appear to be
markedly different with minor functional compensations. For example, deletion of
endothelial Akt1 in Akt2−/− mice displays either impaired proliferation and aberrant
angiogenesis if excised during development, 65 or loss of mural cell coverage and organ
failure if deleted in adult mice.68 Conversely, AKT2 function is known to promote cell
cycle exit through p21 binding69 and is the primary isoform responsible for endothelial IRsignaling,28,65 which is consistent with our work supporting an isoform-specific role of
AKT2-activity to maintain barrier function of highly quiescent BBB endothelial cells.
It is well-known that the BBB requires additional establishment and maintenance
of TJ proteins to maintain the highly restrictive paracellular clefts of BBB endothelial cells.
Our observation of passaging-induced loss of AKT2 and CLDN5 may partially explain
why elevated TJ protein expression and BMVEC integrity are diminished in cultured
ECs.70,71 It is also well-described that TJ expression continues to increase following
monolayer formation of brain endothelial cells, and a major step in endothelial barrier
formation requires AKT1-dependent inactivation of FOXO1 and increased Cldn5
transcriptional upregulation.13,25 Consistently, peripheral vessels of Akt1-null mice have
baseline vascular leakage.66 Until now, a role for AKT2 in endothelial barrier regulation
had not been established. Recently, however, Zhang et al. showed Akt2 upregulation was
a target of β-catenin/Tcf transcriptional regulation, 72 which is known to be necessary for
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development and maintenance of the BBB. 38,73–76 Additionally, Frisa et al. have
demonstrated in aortic endothelial cells an AKT1-to-AKT2 switch model which was
Notch-induced and dependent upon AKT2 upregulation, inhibition of GSK-3β
phosphorylation, and FOXO1 inactivation. Our work agrees with all these observations,
suggesting that AKT1 drives initial barrier development and that AKT2 expression
regulates barrier maintenance. Interestingly, it was recently shown in brain endothelial cells
that inhibition of GSK-3β increases the half-life of Cldn5 protein.77 Thus, coupled with our
findings, this places AKT2 upstream of both maximal transcriptional regulation and protein
stabilization of CLDN5.
Significant progress has been made in the past decade to understand the
contributions of isoform-specific AKT activity during various diseases.78 In accordance
with AKT-mediated regulation of FOXO1, reports defining a role of AKT isoforms in
vascular disease are largely limited to aberrant vascular remodeling and macrovascular
disease.79 Consistent with the angiogenic role of endothelial AKT1, several reports have
described pro-inflammatory roles for AKT1 in endothelial cells. Though global AKT1
deletion was shown to increase baseline vascular permeability, AKT1-deficient mice are
resistant to acute histamine- and λ-carrageenan-induced microvascular leakage, as well as
infiltration of neutrophils and monocytes. 27,65 Much less is known about the contribution
of AKT activity to BBB function and neuroinflammatory disease, especially as it pertains
to isoform-specificity. Several reports show that loss of BBB integrity involves impairment
of AKT signaling80–82; however, to the best of our ability, we were unable to find any
reports describing a role for AKT2 in BBB endothelial cells. Here, we have identified a
novel isoform-specific role for AKT2 in the maintenance of CLDN5-dependent endothelial
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barrier integrity, which is impaired following inflammatory insult. In similar samples used
to obtain our results of brain endothelial cell FOXO1 activation by IL-1β in vitro,15 and
EAE in vivo, we identified a significant decrease in expression of AKT2 concomitant with
CLDN5, but no changes in AKT1. Similarly, inflammation-mediated changes in AKT2
expression have been reported in other insulin-sensitive tissues, such as the liver and
muscles.83 We never observed complete loss of AKT2 in the inflammatory models
employed here and our results show that activating the remaining AKT2 with DMAQ-B1
to promote restoration of CLDN5 is still possible.
Given the complexity of insulin signaling during inflammation, and the mixed
results pertaining to insulin therapy for endothelial dysfunction, we were unsure if DMAQB1 could attenuate or reverse inflammatory-mediated BBB integrity. Coupled with our in
vitro findings, however, a model of sepsis-induced insulin resistance and brain injury was
attenuated with metformin administration. While this rescue was associated with increased
global AKT phosphorylation and diminished edema, the cellular origin of this AKTdependent neuroprotective effect was not addressed as only whole tissue homogenates
were analyzed.84 Therefore, we chose the primary focus of our culminating in vivo work to
be whether DMAQ-B1 could rescue CLDN5 expression and CLDN5-dependent barrier
integrity. For the underlying intracellular signaling mechanisms, we tested the
IR/AKT2/FOXO1/CLDN5 pathway in endothelial monolayers and while it would have
been ideal to quantitatively measure the signaling activity of these proteins in vivo or within
intact microvessels, such experiments were hindered by several technical limitations. In
particular, the abundance of AKT2 and FOXO1 expressed within brain microvessels is
very low and there exist no commercially available pAKT2 isoform-specific antibodies,
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thereby making it challenging to quantitatively compare the levels of their expression or
isoform-specific AKT2 activity under basal and EAE conditions following administration
of DMAQ-B1. Nevertheless, the profound rescue in BBB integrity we observed following
DMAQ-B1 treatment, suggests that during neuroinflammation the AKT2/FOXO1/CLDN5
signaling axis remains responsive to pharmacologic intervention and, therefore, might be
a viable therapeutic strategy for restoration of BBB function.
In summary, our current findings define a regulatory role for IR/AKT2/FOXO1mediated regulation of CLDN5 which can be selectively triggered by the IR agonist,
DMAQ-B1, to restore submaximal CLDN5 expression and barrier integrity back to the
BBB during neuroinflammation.
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Figures

Figure J.1. Brain microvessels from mice with EAE-induced BBB dysfunction
have increased nuclear FOXO1 and decreased tight junctional expression of
CLDN5.
EAE or mock-EAE (Ctrl) were induced per standard protocols and analyzed for BBB
dysfunction eight days post-induction (d.p.i.). (a) Proof-of-principle that EAE mice
8 d.p.i. have BBB dysfunction. Qualitative plasma protein leakage into the mouse brains
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was determined by imaging Evans blue (EB) extravasation. Representative images of
1 mm coronal brain slices (olfactory bulbs not included) showing EB leakage captured at
700 nm (pseudo-colored blue) and brain autofluorescence at 800 nm (pseudo-colored
grayscale) with a near-infrared imaging scanner. (b) Representative confocal micrographs
of isolated brain microvessels (those ≤ 30 µm in diameter) immunostained for either
FOXO1, ZO-1, and/or CLDN5, then counterstained with DAPI to demarcate nuclei. In
total, 27 mice per group were used and microvessel pellets were pooled together from 3
mice each for a total of 9 pools per group. (c–f) Imaris 3D visualization software was
used to analyze confocal micrographs and quantify: (c) total FOXO1 (tFOXO1) density;
(d) nuclear-localized FOXO1 (nFOXO1) per uniform spherical volume of interest (VOI)
centered within each nucleus; and 3D density of ZO-1 (e) and CLDN5 (f) at endothelial
cell–cell contacts. Data are represented as aligned dot plots, where each dot represents a
microvessel pool. (g–h) Representative Western blots and densitometry analysis for
t
FOXO1 (g) and CLDN5 (h). In total, nine mice per group were used and microvessel
pellets were pooled together from three mice each for a total of three pools per group.
Data are represented as scatter dot plots overlaid with mean fold change compared to
control group plus corresponding p-value reported above each comparison.
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Figure J.2.

The AKT2 isoform is distinctly correlated with primary BMVEC
barrier integrity and changes in CLDN5 expression.

(a) Freshly isolated BMVECs were seeded at confluence in cultureware (P0). Additional
cells were passaged three times (P1–P3). BMVECs from each passage were allowed to
mature for two days post-confluence (P.C.). Lysates were collected and expression levels
of AKT1, AKT2, and CLDN5 were determined by Western blotting. Bar graphs are
divided into individual datasets for each protein target and represent the mean ± S.D.
Groups with the same symbol within each individual dataset are not significant from each
other (p ≥ 0.05). (b) Conversely, total mRNA from P3 BMVECs was collected from
sub-confluent (SC) cells and confluent monolayers each day through seven days P.C.
Relative mRNA expression (ΔΔCq; fold change relative to SC samples normalized to βactin as the reference gene) for Akt1, Akt2, and Cldn5 was determined by qRT-PCR. Bar
graphs are divided into individual datasets for each mRNA target and represent the
mean ± S.D. Asterisks indicate p < 0.05 versus 1 day P.C. for each target mRNA. (c–e)
AKT1 and AKT2 were silenced in BMVECs by siRNA (siAkt1 or siAkt2). Confirmation
of knockdown and the effect on CLDN5 expression was determined by Western blotting
(c–d). Bar graphs are divided into individual datasets for each protein target and are
represented as mean fold change compared to the siCtrl group plus corresponding p-value
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reported above each comparison. (e) Representative ECIS tracings demonstrating the
impact of AKT1 or AKT2 knockdown on BMVEC barrier integrity from 24 to 120 h
post-transfection. At least three independent experiments for each transfection were
performed with cells from three separate BMVEC isolations. Each tracing was
normalized to the first time point and the peak change in TEER was determined.
Embedded bar graphs represent mean normalized peak change ± S.D. and groups with the
same symbol are not significant from each other (p ≥ 0.05). (f–g) Comparison of
inflammatory-mediated changes in AKT isoform expression levels in vitro and in vivo.
(f) In vitro, mature BMVECs (P1; 7 days P.C.) were stimulated with IL-1β [100 ng/mL]
or vehicle control (−) for 24 h and expression levels of AKT1 and AKT2 were compared
by Western blotting. Bar graphs are divided into individual datasets for each protein
target and are represented as mean fold change compared to the control group plus
corresponding p-value reported above each comparison. (g) In vivo, EAE was induced in
mice and compared to mock controls. After 8 d.p.i., brain microvessels were isolated
from both groups and AKT1-2 expression was determined by Western blotting. Bar
graphs are divided into individual datasets for each protein target and are represented as
mean fold change compared to the control group plus corresponding p-value reported
above each comparison.
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Figure J.3.

The AKT2 isoform is distinctly correlated with primary BMVEC
barrier integrity and changes in CLDN5 expression.

BMVECs were allowed to mature for 48 h P.C. and then treated with varying
concentrations of insulin, IGF-1, or DMAQ-B1. (a–c) After 45 min, cell lysates were
analyzed with a sandwich FLISA (capture Ab = anti-IRS-1, detection Ab = anti-pY) to
determine total tyrosine phosphorylation on IRS-1 (pY IRS-1). Dots represent median
percentage of maximal dose-response ± IQR and EC50 values were obtained from doseresponse curves. (d–e) Representative Western blots and densitometry analyses for active
AKT (pT308), active Erk1/2 (pT202/pY204), and nFOXO1 (blotting nuclear lysates for
FOXO1) were determined after treating BMVECs for 45 min with insulin [2 nM], IGF-1
[20 nM], or DMAQ-B1 [5 μM]. Subsequent changes in CLDN5 expression 6 hours after
treatment were also determined by Western blotting and densitometry (e). Data for each
protein target are represented as mean fold change compared to the no treatment
group ± S.D. Within each individual protein target dataset, groups with the same symbol
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are not significant from each other (p ≥ 0.05). Target proteins were not compared against
each other. (f–h) Changes in BMVEC barrier resistance to insulin, IGF-1, or DMAQ-B1
were evaluated for 6 h after treatment. At least three independent ECIS experiments were
performed with cells from three separate BMVEC isolations. Each tracing was
normalized to its baseline and peak change in TEER was determined. Representative
tracings for treatment groups are depicted by colored lines and untreated controls are
depicted by black lines. Embedded bar graphs represent mean normalized peak changes
in TEER ± S.D. Asterisks indicate p < 0.05 versus untreated controls and n.s. indicates no
significance.
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Figure J.4. DMAQ-B1 dose-dependently increases AKT2 activity, decreases
FOXO1 nuclear accumulation, and upregulates Cldn5 mRNA.
(a–d) BMVECs (P3; two days P.C.) were treated with DMAQ-B1 [0, 2.5, 5, or 10 μM]
for 45 min and lysates were analyzed for AKT2 activity, nFOXO1 levels, and Cldn5
mRNA levels. (a) AKT activity was determined by Western blotting for pT308 on AKT
(pAKT; not isoform-specific) and normalizing against total AKT (tAKT; not isoformspecific). Data are represented as mean fold change compared to the no treatment
group ± S.D. Groups with the same symbol are not significant from each other (p ≥ 0.05).
(b) AKT isoform-specific phosphorylation in response to DMAQ-B1 was determined by
FLISAs using AKT1- or AKT2-specific antibodies as capture antibodies and pT308-AKT
as the detection antibody. Bar graphs are divided into individual datasets for each protein
target and are represented as mean fold change compared to the vehicle control (−)
group ± S.D. and corresponding p-values reported above each comparison. (c) FOXO1
levels in BMVEC nuclear lysates were determined by Western blotting with lamin A/C
used as a nuclear loading control. Data are represented as mean fold change compared to
the vehicle control (0 μM) group ± S.D. Groups with the same symbol are not significant
from each other (p ≥ 0.05). (d) Relative Cldn5 mRNA was determined by qRT-PCR. Data
are represented as mean fold change compared to the no treatment group ± S.D. Groups
with the same symbol are not significant from each other (p ≥ 0.05).
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Figure J.5.

DMAQ-B1-mediated upregulation of CLDN5 increases the density of
CLDN5 protein at BMVEC tight junctions.

BMVECs (P3; two days P.C.) were grown on glass coverslips and treated with DMAQB1 [0, 2.5, 5, or 10 μM] for 6 h. BMVEC monolayers (n = 5) were fixed and
immunostained for ZO-1 and CLDN5, then counterstained with DAPI to demarcate
nuclei (Blue). Confocal micrographs were obtained and Imaris software was used for
image analyses and 3D rendering. Representative 2D images of ZO-1 (Red) and CLDN5
(Green) and corresponding graphs of intensity analyses are displayed in the top two rows.
ZO-1 at BMVEC cell–cell contacts was used to establish a VOI at tight junctions and a
3D colocalization channel (Yellow; ZO-1+ and CLDN5+ voxels) was established for
visual evaluation of CLDN5 expression at BMVEC tight junctions. Representative 2D
merged images with 3D rendering of the colocalization channel displayed en face, and
graph of CLDN5 intensity per VOI are displayed in the third row. The last row is the
same 3D image area as those shown for 0 and 10 μM DMAQ-B1, but expanded and tilted
to enhance visual representation. All graphs are represented as aligned dot plots overlaid
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with mean value (black line) and groups with the same symbol within each plot are not
significant from each other (p ≥ 0.05).
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Figure J.6.

CLDN5 upregulation is necessary for DMAQ-B1-mediated BMVEC
barrier enhancement.

(a–c) DMAQ-B1 dose-dependently enhances BMVEC barrier function. (a)
Representative ECIS tracings in response to DMAQ-B1 [0, 2.5, 5, or 10 μM]. At least
three independent experiments for each treatment were performed with cells from three
separate BMVEC isolations. Each tracing was normalized to the first time point and the
filled area for each group represents mean change in TEER ± S.D. Alternatively, after 6 h
of treating BMVEC monolayers grown in transwell inserts (P3; two days P.C.) with
DMAQ-B1, sodium fluorescein permeability coefficients (Ps) were obtained (b) and
transwell-TEER was measured (c). Data are represented as scatter dot plots overlaid with
mean value (black line) and groups with the same symbol within each plot are not
significant from each other (p ≥ 0.05). (d–f) The effects of CLDN5 knockdown on
DMAQ-B1-mediated BMVEC barrier enhancement were determined with ECIS and
transwell permeability assays. (d) Knockdown efficiency of CLDN5 in BMVECs as
verified by Western blotting. Data are represented as scatter dot plots overlaid with mean
value (black line) plus corresponding p-value reported above. (e) Representative
spaghetti plots of individual ECIS tracings of BMVECs transfected with siCldn5 or siCtrl
and then treated 24 h later with DMAQ-B1 [5 μM]. Each tracing was normalized to the
first time point. (f) The effects of CLDN5 knockdown on BMVEC monolayer
permeability to sodium fluorescein with or without DMAQ-B1 were measured. DMAQB1 [5 μM] was applied to BMVEC monolayers for 6 h, and permeability was calculated
based on sodium fluorescein transendothelial diffusion rate. Data are represented as
scatter dot plots overlaid with mean ± S.D. lines. Groups with the same symbol are not
significant from each other (p ≥ 0.05).
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Figure J.7.

DMAQ-B1 reverses inflammation-mediated brain endothelial barrier
dysfunction in vitro and in vivo.

(a-d) BMVEC monolayers (P3; two days P.C.) were divided into four groups: (1) vehicle
control (Ctrl), (2) IL-1β [100 ng/mL], (3) DMAQ-B1 [5 μM], or (4) DMAQ-B1 + IL-1β.
(a) The ability of DMAQ-B1 to attenuate IL-1β-mediated AKT inactivation, FOXO1
nuclear accumulation, and CLDN5 downregulation was determined by Western blotting.
Representative Western blots from three independent experiments are shown (b–d) The
ability of DMAQ-B1 to reverse IL-1β-mediated BMVEC barrier dysfunction was tested
with ECIS-TEER measurements or transwell permeability assays. DMAQ-B1 was added
1 h after IL-1β challenge. (b) Representative normalized ECIS tracings, (c) normalized
peak TEER changes, and (d) sodium fluorescein permeability coefficients. All values
were obtained from at least 3 independent experiments. Data for (c) and (d) are
represented as scatter dot plots overlaid with mean value (black line) and groups with the
same symbol within each plot are not significant from each other (p ≥ 0.05). (e–h) EAE or
mock-EAE (Ctrl) were induced and analyzed 8 d.p.i. for BBB dysfunction and CLDN5
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expression changes. 24 h prior to harvest (7 d.p.i.), mice from each group were split into
two additional groups that received DMAQ-B1 [5 mg/kg] or vehicle (0.5%
methylcellulose) via oral gavage. In total, 8–10 mice per group were used and harvested
brains were split by hemisphere to allow for simultaneous determination of BBB
dysfunction and CLDN5 expression. (e–g) Plasma protein and solute leakage into the
mouse brains were determined by EB (n = 5–6) and sodium fluorescein (n = 3–4)
extravasation assays. (e) Representative images from EB extravasation assay showing
plasma protein leakage into the right hemisphere. Images were captured at 700 nm
(pseudo-colored blue) and brain autofluorescence at 800 nm (pseudo-colored grayscale).
Quantitative results from EB (f) and sodium fluorescein (g) permeability assays. (h)
CLDN5 expression from left hemisphere brain homogenates was determined by Western
blotting. All in vivo values were normalized to the vehicle-treated group subjected to
mock EAE (Ctrl) and graphs are represented as dot plots or bar graphs overlaid with
mean ± S.D. lines. Groups with the same symbol within each graph are not significant
from each other (p ≥ 0.05).
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Supplementary Methods
Cell-cycle Analysis and Viability Assay
Imaging-based cell-cycle analysis was performed as described elsewhere with
some minor modifications.44 Briefly, after DMAQ-B1 treatments, BMVEC monolayers
from four independent isolations were fixed, stained with DAPI and imaged (n = 20; 5
micrographs per isolation and treatment group) with an EVOS FL Imaging System
(ThermoFisher Scientific). To determine the total number of BMVECs within each
monolayer and generate cell-cycle histograms, micrographs were processed with ImageJ
(NIH; Version: 2.0.0.rc-65/1.51s) and image analysis–based quantification of integrated
nuclear (DAPI) intensity was performed. Relative frequency (%) distributions of nuclear
areas were created with Prism (Version 7.0e; Graphpad Software, Inc.) to generate cell
cycle profiles, and cell cycle phases (G1/G0, S, and G2/M) were identified by applying
visually selected cutoffs. To assess whether DMAQ-B1 may affect BMVEC viability,
BMVEC monolayers (P3; 2 days P.C.) were incubated with either a vehicle control,
DMAQ-B1 [5 μM], or doxorubicin [0.4 μM] (as a positive control) for 6 hours (n = 15; 5
micrographs per isolation and treatment group), then a commercial live/dead
viability/cytotoxicity kit was used according to manufacturer's instructions. Fluorescent
micrographs were acquired with an EVOS FL Imaging System using light cubes
appropriate for the kit (GFP for calcein AM and RFP for propidium iodide) and the number
of positive cells for each stain were tabulated to calculate the ratio of viable to nonviable
cells for each group.

Company
Lonza
Sigma
Sigma
Advanced BioMatrix
Sigma
ThermoFisher
Tocris
Gibco
Sigma
Sigma
Hooke Labs
Cell Biologics
Sigma

Amaxa® Cell Line Nucleofector® Kit V

Boric Acid

cOmplete™ protease/phosphatase inhibitor

Collagen Type IV

Dextran ~70 kD

DNAse I

DMAQ-B1

DMEM

Donkey serum

Doxorubicin

EAE Induction Kit

Endothelial Growth Medium

Evans blue

Reagents used in these studies.

Reagents

Table J.1.

Supplementary Tables

E2129

M116

EK-2110

D1515

D9663

31053028

LM22B 10

EN0521

31390

5022

5892970001

B6768

VCA-1003

Catalog Number

298

Company
Sigma
LI-COR
ThermoFisher
Sigma
Sigma
Sigma
Sigma
SCBT
SCBT
SCBT
SCBT
Sigma
Sigma
Vector Laboratories

Reagents

Formamide

Laemmli sample buffer

LIVE/DEAD viability/cytotoxicity kit, for mammalian cells

Nα-Tosyl-L-lysine chloromethyl ketone hydrochloride

Paraformaldehyde

Percoll

RIPA lysis buffer

siControl

siAkt1

siAkt2

siCldn5

Sodium fluorescein

Trichloroacetic acid

Vectashield with DAPI

H-1200

T6399

F6377

sc-43045

sc-38910

sc-29196

sc-37007

20-188

GE17-0891

P6148

90182

L3224

928-40004

F9037

Catalog Number

299

Fig.
S2A
1G,H; 2A,C,D,F,G; 3D; 6D; 7A,H; S2A
S2A
S2A
S2A
3D; 4A; 7A
2A,C,F,G; 4B
2A,D,F,G; 4B
S2A
1B,H; 2A,C,D,F,G; 6D; 7A,H; S2A
5
S2A
3D
1B,G; 3E; 4C; 7A
4C; 7A
S2A
3D; 4A,B; 7A
3D
3A,B,C
3A,B,C

α-catenin

β-actin

β-catenin

δ-catenin

γ-catenin

AKT

AKT1

AKT2

Claudin-3

Claudin-5

Claudin-5 (AF 488)

Claudin-12

ERK 1/2

FoxO1

Lamin A/C

Occludin

pAKT(T308)

pERK 1/2

IRS-1

Phosphotyrosine (pY)

Antibodies used in these studies.

Antibody

Table J.2.

Millipore-Sigma

CST

CST

CST

Invitrogen

CST

EMD Millipore

CellSciences

Invitrogen

ThermoFisher

Invitrogen

ThermoFisher

CST

CST

CST

SCBT

SCBT

CST

LI-COR

SCBT

Company

05-321

2382

4695

4056

33-1500

4777

05-1075

CPE201

38-8200

352588

35-2500

34-1700

2938

3063

2966

sc-514115

sc-81793

2677

926-42214

sc-7894

Catalog #

300

Fig.
S2A
1B; S2A
5

Antibody

VE-Cadherin

ZO-1

ZO-1 (AF 594)

ThermoFisher

Invitrogen

SCBT

Company

339194

40-2200

sc-52751

Catalog #

301

Unpaired t-test
One-way ANOVA
One-way ANOVA
Unpaired t-test
One-way ANOVA
Unpaired t-test
Variable slope
One-way ANOVA
Unpaired t-test
One-way ANOVA
Unpaired t-test
One-way ANOVA

Scattered dot plots – normalized mean - no error bars

Bar graphs – normalized mean for each protein ± S.D.

Bar graphs – normalized mean for each mRNA ± S.D.

Bar graphs – normalized mean for each protein ± S.D.

Representative ECIS tracings – normalized mean – bar graphs
of normalized mean peak changes in TEER ± S.D.

Bar graphs – normalized mean ± S.D.

Dose-response curves - median ± IQR

Bar graphs – normalized mean ± S.D.

Representative ECIS tracings – normalized mean – bar graphs
of normalized mean peak changes in TEER ± S.D.

Bar graphs – normalized mean ± S.D.

Bar graphs – normalized mean for each protein ± S.D.

Bar graphs – normalized mean ± S.D. One-way

Aligned dot plots - mean - no error bars

Fig. 1G,H

Fig. 2A

Fig. 2B

Fig. 2C,D

Fig. 2E

Fig. 2F,G

Fig. 3A-C

Fig. 3D,E

Fig. 3F-H

Fig. 4A

Fig. 4B

Fig. 4C,D

Fig. 5

One-way ANOVA

Unpaired t-test

Aligned dot plots - mean - no error bars

Fig. 1C-F

Statistical Test

Summary Statistics

Statistical Analyses used in these studies.

Fig. #

Table J.3.

Tukey’s

Tukey’s

N/A

Tukey’s

N/A

Tukey’s

N/A

N/A

Tukey’s

N/A

Dunnett’s

Tukey’s

N/A

N/A

Post-Hoc Test

302

One-way ANOVA
One-way ANOVA

One-way ANOVA
Unpaired t-test
One-way ANOVA
One-way ANOVA

Scattered dot plots - normalized mean - no error bars

Scattered dot plots - normalized mean ± S.D.

Scattered dot plots – normalized mean - no error bars

Scattered dot plots - normalized mean ± S.D.

Bar graphs - normalized mean ± S.D.

Scattered dot plot – normalized mean ± S.D.

Scattered dot plot – normalized mean ± S.D.

Bar graphs – normalized mean ± S.D.

Fig. 6D

Fig. 6F

Fig. 7C,D

Fig. 7F,G

Fig. 7H

Fig. S1A

Fig. S1D

Fig. S2B

One-way ANOVA

Unpaired t-test

One-way ANOVA

Scattered dot plots - mean - no error bars

Fig. 6B-C

Statistical Test

Summary Statistics

Fig. #

Tukey’s

Tukey’s

N/A

Tukey’s

Tukey’s

Tukey’s

Tukey’s

N/A

Tukey’s

Post-Hoc Test

303

304
Supplemental Figures

Figure J.8.

DMAQ-B1 does not alter BMVEC proliferation, viability, or
cytotoxicity.

BMVEC monolayers (P3; 2 days P.C.) were treated with DMAQ-B1 [5 μM] for 6 hours
and two different assays were used to determine the effect of DMAQ-B1 on BMVEC
proliferation, viability, and cytotoxicity. (A-C) Following DMAQ-B1 treatment, BMVEC
monolayers from four independent isolations and experiments were stained with DAPI
and fluorescence micrographs (n = 20) were used to: (A) determine the total number of
endothelial cells within each imaged monolayer, which are presented as scatter dot plots
overlaid with mean ± S.D. lines plus corresponding p-value reported above; or, (B,C)
generate cell-cycle histograms to determine the percentage of BMVECs in G1/G0, S, or
G2/M phases which are provided as percentages and as ‘parts of a whole’ in donut charts.
(D,E) In a separate set of experiments (n = 3), the number of viable (‘live’) and nonviable (‘dead’) cells in each BMVEC monolayer was determined by using a live/dead cell
viability and cytotoxicity assay. Doxorubicin – [0.4 μM] for the same time frame – was
used as a positive control for cell death and/or cytotoxicity. (D) Representative
fluorescence micrographs of BMVEC monolayers with live cells (green) and dead cells
(red), and insets displaying only the red channel. Scale bars = 0.1 mm. (E) Quantification
of the percentage of non-viable, or ‘dead’ cells, within each BMVEC monolayer.
Percentages are presented as scatter dot plots overlaid with mean ± S.D. lines and groups
with the same symbol are not significant from each other (p ≥ 0.05).
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Figure J.9.

Compared with other common adherens and tight junctional proteins
DMAQ-B1 uniquely upregulates CLDN5.

(A-B) BMVECs (P3; 2 days P.C.) were treated with DMAQ-B1 [0, 2.5, 5, or 10 μM] for
6 hours and adherens and tight junction proteins (adherens junction proteins = α-, β-, δ-,
γ-catenin and VE-cadherin; tight junction proteins = ZO-1, claudin-1, -3, -5, -12, and
occludin) expression levels were determined by two-color near- infrared western blotting
for each protein (pseudo-colored green) and β-actin (pseudo-colored red). Representative
western blots are provided (A), and densitometry results (B) are reported as normalized
fold changes compared to vehicle control (0 μM) treated BMVECs. Bar graphs are
divided into individual data sets for each protein target and represent the mean ± S.D.
Groups with the same symbol within each individual target protein data set are not
significant from each other (p ≥ 0.05).

